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Preface 
Vignette 
Mike is 40 years old, divorced, and homeless. Over recent years he has been involved with the 
police several times, mostly for minor offences.  
About three years ago he started to blame his mother for obstructing him in the 
pursuit of his life goals. He also believed that she had been spying on his ‘important’ projects. 
From that time on, he became quick to anger. Once he became so angry, threatening and 
pushing his mother – then 64 – that he was committed to a psychiatric hospital. Here he was 
diagnosed with schizophrenia and alcoholism. Unfortunately, he refused to accept any kind of 
treatment.  
Later, Mike was referred to an outpatient program: Assertive Community Treatment 
(ACT). At first he wanted nothing to do with it. But after continuous offers, he finally accepted 
help with his housing and finances, a process that helped greatly to build a relationship based 
on trust. Eventually, he accepted treatment for his psychosis and alcoholism, and got back on 
speaking terms with his mother. 
This real-life vignette reflects several key features of ACT: its patients, their difficulties in 
engaging with treatment, and the integrated approach to delivering ACT services. ACT helped 
Mike to find a safe place to stay, to organize his finances, to manage his illness, and a 
meaningful reconnection with his mother.  
But while the example clearly shows some of the merits of ACT, these services are 
difficult to study empirically: Mike would have been unlikely to agree to inclusion in a 
research program that intended to study a treatment he had at first refused. The difficulty in 
determining the value of these services is highlighted by simple facts, such as the fact that 
patients fail to show up for research projects, even to fill in a questionnaire. Such things mean 
that there is a gap in our knowledge-base on these patients – especially at the start of 
treatment. 
To overcome this research gap, gathering of empirical data on patients in contact with 
ACT services might be ameliorated by the addition of routinely collected outcomes data for 
which no informed consent is needed. In this manner outcome data can provide real-life 
information on outcomes, which allows us to make an adequate evaluation of the performance 
of mental healthcare. It is thus inspiring to learn that the collection of routine outcome data is 
now one of the most rapidly advancing developments within the field of mental healthcare.  
Accordingly, over ten years, many mental-healthcare institutions in the Netherlands 
have implemented Routine Outcome Monitoring (ROM) procedures. Currently, several Dutch 
Part 1 - Introduction 
   


 

ϭϭ
working groups are trying to reach a consensus on instruments for ROM procedures, and are 
exploring the options how to analyze these data. With regard to consensus, much has already 
been achieved, such as the instruments of choice – a limited set of instruments for each group 
of patients, such as the HoNOS, CANSAS or MANSA for patients with a severe mental 
illness (Mulder et al., 2010).  
Although the primary goal of ROM – “to improve the quality and effectiveness of 
healthcare” (Slade, 2002) – still predominates, other parties beyond clinicians and patients 
have an interest in these data, researchers, managers and insurance companies among them. 
Thus, while healthcare professionals and patients may be interested in using ROM as a direct 
means to evaluate the outcome of treatment, managers may want to use ROM data not only to 
improve overall services, but also to fulfill transparency and accountability obligations 
towards insurance companies. Meanwhile, to empirically study the performance of mental 
healthcare, researchers focus on high-quality design and the use of instruments with 
satisfactory psychometric properties (Mulder et al., 2010).  
As the proper interpretation of aggregated ROM data is thus important to this broad 
range of interests, it now receives a great deal of attention in the ROM working groups. By 
providing unique data on the long-term outcomes of psychiatric patients, ROM procedures  
can be used to measure the effectiveness and relevance of treatment in daily practice 
(Newnham & Page, 2010).  
The studies described in this thesis used such data to provide practice-based evidence 
(Barkham & Mellor-Clark, 2003) on the ACT services for patients like Mike, who represent a 
group that is exceptionally difficult to engage not only in treatment, but also in research, as 
they require assertive outreach and are often unwilling or unable to participate in office-based 
treatment. We trust that our outcomes research on ACT will afford insight into real life 
outcomes in patients receiving ACT, and that this will lead to better decisions on mental 
healthcare – such as improved approaches to treatment (Trauer, 2010 b) – that will better meet 
the needs of these difficult-to-engage patients. 
The plan of the thesis 
This thesis presents data on outcomes in patients with a severe mental illness (SMI) treated in 
ACT-teams, and is organized into five successive parts. Part I states our underlying 
contention and sets out our theoretical orientation. For readability purposes, Part I starts with 
discussing authoritative works on Severe Mental Illness, Assertive Community Treatment, 
Routine Outcome Monitoring, and research paradigms, it ends by stating the aim of the thesis. 
Parts II, III and IV constitute the main body of the thesis, each setting forth its 
findings. Part II consists of a study of the biases that may be manifest in ROM data, and their 
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implications for outcomes research within the context of ACT. Part III consists of two studies 
of clinical outcome of patients in contact with ACT. Part IV presents two studies on 
motivation for treatment and its relation with clinical outcome.  
Part V, the discussion, presents the overall findings and answers the research 
questions, whose relevance is tested against existing knowledge and developments in the field 
of mental healthcare. For this purpose, we summarize implications for treatment and service 
planning, and present suggestions for future research. The thesis ends with a critique of the 
research, whose overall strengths and weaknesses are evaluated. 
Study setting 
The studies were conducted at Bavo-Europoort, a public mental healthcare organization in the 
city of Rotterdam, the Netherlands. Bavo-Europoort is part of the Parnassia Groep, an 
institution for mental healthcare in the greater Rotterdam area that treats adults and elderly 
patients with psychiatric disorders as well as patients with traumatic brain injury. The total 
population in its catchment area is approximately 1,300,000. Bavo-Europoort employs a staff 
of some 1,200 at 23 sites (see: www.Bavo-Europoort.nl). 
Treatment for adults focuses on patients with a serious and persistent psychiatric 
disorder and with psychosocial problems in several life domains. Inpatient and outpatient 
services are both provided, the latter consisting mainly of office-based community psychiatric 
care (Illness Management and Recovery teams) and ACT programs. From 2002 – 2011, 
Bavo-Europoort had seven ACT teams providing treatment for difficult-to-engage patients 
with a SMI, which in this context usually involved a psychotic disorder with or without a 
comorbid substance-abuse disorder. In 2003, ROM was introduced in all ACT teams and all 
available ROM data were used for the studies described in this thesis.   
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1.1 Severe Mental Illness  
1.1.1 Severe Mental Illness 
This thesis focuses on patients suffering from a Severe Mental Illness (SMI). Although this 
term is difficult to define, most definitions currently include criteria for diagnosis, duration 
and dysfunctioning (Bachrach, 1988; Kroon, Theunissen, van Bussenbach, van Raven, & 
Wiersma, 1998). In accordance with these expert opinions, we used a three-dimensional
definition of SMI that consisted of 1) a diagnosis of a severe psychiatric disorder (mostly a 
psychotic disorder); 2) a history of illness or treatment for two years or more (displaying its 
persistence); and 3) several disabilities (Ruggeri, Leese, Thornicroft, Bisoffi, & Tansella, 
2000).  
As well as their primary psychiatric DSM-IV Axis I disorder, most of these patients 
also suffer from complex problems such as coexisting substance-use disorders, physical 
symptoms or a poor medical condition, problems in organizing their daily activities, poor 
living conditions, few social contacts or severely disrupted relationships, financial problems 
and debts, and sometimes even victimization or problematic behavior leading to criminal 
convictions (Mulder et al., 2010). Pre-existing problems (developmental disorders) are also 
common. 
It should thus be clear that these patients’ psychiatric illness has created great personal 
turmoil and emotional distress, inevitably reducing the patients’ ability to function in daily 
life, and causing untold suffering for themselves and their families. Unfortunately, treatment 
outcome in these patients is usually poor (Drake & Mueser, 2000; RachBeisel, Scott, & 
Dixon, 1999). One factor contributing to this is a lack of motivation for treatment, as some do 
not seek treatment for their mental illness. 
Household  of a patient treated in ACT
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1.1.2 Motivation for treatment 
Motivation for treatment is often described as “the probability that a person will enter into, 
continue, and adhere to a specific change strategy” (Miller & Rollnick, 1991). While it is 
obvious that motivation for treatment is necessary for a patient to benefit from treatment, 
(Rüsch & Corrigan, 2002) things are not necessarily so simple, as problems with motivation 
for treatment are not always synonymous with resistance to change or simply acceptance of 
treatment. It turns out that what we perceive as motivation for treatment actually is a rather 
ambiguous concept. And the concept of motivation for treatment is often defined as some sort 
of treatment related behavior, but it frequently is unclear to what specific behavior motivation 
for treatment refers (Drieschner, Lammers, & van der Staak, 2004). 
Despite the fact that motivation for treatment mostly relies on internal factors (Miller, 
1999) such as distress, outcome expectancy or problem recognition it is important to 
emphasize that it is not just a patient characteristic or attribute, rather it can be conceived as a 
state of being within an interpersonal context, implicating that therapist attitudes  (e.g. 
friendly, emphatic etc.), external pressure and social support greatly influences a patients 
motivation for treatment (Miller, 1985).  
“The concept of sufficient motivation and “really trying” quickly reduce to the 
notion of will power, and the client is left with moral culpability for treatment 
failure.” (Miller, 1985) 
There may be several inter- and intrapersonal reasons contributing to lack of 
motivation for treatment: The first is avoidance of stigmatizing behaviors, which can be 
influenced by personality traits that affect the need for acceptance (agreeableness) (Lecomte, 
et al., 2008). In such cases, patients may be aware of their problems, but seek solutions 
outside psychiatry because they feel that contact with psychiatric services is embarrassing.  
The second reason is an insecure attachment style (Lecomte et al., 2008) due to a 
history of childhood trauma (Mueser, Rosenberg, Godman, & Trumbetta, 2002). This could 
mean that a patient does not want the involvement of others, as previous traumatic 
experiences have led them to mistrust other people.  
The third reason lies in earlier or anticipated negative treatment experiences, such as 
court ordered commitment, bothersome side effects of medication or other distressing 
experiences in treatment (e.g. drug withdrawal or exposure to traumatic memories). 
Fourthly, what potentially explains poor motivation for treatment, is a patient’s 
demoralizing belief that his or her problems are beyond help or that therapy will not provide 
relief and/or that other strategies may be more promising (Drieschner et al., 2004).  
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Finally, (perceived) problems with motivation for treatment or non-adherence with 
treatment may be underlain by impairments such as deficits in cognition (e.g. working 
memory or concentration) (Silverstein, 2010); illness insight; anhedonia or avolition (Tattan 
& Creed, 2001); or recovery style (sealing over) (Tait, Birchwood, & Trower, 2009). 
Impairments such as cognitive problems may thus mean that patients forget appointments 
because they are paying too much attention to internal stimuli or feel that there is no need for 
psychiatric treatment as there is no or little problem recognition.  
These explanations for problems with motivation for treatment (e.g. entering into or 
continuing treatment) can be divided roughly into two types of reason: those reflecting 
unwillingness and those that reflect intrinsic impairments and disabilities (Staring, Mulder, 
van der Gaag, Selten, & Hengeveld, 2006). Besides this, it is also worth mentioning that 
situational factors may also be a crucial factor for not entering into or continuing treatment 
(Drieschner et al., 2004), as co-payment or public transport tickets are not always financially 
feasible, therefore patients may decide that treatment is not an option at this moment or 
perceive it as being too expensive. Other circumstances such as having a full-time job can 
make the use of health care during office hours quite difficult, but also being a single parent 
of young children may add to the feeling that treatment takes too much of their time. 
1.1.3 Evidence-based practices for patients with a SMI  
During the last decades, psychiatric services have undergone considerable development, and 
it is now possible to claim that there are treatments for most mental illnesses whose efficacy 
as well as effectiveness has been proven (Lehman, Goldman, Dixon, & Churchil, 2004). So 
despite these patients’ severe and persistent problems, there is hope that their disabling 
symptoms can be overcome, and that they can escape the invalidating environments that so 
trouble and impair them. For, given the provision of proper pharmacologic and ongoing 
psychosocial interventions, most patients can be helped and treated (Drake et al., 2000). Such 
interventions may be especially effective if they target a patient’s current and most prominent 
needs (Drake et al., 2000).  
Several evidence-based practices (EBPs) in treatment of this complex patient group 
exist: 1) Assertive Community Treatment (ACT) (Marshall & Lockwood, 1998; Marshall & 
Lockwood, 2000); 2) Illness Management Recovery (IMR) (Mueser et al., 2002); Both 
programs include psycho education, learning skills to take medication effectively/ behavioral 
tailoring, coping skills training, and relapse prevention; 3) Cognitive behavioral therapy 
(Dixon et al., 2009); 4) Family Interventions (Pilling et al., 2002); 5) Individual Placement 
and Support (IPS) (Bond, Drake, & Becker, 2012); 6) Token economy interventions (Dixon et 
al., 2009); 7) Integrated Dual Disorder treatment (IDDT) (Brunette & Mueser, 2006; Drake & 
Part 1 - Introduction 
   


 

ϭϲ
Mueser, 2000); 8) Motivational Interviewing (Manthey, Blajeski, & Monroe-DeVita, 2012); 
9) Cognitive remediation (McGurk, Twamley, McHugo, & Mueser, 2007); 10) and 
interventions for weight management (Dixon et al., 2009). Although this list of interventions 
is not complete, these interventions may be successful in helping patients with complex 
problems, particularly when they are implemented properly (McHugo, Drake, Teague, & Xie, 
1999). However, we should acknowledge that while these interventions can be helpful, they 
are no panacea, as the introduction of guidelines, or new treatments and interventions for 
patients with SMI has not prevented high levels of disability (Hunter, Cameron, & Norrie, 
2009) and social exclusion (Huxley & Thornicroft, 2003).  
As these interventions have been demonstrated to be effective, it is surprising that little 
is known about the extent to which they are actually implemented and used in community 
mental healthcare (Lehman et al., 2004; McHugo et al., 2007; Puschner et al., 2010; 
Schoenwald & Hoagwood, 2001; Wells, Miranda, Bruce, Alegria, & Wallerstein, 2004) – and 
thus about their bearing on outcome. In the public mental health sector, this has generated an 
increasing demand for transparency and accountability. Therefore a key empirical question 
always remains whether patients who are in contact with mental health services actually get 
better and achieve significant health gains (Burgess, Pirkis, & Coombs, 2006). 
1.2 Assertive Community Treatment (ACT) and Flexible-ACT (F-ACT) 
1.2.1 Assertive Community Treatment (ACT) 
Assertive Community Treatment (ACT) is an EBP consisting of an integrated, rehabilitation 
oriented, community-based service-delivery model for patients suffering from a SMI (Dixon, 
2000). The ACT approach is greatly influenced by the work of Stein and Test (1980), who 
believed that it is in the community, not in the hospital, that patients need help.  
“Finally, we believe that until we are able to prevent or cure chronic 
psychiatric disease we should change our treatment strategy from preparing 
patients for community life to maintaining patients in community life.” 
 (Stein & Test, 1980) 
ACT services are provided for those in need of ongoing mental healthcare and an 
assertive outreach approach (Wright et al., 2003). According to van Veldhuizen (2007), the 
ACT target group comprises about 20% of all SMI patients, a proportion that matches the 
proportion of patients treated in ACT teams (700-800 patients) and standard care (3200 
patients) by Bavo-Europoort. As most patients in need of ACT are unwilling or unable to 
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participate in standard community care, there is considerable emphasis on out-of-office 
interventions and home visits, not least because ACT also focuses on keeping these patients in 
contact with services (Sytema, Wunderink, Bloemers, Roorda, & Wiersma, 2007). However, 
when patients in ACT teams constitute a danger to themselves or others and are not motivated 
for treatment, clinicians can start a procedure for them to be committed to a psychiatric 
hospital.  
Besides its key feature – assertive outreach – the delivery of ACT comprises several 
basic principles that can be characterized as time-unlimited and as a complete and customized 
approach to service delivery. More specifically, this means that ACT services provide not 
only pharmacotherapy, psycho-education, coping-skills training, crisis-intervention, and 
substance-abuse treatment; but that they also help organize proper housing, finances, and day-
to-day problems in life – and sometimes family or occupational therapy (Dixon, 2000; Philips 
et al., 2001).  
Bond, Drake, Mueser and Latimer (2001) described several critical components for 
ACT to be effective, including multidisciplinary staffing, shared caseloads, integrated 
services, low client-staff ratios, more than 75% of contacts in the community, frequent patient 
contact, assertive outreach, focus on symptom management, day-to-day problems in life, 
ready access in times of crisis (24/7) and time-unlimited services. 
Since then, ACT has become one of the most investigated treatment models (Bond et 
al., 2001). The Cochrane Review (Marshall & Lockwood, 1998; Marshall & Lockwood, 
2000) found that it was effective in keeping patients in contact with services, reducing the 
length of hospitalization, and improving clinical and social outcome. 
The most authoritative studies to show superior results were performed some time ago 
in the US, and compared ACT to standard care. However, their results were not replicated in 
more recent European studies, possibly due to differences in the standards of community care 
in the US and in the European countries that had already implemented certain aspects of ACT 
(Burns, Fioretti, Halloway, Malm, & Rossler, 2001; Fiander, Burns, McHugo, Drake, 2003), 
or due to differences in model fidelity (McHugo et al., 1999; van Vught et al., 2010).  
1.2.2 Recent developments: ACT now turning into F-ACT 
Recently a Dutch alternative for ACT, Flexible-Assertive Community Treatment (F-ACT), 
has become increasingly popular in the Netherlands as a service-delivery model for patients 
with SMI (van Veldhuizen, 2007). In our study setting ACT programs are currently  
transitioning into F-ACT. F-ACT involves regular office-based case-management teams who, 
when necessary, can intensify their treatment  on the basis of the principles of ACT (van 
Veldhuizen, Bähler, Polhuis, &  van Os, 2008).  
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The appeal of F-ACT may lie in the flexibility it offers with regard to matching the 
intensity of services to current patient needs (Bond & Drake, 2007). This means that F-ACT 
delivers two types of care: 1) individual case management for patients with a SMI who are 
relatively stable, and 2) shared case management and assertive outreach (i.e., ACT) for 
patients with a SMI who are at risk of relapse and hospital readmission (van Veldhuizen, 
2007).  
An essential aspect of F-ACT is its flexibility in delivering ACT or case-management. 
Van Veldhuizen (2007) regards patients with a SMI as a relatively homogenous group in 
which there are considerable overlaps between patients treated in ACT and those under 
individual case-management.  
Due both to this overlap between the two patient groups and to their changing needs, 
there is a considerable need for a service model that facilitates the continuity of care (Drukker 
et al, 2008; van Veldhuizen, 2007) and provides care economically (through stepped care: 
balancing between over- and under-treatment). This explains why investments in F-ACT 
teams are increasing in the Netherlands, even though F-ACT has not been shown to be more 
effective than other individual types of outpatient care (Drukker et al., 2008).  
While F-ACT is described as a rehabilitation-oriented service delivery model (van 
Veldhuizen, 2007), Bond and Drake (2007) express their concerns that F-ACT case 
management may simply lead to brief contacts for patients who are not in crisis. Although van 
Weeghel (2008) attempted in the F-ACT handbook to specify critical EBPs that should be 
included in the F-ACT model (e.g. IMR, family interventions, IDDT and IPS).  
Within the context of this thesis, however, we studied patients in ACT teams, as the 
transformation from ACT to F-ACT took place after the ROM data for this thesis had been 
collected.  
1.3 Routine Outcome Monitoring (ROM)  
1.3.1 Routine Outcome Monitoring in clinical practice 
The understanding that clinicians should follow up patients to assess the results of their 
treatment was first proposed a century ago by Ernest Codman in his end-result idea (1924). 
However, at that time, the proposal received little approval (Swensen & Cortese, 2008).  
“In the first place, what is the end-result idea? It is that every hospital should 
trace each patient with the object of ascertaining whether the maximum benefit 
has been obtained and to find out if not, why not.”  
(Codman, 1924; Codman, 2009)
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It was after publications by Donabedian (1988) on the assessment of the quality of 
care and by Ellwood (1988) on outcomes management that measuring health outcomes gained 
momentum. 
  
“There was a time, not too long ago, when this question could not have been 
asked.  The quality of care was considered to be something of a mystery: real 
capable of being perceived and appreciated, but not subject to measurement.” 
(Donabedian, 1988)
  
“The problem is our inability to measure and understand the effects of the 
choices of patients, payers, and physicians on the patients aspirations for a 
better quality of life. The result is that we uninformed patients, skeptical 
payers, frustrated physicians and besieged health care executives”  
(Ellwood, 1988)
Today, monitoring outcome – the routine collection of clinically relevant outcome data 
on patients in everyday clinical practice (de Beurs et al., 2011; Slade, 2002) – is considered 
important, and is increasingly becoming part of everyday clinical practice (Slade et al., 2006), 
mainly due to its aim of improving the effectiveness and quality of care (Harrison & Eaton, 
1999; Slade, 2002).  
ROM assessments quantify and record the situation of a patient at a certain point in 
treatment. By using repeated assessments per individual patient, the clinician can determine 
empirically whether the use of services brought the patient any benefit (de Beurs et al., 2011; 
Trauer, 2010 a). However, as service use may have preceded beneficial change but not have 
caused it (Trauer, 2010 a), problems of attribution remain an issue (Lakeman, 2004).  
Despite this attributional problem, the process of treatment evaluation provides an 
opportunity to prevent potential treatment failures, as early response to treatment – or the lack 
of it – can be detected (Lambert, 2010). This makes it possible to detect patients who fail to 
progress or respond as expected (Newnham & Page, 2010). This is particularly important, as 
early response predicts treatment outcome (Howard, Moras, Brill, Martinovich, & Lutz, 
1996), and outcomes may be improved by informing the therapist whether or not the patient is 
on track (Azocar et al., 2007; Lambert, 2007; Reese, Norsworthy, & Rowlands, 2009). 
However, it should be noted that these favorable effects of feedback were found in studies in 
relatively young patients whose prognosis was good, and who were assessed on an ongoing 
basis, not intermittently (Lambert, 2010).  
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A ROM procedure in which assessments were made intermittently (e.g. each year or 
more frequently) maybe useful nonetheless. Although, we must admit that there is no 
evidence to suggest that an intermittent outcome procedure improved treatment effectiveness 
in patients with a SMI.  Still we feel it remains promising, as it allows treatment progress to 
be evaluated, and is helpful in the development of individual care plans. This delivers 
valuable information for the treatment planning of patients with a SMI, who are often 
characterized by a combination of serious problems, such as a coexisting substance-use 
disorder, physical problems, or problems with daily activities, housing or contacts (Drukker et 
al., 2010). This cocktail of complex problems adds to the complexity of delivering effective 
psychosocial interventions. In this context, care is optimal care if the interventions target 
changing needs and various degrees of motivation (Essock, Drake, Frank, & McGuire, 2003). 
All-in-all, if a ROM procedure includes the collection of structured and standardized 
clinical relevant information, it provides an accurate quantitative profile at a given period of 
individual patients’ needs and psychiatric problems, and also of their motivation for 
treatment, their quality of life, and their satisfaction with services. This profile can help the 
clinician to create or adjust a treatment plan that represents the perspectives of patient and 
clinician, and that also targets the patient’s current needs (Drukker et al., 2010). At the same 
time, we should underline that there is no (inter)national consensus on how often outcomes 
measures should be administered. Based on pragmatic feasibility criteria a minimum of once a 
year for SMI patients is proposed in the Netherlands (Stuurgroep ROM ggz, 2011). As a 
consequence it is left up to the clinician to decide whether or not the patient should be 
assessed more frequently than the minimum of once a year (prior to the treatment plan 
evaluation).  
Despite its clinical relevance, (mandatory) outcome measurement has not been equally 
popular among all clinicians (Gillbody, House, & Sheldon, 2002). This may be because they 
feel that it does not quite capture the individual patient (Lakeman, 2004), that it takes too 
much time and there is no benefit in filling in what you already know, or that it is both too 
non-specific and too insensitive to be truly useful (Davies, 2006). In this context, Lakeman 
(2004) describes outcome measurement using the Health of the Nation Outcome Scales 
(HoNOS) as “an exercise akin to asking someone to describe a Picasso in 12 words or less”. 
And of course it is only proper to acknowledge that the quality of a ROM procedure is only as 
good as the combination of the instruments that are used (Lambert, 2010).  
1.3.2 Why use aggregated ROM data? 
Aggregating individual outcome data may support resource allocation and service 
development (Meehan, McCombes, Hatzipetrou, & Catchpool, 2006), as well as helping to 
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develop a case-mix classification system in which outcome data contributes as a predictive 
factor for costs of episodes of care (Eagar et al., 2004). In this manner, outcome measurement 
could meet the demands for accountability, which, despite its various claims and promises, 
has not yet taken place (Trauer, 2010 a). While understanding its attributional problems, 
experts still believe that ROM has the capacity to achieve best quality of care by providing 
information on overall treatment progress and the provision of mental healthcare for a defined 
regional population (Slade, 2010 b). This will make it possible to make informed choices for 
modifying the mental-health infrastructure (Drukker et al., 2010). In both contexts – 
individual and aggregated – ROM can be used for quality improvement by monitoring the 
performance of the health services as part of a simple and repetitive “plan, do, check and act” 
cycle (PDCA cycle) (Durman, Lucking, & Robertson, 2008).  
Furthermore aggregating outcome data may also create opportunities to compare 
performances of local healthcare programs. As local comparisons may set higher standards 
and attainable goals for treatment progress, the organizations in question will then be able to 
optimize treatment by modifying their service delivery. Therefore a regional benchmark can 
play a relevant part in this PDCA process (Axford et al., 2004), ensuring that the therapy is 
both effective and efficient (Enderby, Hughes, John, & Petheram, 2003).  
However building a valid benchmark may not be so easy to achieve, because 
differences between healthcare programs in patient characteristics may be a potential source 
of confounding (van Os et al., 2012). Also we must be sure that the samples consist of 
sufficient assessments to be representative of the target population. Therefore, despite its 
appeal serious concerns have nonetheless been raised about whether the implementation of 
ROM procedures is the holy grail of quality improvement (Liptzin, 2009). In addition to the 
ROM as part of a plan, do, check and act cycle 
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above concerns there may be other potential problems with outcome-driven benchmarks such 
as the risk of overlooking a group of patients in whom poor outcome does not mean poor 
treatment – one example being patients suffering from chronic conditions, of which the 
maintenance of a “stabilized” health status is a valid therapeutic goal (Trauer, 2010 b). In such 
cases, where follow-up assessments show little measurable change, it may be difficult to 
distinguish between effective and ineffective services (Mckay & MacDonald, 2010), “before 
and after” outcome comparisons being less appropriate for measuring the effects of 
psychiatric services (Trauer, 2010 b) than “with care” and “without care” ones (Trauer, 2010 
b). Although it is clearly understood that it is ethically unrealistic to make a valid comparison 
of “with care” and “without care”, the lack of such knowledge makes it very difficult to 
interpret ROM data properly. An outcome-driven benchmark for patients with chronic 
conditions may thus be flawed, and may even create incentives to treat patients with a 
relatively good prognosis (Blais, Frank, Nierenberg, & Rauch, 2009). It would also neglect 
the quality of the services delivered, i.e., the application of best practices of care (Weisman, 
Grason, & Strobino, 2001), which is presumably at least as important as outcome in this 
context, if not more important. 
1.3.3 ROM data and research 
When outcome data are used for research purposes, they provide real-life information on 
outcomes during the course of a patient’s treatment. In this context, they can be used to 
empirically study the effectiveness of mental health services (Harrison & Eaton, 1999). This 
kind of research can be characterized as both naturalistic and observational, as it studies 
effectiveness using data from an existing database (ROM records) that lacks randomization 
and the experimental features linked to the treatment (Stroup et al., 2000). In consequence, 
this kind of research does not assess efficacy, as it does not measure whether the intervention 
has the capacity to achieve a result, but does measure effectiveness, i.e., whether the treatment 
works in real life under circumstances that are sometimes far from ideal (Haynes, 1999). 
However, it also means that there are serious methodological limitations: as strong assertions 
on attribution cannot be made, interpretation is very difficult. But despite its inherent design 
flaws, it does answer questions, such as those with respect to whether the health of patients in 
contact with mental health services improves significantly (Burgess et al., 2006). And to keep 
up with the advances and changing circumstances in contemporary mental health care, it is 
valuable to have an indication of what has been achieved in daily practice.  
Observational research is considered appropriate under conditions where experimental 
research has serious drawbacks or is simply unrealistic (Rosenbaum, 2005), either due to 
uncooperativeness, huge dropout proportions, or complex problems, which are often the very 
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reason for excluding patients in research protocols. To provide information on real-life 
settings and patients with complex problems, it is therefore clear that an observational study 
design has certain advantages, even though its design departs from the gold standard for 
research designs, which is the randomized controlled trial (RCT) (Sackett, Rosenberg, Gray, 
Haynes, & Richardson, 1996). Because RCTs have higher internal validity than observational 
studies (Cartwright, 2007), and because they allow dissimilarity in outcomes to be related to 
differences in treatment, they are seen as the most reliable method of research (Evans, 2003). 
The type of evidence they provide – and particularly the meta-analysis of this type of 
data – are therefore dominant within the evidence-based practice (EBP) paradigm (for 
example the Cochrane review on ACT) (Cooper, 2003). This paradigm promotes practices 
that have proved to be better than other or no intervention (Essock et al., 2003). By supporting 
informed decisions on treatment, EBPs provide guidelines for clinical practice (Dassori, 
Chiles, & Swenson-Britt, 2000).   
Is it is clear, then, the knowledge on which we base our treatments is based on 
evidence gathered in research and, it is this evidence that depends on scientific premises. So, 
to be able to understand our knowledge on treatments we must take into account the 
consequences of these premises. Therefore it is interesting to note that there is a vast amount 
of literature on the limitations of the RCT design (Hodgson, Bushe, & Hunter, 2007), which 
acknowledges that RCTs cannot address all relevant questions in healthcare (von Elm et al., 
2007), especially with regard to SMI patients. In this context, long-term outcomes provide 
more accurate and clinical relevant information than short-term ones. Gathering evidence on 
long-term outcome requires long-term studies and because RCTs are much more expensive 
than observational studies, it can be financially difficult to complete one with long-term 
follow-up (Walwyn & Wessely, 2005). 
Another important drawback of RCTs is their rigorous methodology, which is 
complicated when applied to SMI patients. When patients are excluded on a rather restrictive 
criterion, i.e., when selection criteria are conservative (Gilbody, Wahlbeck, & Adams, 2002), 
large numbers of patients suffering from SMI are excluded from an RCT, thereby 
compromising the extent to which the results can be generalized to the entire patient 
population (Walwyn & Wessely, 2005). Similarly, when experimental designs have impacted 
the implementation of a particular service to a level that does not necessarily correspond to 
the routine service delivered in clinical practice, the external validity of an RCT can be 
seriously compromised (Summerfelt & Meltzer, 1998) – a situation that is exacerbated when 
the quality of the services in the control condition has been somewhat neglected. So it can be 
argued that the notion of the hierarchy of research designs, which is so popular nowadays 
serves to conceal the reality, i.e.  that the choice of research designs depends on the type of 
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knowledge we seek (Krumholz, 2009) and potentially functions to disguise what we see in 
daily practice. 
“The popular belief that only randomized, controlled trials produce 
trustworthy results and that all observational studies are misleading does a 
disservice to patient care, clinical investigation, and the education of health 
care professionals.” (Concato, Shah, & Horwitz, 2000)
Thus, despite the attractive internal validity of RCTs, extra evidence may be needed 
on external validity (Rothwell, 2005). This is in line with the expert opinion of Barkham and 
Mellor-Clark (2003), who conclude that no single research paradigm can deliver research that 
is both rigorous and relevant. It is therefore important to stress that observational study 
designs have strong external validity, as they closely represent “real life”, meaning that their 
results can be generalized to the patient population, local or otherwise (Essock et al., 2003). 
To ensure that this is done properly, von Elm et al. (2007) provided guidelines for reporting 
observational studies (STROBE), and emphasizes that patient selection, exposure, outcomes 
used, potential confounders, biases and assessment methods should all be described in detail. 
Ultimately, this prevents observational data from being no more than projection material.  
A persuasive example of the differences between RCTs and observational studies can 
be found by consulting two Dutch studies on ACT. Whereas an RCT in the north-eastern of 
the Netherlands with a follow-up of 1 - 2 years (Sytema et al., 2007) showed 0% drop-out in 
ACT, naturalistic data on ACT in the city of Rotterdam (south-west Netherlands) showed that 
22% of patients left care after 1 year and another 9% after 2 years (Kortrijk & Mulder, 2011). 
We found that a significant proportion of these patients had not been referred to other services 
(Mulder & Kortrijk, 2012). These discrepant results demonstrate that the research population 
may be somewhat different from real-life examples found in observational research. In turn, 
this means that knowledge derived from RCTs is not the only point of reference from which 
one should navigate, and that the gap between the two paradigms demonstrates the need to 
integrate evidence-based practices and practice-based evidence (Page & Stritzke, 2006). This 
would allow us to examine the relationship between efficacy and effectiveness (Swartz, 
Swanson, & Hannon, 2004). While, admittedly, this turns out to be not so easy to achieve 
(Slade, 2010 b), it is nonetheless highly relevant.
Despite their differences, both study designs – when used in the study of the 
performance of healthcare – also have certain similarities. Usually, for instance, evidence 
found in RCTs and observational studies both reflects local evidence. Meaning that 
differences between study outcomes may also be due to different healthcare infrastructures 
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(Cooper, 2003), this may (partly) explain the differences in outcomes between the RCTs 
performed in Europe and the US on the efficacy of ACT (Burns et al., 2001; Fiander et al., 
2003) – a major issue that needs to be considered, as it makes the interpretations of effects 
very difficult.  
A complicating factor for patients with a SMI is the difficulty in determining what has 
been delivered, as psychosocial interventions tend to co-occur. As these interventions usually 
comprise pharmacotherapy, psychotherapy and/or coaching, it is hard to unravel their 
working ingredients (Trauer, 2010 a). As well as these integrated services, patients with a 
SMI often receive other forms of support, mostly from outside mental healthcare (Essock et 
al., 2003), that are thus strongly dependent on a given city’s priorities and policies.  
When all things are considered, we feel that, despite important methodological 
limitations, ROM data should be used to enrich the knowledge derived from RCTs. Then it 
would be possible to provide EBPs with more accurate data from the real world 
(Vandenberghe, 2008).  
1.3.4 Routine Outcome Monitoring in this thesis  
In agreement with expert opinions derived from the Dutch national remission working group, 
most instruments selected for patients with a SMI in our ROM procedure are short, valid, 
reliable, simple to use, sensitive to change, and, as well as assessing several relevant domains 
(Salvador-Carulla, 1999), take both the patient's and clinicians’ perspectives into account 
(Mulder, et al., 2010). The ROM assessment includes clinician-rated instruments and self-
reports on important outcome domains, including quality of life, clinical symptoms, 
psychosocial functioning (Juckel & Morosini, 2008), needs for care, satisfaction, and general 
health status (Salvador-Carulla, 1999).  
The instruments used in the ROM assessments in ACT teams in Rotterdam included 
the Health of the Nation Outcome Scale (HoNOS; Mulder et al., 2004; Wing et al., 1998), the 
Camberwell Assessment of Need Short Appraisal Schedule (CANSAS; Slade, Beck, 
Bindman, Thornicroft, & Wright, 1999), the Positive and Negative Syndrome Scale (PANSS; 
Kay, Fiszbein, Opler, 1987; Kay Opler, Lindenmayer, 1989), remission criteria items 
(Andreasen et al., 2005), Global Assessment of Functioning (GAF-S (symptoms) and GAF-D 
(disabilities); Pedersen, Hagtvedt, & Karterud, 2007), quality of life (QoL; Drukker et al., 
2010, MANSA; Priebe, Huxley, Knight, & Evans, 1999), and a scale for assessing motivation 
for treatment (Mulder, Koopmans, & Lyons, 2005) and for assessing satisfaction with 
services (van Os et al., 2001). Further, data were collected on DSM IV diagnosis and several 
socio-demographic variables such as: gender, age, age at first contact with mental healthcare, 
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age at first psychotic symptoms, living conditions, country of birth, education, legal status and 
the use of medication.   
ROM data were collected by independent raters (most of them psychologists), 
preferably on the basis of personal interviews. Additional information was collected from 
patient files, electronic and paper based records. In some cases a personal interview with the 
patient appeared to be impossible. Instead raters then tried to organize an interview with the 
clinician to fill in the clinician-rated scales.  
A ROM procedure using independent raters has potential benefits over the alternative 
(whereby clinicians rate their patients), in that (a) the clinicians are involved in the patients’ 
treatment, which may make them biased. (b) The use of independent raters may also 
positively affect the reliability of the data, since they usually have more experience and 
training in ROM instruments. (c) The number of missing ROM data may also be lower, since 
the number of ROM records is higher in Bavo-Europoort under the condition of independent 
raters compared to the situation were clinicians rate their own patients. This favorable 
outcome may have occurred under the circumstances that independent raters gave ROM more 
priority. Despite these benefits we also identified disadvantages inherent to the use of 
independent raters, in that (a) more time may be needed to assess the patient, (b) some 
patients may be more hesitant to discuss personal information with someone they are not 
familiar with and (c) the ROM data may not be used by the clinician to evaluate the treatment 
plan (Mulder, et al., 2010). It is not known which of the two procedures is more expensive, 
however, it appears that there may be a trade-off between both procedures (clinical utility 
versus a higher number of assessments and/or more reliable assessments).  
The Bavo-Europoort ACT teams administered ROM instruments once or twice 
annually: twice annually from February 2003 to January 2010, and once from then on. This 
decision was made to make sure that ROM was capable of being done for all patients in 
contact with Bavo-Europoort, not just those in contact with the outreaching programs. In an 
effort to enhance the clinical utility ROM assessments were planned to occur annually in 
advance of the evaluation of the treatment plan. The ROM assessments were available to the 
clinicians in their electronic patient files, so they could use all outcome data in their 
discussions of treatment progress with the patient. In these computerized records we 
presented the scores on the individual items and total scores of each ROM instrument, 
provided a graphical display of the scores over time, also including  a legend to interpret 
scores properly (see appendix). Clinicians were also trained in the interpretation and use of 
the outcome scales.  
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1.4 Aims of the thesis  
This thesis addresses three aims related to the issues specified above (part I), for which we 
used ROM data on a group of patients treated in ACT teams.  
(1)  The first aim involved the methodological issue of biases in 
observational research (part II). To understand this more comprehensively, we 
investigated: 1a) whether there were selection biases in our ROM dataset, and 1b) 
whether any potential biases may impact estimates of the effectiveness of ACT 
services. 
(2) In the public mental health sector for patients with a SMI treatment 
outcome research is needed. Among other reasons we feel this is important 
because a) there is only a limited knowledge base on the actual implementation 
and use of interventions in clinical practice (Lehman et al., 2004; McHugo et al., 
2007; Puschner et al., 2010; Schoenwald & Hoagwood, 2001; Wells et al., 2004), 
b) most of the relevant research on ACT was performed some time ago in the US 
(Burns et al., 2001; Fiander et al., 2003), and, c) new developments in treatment 
approaches (better and/or cheaper) are always under way. As a result, a key 
empirical question remains: whether patients in contact with public mental health 
services get better and achieve (more) health gains (Burgess et al., 2006). As our 
second research question therefore focused on outcomes of patients in contact 
with ACT (part III), we wished to determine 2a) the clinical outcomes of patients 
receiving ACT, 2b) the clinical outcomes of patients who had been involuntarily 
admitted, and 2c) which patients treated in ACT had a poor or good outcome.  
(3) As problems with motivation are one of the main inclusion criteria for 
ACT, we wished to elaborate on this issue (part IV) by determining 3a) the extent 
to which problems with motivation for treatment are manifest in patients in 
contact with ACT services, 3b) whether patients who are not motivated for 
treatment at the start of ACT become motivated for treatment during ACT, but 
also for those patients who were  involuntarily admitted during their ACT and, 3c) 
whether problems with motivation for treatment are related to clinical outcomes. 
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Chapter 2 - Outcome measurement 
Duration of Assertive Community Treatment and the interpretation of 
routine outcome data 
Kortrijk, H.E., Mulder, C.L., Drukker, M., Wiersma, D., & Duivenvoorden, H.J. (2012). 
Duration of Assertive Community Treatment and the interpretation of routine outcome data. 
Australian and New Zealand Journal of Psychiatry, 46, 240-248.
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Abstract  
Objective: Statistical inferences based on routine outcome monitoring data are susceptible to 
biases. Because this process may be influenced by differences in attrition and treatment 
duration, we wished to gain insight into the relationship between treatment duration and 
clinical outcome. 
Method: We enrolled 569 Assertive Community Treatment team patients. As part of a six-
monthly routine outcome-monitoring (ROM) procedure, we used the GAF scale, the HoNOS, 
and a scale to assess their treatment motivation and satisfaction with services. Duration of 
ACT showed that treatment duration was short for 292 patients ( 3 ROM assessments; 11.6 
(SD=6.1) months), medium for 191 (4-6 ROM assessments; 26.9 (SD=7.3) months), and long 
for 86 ( 7 ROM assessments; 44.06 (SD=7.1) months). Chi-square and ANOVA were used 
to compare patient characteristics and baseline values across different treatment-duration 
groups, and structural equation modeling to unravel interdependencies between the baseline 
and outcome variables. 
Results: More patients receiving long-term Assertive Community Treatment were diagnosed 
with a psychotic disorder and/or substance abuse than those whose treatment was shorter. 
Patients whose treatment lasted longer had worse baseline GAF and HoNOS scores than those 
whose treatment was shorter. Structural equation modeling showed that the interdependencies 
between determinants and outcome variables (concerning the relationships between both 
identical and nonidentical variables over time) were different for each of the treatment-
duration categories.  
Conclusions: Patients in Assertive Community Treatment teams with different treatment 
durations constitute distinguishable groups with different outcomes. This should be taken into 
account when using outcome data for benchmarking purposes.  
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Introduction  
Routine Outcome Monitoring (ROM) consists of evaluating psychiatric treatment by 
repeatedly assessing patient-level outcomes. Its primary goal is to improve efficacy and 
quality of care (Slade, 2002); one secondary goal is to empirically study mental health 
outcomes to supplement findings of randomized controlled trials (Holloway, 2002), and thus 
to bridge the gap between the research world and the real world (Harrison & Eaton, 1999). 
Although ROM is being widely implemented, several important problems are involved in 
basing valid statistical inferences on ROM data (Gilbody, House, & Sheldon, 2002; Young, 
Grusky, Jordan, & Belin, 2000).These include reporter bias, insufficient characterization of 
interventions, and the impact of potential confounding variables, such as treatment duration.  
Differences in treatment duration may be influenced by several factors, such as patient 
attrition (i.e. patients who leave care in an untimely fashion). A study by Herinckx, Kinney, 
Clarke and Paulson (1997) showed that drop-out over time in community mental health care 
ranged between 32 and 57%. In the context of Assertive Community Treatment (ACT), a 
recent study by Mohamed, Rosenheck and Cuerdon (2010) showed that 42% of patients 
terminated health care after 3 years of treatment. 
Attrition has been found to be related to patients’ level of functioning, their motivation 
for treatment, and their satisfaction with services (Joe, Simpson, & Broome, 1999; Primm et 
al., 2000; Romney, 1988; Sue, McKinney, & Allen, 1976; Young et al., 2001). When 
outcomes data are used to evaluate the performance of mental healthcare services, biases 
caused by differences in treatment duration may lead to invalid conclusions, particularly when 
patients leave care because their level of functioning has changed (i.e. outcome dependent). 
This means that patients whose treatment duration was shorter may have been different at 
baseline and have different outcomes than those who remain in care (Reynolds, Frank, & 
Kathy, 2005). If patients leave care after relatively short treatment because their condition is 
worsening, this may lead the success of their treatment to be overestimated (Bond, McGrew, 
& Fekete, 1995). Conversely, if they leave care when they have completely or partly 
recovered, treatment success may be underestimated (Young et al., 2000), thereby filtering 
patients who remain in need of long term treatment as they have not yet recovered from their 
psychiatric condition. In both cases, attrition can produce selection bias, which can in turn 
impact benchmarking, making it important to be acknowledged.  
We therefore wished to gain insight into the relationship between treatment duration 
and clinical outcome in the context of ACT. We did so by exploring the relationships between 
duration of ACT and clinical outcome variables. 
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Methods 
Setting 
The study involved patients from six ACT teams in the city of Rotterdam, the Netherlands. 
There were three selection criteria for treatment by an ACT team: (a) age 18 and older, (b) 
having a severe mental illness (usually a psychotic or bipolar disorder, with or without a 
comorbid substance-use-related disorder); and (c) lack of motivation for treatment at the start 
of ACT, which made assertive outreach necessary. The fidelity of ACT programs can be 
assessed using the Dartmouth Assertive Community Treatment Scale (DACTS) (Bond, 
Drake, Mueser, Latimer, 2001; Salyers et al., 2003; Teague, Bond, & Drake, 1998), whose 
fidelity score showed that our six teams had implemented ACT moderately successfully 
(Kortrijk, Mulder, Roosenschoon, & Wiersma, 2010). 
Data collection 
Data were collected as part of a ROM procedure used in clinical practice to discuss treatment 
course and outcome between patient and the clinician. ROM assessments, which were 
planned to take place on entry to the service and every six months thereafter, were performed 
by independent raters, most of them psychologists. The actual saturation of ROM records in 
our dataset showed that, on average, the ROM assessments had taken place 9 months apart 
(SD = 3.6). ROM data-collection was approved by the Dutch Committee for the Protection of 
Personal Data. Data for this study refer to the period from January 2003 to February 2009; 
they were used anonymously.  
Instruments 
We collected socio-demographic data on gender, age, and level of education, and on the 
diagnosis made by the ACT team psychiatrist. 
Four instruments were used. The first was the Global Assessment of Functioning
(GAF),  (World Health Organization, 1992), which was divided into a symptom scale (GAF-
S, range 1–100) rating the global symptom severity, and a functioning scale (GAF-F range 1–
100) rating the level of impairment of psychosocial functioning (Pedersen, Hagtvet, & 
Karterud, 2007).   
To assess psychosocial functioning more specifically, we used the Health of Nation 
Outcome Scales (HoNOS), which was originally developed as a standardized assessment tool 
for routine use by the mental-health services. It consists of 12 five-point clinician-rated scales, 
each ranging from 0 (no problem) to 4 (severe/very severe), and thus yielding a total score 
from 0 to 48. The psychometric properties of the English and Dutch HoNOS version have 
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been found to be acceptable (Mulder et al., 2004; Wing et al., 1998). For the present study, we 
used only HoNOS total scores. The HoNOS covers the following domains: (1) overactive, 
aggressive, disruptive or agitated behaviour, (2) non-accidental self-harm, (3) problem 
drinking and drug-taking, (4) cognitive problems, (5) physical illness and disability, (6) 
hallucinations and delusions, (7) depressed mood, (8) other psychological symptoms, (9) 
relationship problems, (10) problems with activities of daily living, (11) problems with living 
conditions, and (12) problems with occupation and activities.  
Motivation for treatment was assessed using one item adapted from the Severity of 
Psychiatric Illness scale (Lyons, 1998; Mulder, Koopmans, & Lyons, 2005); it was scored in 
five categories (score range 0-4) similar to those in the HoNOS. The motivation for treatment 
scale was scored on the basis of an interview with the patient and the clinician. 
Finally, we assessed satisfaction with services using an item adapted from the 
Manchester Short Assessment of Quality of Life (MANSA) (Priebe, 1999).This item was 
scored on a seven-point scale similar to the MANSA scale from ‘couldn't be worse’ to 
‘couldn't be better’ (scored 1-7) (van Os et al., 2001).   
Statistical analyses   
Assessments (including records of missed assessments) were handled using a blocked design 
of six-monthly assessments. On the basis of the number of assessments and time since start of 
ACT, duration of ACT was trichotomized into short duration (2-3 ROM assessments, with a 
mean treatment duration since first assessment of 11.6 (SD=6.1) months); medium duration 
(4-6 ROM assessments, with a mean treatment duration since first assessment of 26.9 
(SD=7.3) months); and long duration (7 and more ROM assessments, with a mean treatment 
duration since first assessment of 44.06 (SD=7.1) months). We used ANOVA and chi-square 
tests to analyze differences in diagnosis and baseline characteristics between patients with 
different treatment durations.  
To clarify the relationship between the clinical variables, Pearson product-moment 
correlations were calculated: this enabled us to estimate the bivariate associations of the 
determinants (gender, age, and level of education, and, at baseline, GAF-S and GAF-F, 
HoNOS total score, motivation for treatment, and satisfaction with services); and the outcome 
variables (GAF-S and GAF-F, HoNOS total score, motivation for treatment, and satisfaction 
with services at the last assessment).  
 To unravel the interrelationships between determinants and outcome variables, we 
used structural equation modeling (SEM). This statistical tool, which performs prediction 
analyses and solves several equations simultaneously, makes it possible to unravel 
interdependencies between determinants and outcome variables. It is used in clinical research 
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to visualize the interrelationship between determinants and outcome variables, and to estimate 
the magnitudes of the effects of the determinants. Although there are no absolute standards 
concerning sample size in relation to model complexity, it is desirable to have a minimum of 
10 patients for each parameter to be estimated. The modeling was based on the data of 569 
patients. In the final model, the number of clinical and statistical relevant parameters to be 
estimated equaled 25. As a result, the patient/parameter ratio turned out to be greater than 
10:1, which indicates a sufficiently large sample size.  
When outcomes data are used to compare the performances of the mental health care it 
can be assumed that the interdependencies between the relevant parameters are all the same, 
even for patients with different treatment durations. That is, that they ‘behave’ identically 
over time. If they do not, patients with different treatment durations represent different 
groups, which should be assessed for their outcomes separately. To test this assumption, we 
examined several SEM models to identify the best performing model using different  
treatment-duration categories; our purpose was to establish whether it was acceptable to 
impose equality constraints between the categories of treatment duration for the auto-
regressions or cross-regressions in the model. We started with a model in which the auto-
regressions between the determinants and outcome variables (identical variables) were 
constrained to be equal across patients with different treatment durations. Next, we tested a 
model in which the cross-regressions between the determinants and outcome variables 
(nonidentical variables) were constrained to be equal across patients with a different treatment 
duration. Finally, we tested a model in which no equality constrains were imposed.   
In the modeling process we started with the following determinants: gender, age, level 
of education and GAF-S, GAF-F, HoNOS total score, motivation for treatment, and 
satisfaction with services at baseline; and with the following outcome variables: GAF-S, 
GAF-F, HoNOS total score, motivation for treatment, and satisfaction with services at the last 
assessment. We used maximum likelihood estimation, as it is a statistically efficient method 
(Jöreskog, 1973) for fitting the statistical model to the data, and for providing estimates for 
the model's parameters. To allow parsimonious modeling (thereby reducing the complexity), 
we also determined whether it was acceptable for each path to be removed while remaining a 
good fit. We started at the end of the model, guiding this process by the Modification Index 
(Sörbom, 1989). We used standardized regression coefficients as estimates of the magnitude 
of the effect of the path; theoretically, these ranged from -1.00 (perfect negative association) 
to 1.00 (perfect positive association). For each model, we evaluated the fit by examining the 
individual parameter estimates, measures of overall fit, and detailed assessment of fit (fitted 
and standardized residuals and modification indices).     
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To evaluate the model fit, we used the following performance measures: 1) chi-square 
for model fit (low and non-significant values of the chi-square are desired); 2) chi-
square/degrees of freedom-ratio (a value <2.0 was predefined as being acceptable); 3) 
Comparative Fit Index (CFI); 4) Tucker-Lewis Index (TLI) (CFI and TLI: values of >0.95 
suggest a good fit; high values are desired, but values >1.0 indicate over-identification); 5) 
root-mean-square error of approximation (RMSEA; a value <0.05 indicates a close fit); and 6) 
standardized root mean square of residuals (SRMR; a value of <0.05 indicates a good fit). 
 The SPSS statistical package version 15.0 (SPSS, Inc., Chicago, IL) was used for the 
chi-square test, ANOVA and the calculation of correlation coefficients. M-plus version 5.2.1 
(Muthén and Muthén, Los Angeles, CA) was used for SEM. Results of individual parameters 
were regarded as statistically significant if two-sided p was <0.05.  
Results 
Patients 
Five hundred and sixty-nine patients were enrolled, 77% of them male. The mean time 
patients spent in contact with services was 21.7 months (SD = 13.4; range: 3 to 67). The mean 
age at the first assessment was 40.3 years (SD = 11.2; range: 18-79). The diagnosis was 
schizophrenia or other psychotic disorder for 71.7% of all patients; 34% were diagnosed with 
a coexisting substance-use-related disorder. A small proportion of patients (5.6%) were 
diagnosed with an affective disorder (first listed); in 4.7%, the diagnosis or condition had 
been deferred or was missing.  
          
Clinical characteristics  
Table 1 shows the association between patient characteristics and baseline values and 
treatment duration. There were statistical differences in diagnosis and other baseline patient 
characteristics. Fewer patients with shorter treatment duration were diagnosed with a 
psychotic disorder, substance-use disorder or combination of both (dual diagnosis). Patients 
with a longer treatment duration had lower GAF-S and GAF-F scores at baseline. The same 
was found for the baseline values of the HoNOS total scores, which were lower (i.e. there 
were fewer problems) for patients with a shorter treatment duration than for those with a long 
duration of ACT.  
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Interrelations of determinants and outcome variables 
Table 2 presents Pearson product-moment correlation coefficients of determinants 
(demographic and clinical variables at baseline) and outcome variables (the last assessed 
clinical outcome variables). The correlations of the demographic variables with the other 
determinants and with the outcome variables were only small. As expected, the auto-
correlations (i.e., correlations of two identical variables assessed at different moments) of all 
outcome variables turned out to be both substantial and significant (table 2). There were also 
some substantial cross-correlations (i.e., correlations between two different variables assessed 
at different moments). 
  
Treatment-duration models
Table 3 shows the performance measures of the treatment-duration models subjected to SEM 
analysis. To ascertain whether the auto-regressions could be constrained to be equal for the 
three categories of treatment duration, we tested the first model that had some clinical and 
statistical relevant cross-regressions and auto-regressions. This model was rejected because of 
the significant chi-square value for model fit (Ȥ2= 152.17; df=55; p=0.001). 
 The second model was similar to the first, but now the cross-regressions were 
constrained to be equal for the three categories of treatment duration. This model also showed 
a significant chi-square for model fit (Ȥ2 = 76.96; df=55; p=0.03). The model fit was probably 
better because the auto-regressions were no longer constrained to be equal.  
The third model tested was similar to the first, but now with no constraints regarding 
the cross- and auto-regressions between the different treatment-duration categories. This 
resulted in an adequate model fit, as the chi-square test for model fit turned out to be non-
significant (Ȥ2 = 58.69; df=45; p=0.09). The third model was thus considered the best-
performing model, as it showed that associations between the determinants and outcome 
variables were different between the three treatment-duration groups. This reflects 
significantly different treatment courses, each course associated with a different treatment 
duration, among distinguishable patient groups in ACT teams. To differentiate between the 
three categories of treatment duration, Figure 1 shows the standardized coefficients of model 
3. 
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Auto-regressions and cross-regressions for the treatment-duration model 
The auto-regressions of all variables for the three categories of treatment duration were 
dissimilar, ranging from non-significant, to small, medium and large. The cross-regressions 
between all variables were also dissimilar for the three categories of treatment duration. The 
cross-regressions in the short and medium treatment duration categories were minor. For the 
long treatment-duration category, most of the effects could be considered to be moderate.  
Discussion 
We used a large study population (569 ACT patients) to assess the impact of treatment 
duration on the interpretation of Routine Outcome Monitoring (ROM) data. Our results 
showed that diagnosis, clinical characteristics and interdependencies among baseline and 
outcome variables differed between patients who had undergone long-term ACT and those 
whose ACT services had been shorter. This indicates that ROM datasets such as those used in 
our study contain distinct patient sub-populations that may need to be analyzed separately for 
their outcomes. 
Duration of ACT 
Patients’ first contact with the mental health services started about a decade before they 
entered ACT (Kortrijk, Mulder, van der Gaag, & Wiersma, 2012). Our results demonstrate a 
clear association between duration of ACT and patient characteristics: longer treatment was 
associated with higher numbers of patients with a psychotic disorder, with substance-use-
related disorder, with a combination of both (dual diagnosis), and with more severe 
psychosocial problems at baseline.  
Unlike patients without a comorbid substance-use disorder, dual-diagnosed patients 
usually had a poor prognosis (Green, Drake, Brunette, & Noordsy, 2007; Kortrijk et al., 2010; 
Mueser et al., 2000) This was due to higher risks of poor response to pharmacologic 
treatment, non-adherence to psychotropic medication, increased symptom severity, relapses, 
hospitalizations, infectious illnesses, suicide, victimization, violence, incarceration and 
homelessness (Abram & Teplin 1991; Bartels, Drake, & McHugo, 1992; Dixon, 1999; 
Swoffoord, Kasckow, Scheller-Gilkey, & Inderbitzin, 1996). It is therefore understandable 
that those with high levels of psychosocial problems at the start of treatment and those with 
poor prognosis both remain in ACT.  
 There are several more reasons that a particular patient would have been in either the 
short, medium or long-duration treatment group. The first involves the time a patient was 
admitted to ACT. Irrespective of his or her demographic and clinical characteristics, a patient 
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admitted in 2008 would by definition have been treated for a shorter period (and have had 
fewer ROM assessments) than one admitted to ACT in 2003. Despite this, we found 
significant differences in patient characteristics among patient groups with different treatment 
durations. 
The second reason is that patients could drop out of ACT for several reasons – because  
they no longer needed ACT and had been referred elsewhere, for example, or because the 
ACT team had lost contact with them for other reasons (see limitations). 
As our use of Structured Equation Modeling (SEM) showed, the best-performing SEM 
model for treatment duration indicated that the auto- and cross-regressions were not equal 
across groups of different treatment duration (i.e. short, medium or long). This means that the 
interrelationships between the clinical outcome variables and their relation with patient 
characteristics varied from one category of treatment duration to another. These differences 
between the short, medium and long treatment duration groups are unlikely to have been 
caused solely by longer treatment duration: the SEM analyses showed a mix of decreasing 
and increasing sizes of cross-relationships and auto-relationships (i.e. different 
interdependencies for each treatment duration group). Having combined these findings, we 
argue that each of the groups – each of whose ACT was of a different duration – represents a 
distinct patient sub-population that should thus be regarded as a heterogeneous population. No 
group should be analyzed with all the others as if they all comprised a homogeneous group.   
Implications 
In our judgment, our results provide evidence that patient characteristics and the duration of 
follow-up should be taken into account when ROM data are used.  
While Young et al. (2001) suggest that the problem of informative drop-out should be 
overcome by collecting outcome data from patients who have left care, we feel that it is not 
only time-consuming to correct for biases by collecting outcome data, but also inconsistent 
with the primary goal of ROM. As money and clinician-time are required to collect outcome 
assessments from patients who have left care (Walter, Krikby, & Marks, 1998), such a 
procedure would be unlikely to be implemented as part of a ROM system. Neither is it likely 
that these data will actually correct for biases, as these patients no longer receive the same 
treatment.  
A more practical way of dealing with this problem would be to analyze the outcome 
data in more homogenous cohorts – on the basis, for example, of treatment duration. This 
would produce analyses that were more accurate and less biased. Policymakers, researchers 
and clinicians should note that if outcome data were analyzed over a long period, it would 
produce analyses of patients whose serious and chronic psychiatric condition required long-
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term treatment. Keeping this in mind, other more valid questions could then be formulated in 
the context of ROM. If account were taken of treatment duration and patient characteristics, 
one might thus ask not how effective 3 years of ACT is, but what the outcomes are of the 
patients who are treated in it. 
Thus, if one does not consider baseline patient characteristics, treatment duration and 
drop-out scores, it is impossible to compare measures such as the HoNOS in a ROM dataset 
of patients in standard community care with HoNOS scores of patients in ACT, as the drop-
out rates of the former may be higher than those of the latter (Sytema, Wunderink, Bloemers, 
Roorda, & Wiersma, 2007). When outcome data from a patient dataset – of ACT patients, for 
example – was analyzed over a long period of time, it would be possible to pay less attention 
to patients whose treatment duration was shorter. Because such patients differ from those 
whose treatment was longer, no data are randomly missing. In addition, if a patient’s 
condition deteriorates and the patient therefore leaves care (because, for example, he or she 
was committed for a long period), patients may not all be assessed at that critical time point of 
leaving. In such cases, missing data in the ROM dataset would, once again, not be random 
(and may not even depend on the observed outcome data). This also suggests that the impact 
of treatment duration on the interpretation of the outcome data may be different if the 
outcome data includes data from less severely mentally ill patients who did not require ACT 
for a long period. In our opinion, outcome data would thus be analyzed more accurately if the 
analyses accounted for time since start of treatment. By creating more homogeneous 
subgroups, this would deal with one of the problematic confounders in a manner that was 
consistent with the primary goals of ROM.  
Strengths and limitations  
Our study is characterized by a number of strengths, including a large study population of 
difficult-to-engage patients and the use of SEM as a statistical technique for modeling 
complex pathways in our analysis. By unraveling the relationships between variables in a 
ROM dataset from patients receiving ACT, we were able to visualize complex pathways, 
thereby making possible biases more easily comprehensible. These insights into ROM data 
may provide points of departure for the formulation of research questions relevant to 
evaluating the performance of mental health services.  
However this study has several limitations. First of all we stress that, in the 
classification system for treatment duration in ACT services in Rotterdam, it makes sense to 
post-stratify treatment duration the way we did in order to differentiate between patient 
groups. However, these treatment duration periods may not necessarily be identical for other 
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services in other places. Our categorization of patient groups is therefore fairly arbitrary. 
Similarly, because it is unknown beforehand how long patients with a short duration of ACT 
will remain in treatment, heterogeneous groups may still arise.  
Our research focused on treatment duration and did not include information on 
attrition and the reasons for it. It is important to know whether patients stopped ACT because 
their condition improved, or because it worsened, leading to consequences such as long-term 
hospitalization. To generate a more comprehensive understanding of selection biases in ROM 
procedures, future studies should examine attrition and its causes, and relate them to treatment 
duration and clinical outcome. 
With regard to the modeling process, we acknowledge that the position of the 
variables might be debated. In our model, the demographic variables were placed adjacent to 
the determinants, allowing a confounding impact on the outcome variables. The alternative 
would be a non-confounding approach that used the demographic variables as a determinant 
variable for baseline measures. We should also mention that the SEM analyses were based on 
the manifest variable – i.e., those observed. Due to its complexity, we refrained from ideal 
modeling which is latent variable modeling.  
We also feel that the results cannot be generalized to other, non-severely mentally ill 
(SMI) populations. Our SMI patients were receiving long-term treatment in the context of 
ACT: it is inherent to this that they lacked motivation for treatment at the start of ACT, and 
that they had a severe mental illness. If our outcome data had included data on patients in 
whom shorter treatment was more likely (such as those with depressive or anxiety disorders), 
treatment duration might have had a very different impact on our outcome data.  
 
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Chapter 3.1 - Outcome 
Symptomatic and functional remission and its associations with 
quality of life in psychotic disorder patients in Assertive Community 
Treatment teams 
Kortrijk, H.E., Mulder, C.L., van der Gaag, M., & Wiersma, D. (2012). Symptomatic and 
functional remission and its associations with quality of life in psychotic disorder patients in 
Assertive Community Treatment teams. Comprehensive Psychiatry, Epub ahead of print.
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Abstract 
Objectives: (1) to determine the proportion and characteristics of patients treated in 
Assertive Community Treatment (ACT) teams who achieve symptomatic remission (SR) 
and/or functional remission (FR), (2) to explore the association between both types of 
remission, and (3) their bearing on quality of life. 
Methods: Data comprised assessments from 278 patients, who were repeatedly assessed 
using the Positive and Negative Syndrome Scale (PANSS) to assess SR, the Health of the 
Nation Outcome Scales (HoNOS) to assess FR and a shortened version of the Manchester 
Short Assessment (MANSA) to assess Quality of life (QoL). Chi-square tests and a logistic 
regression analysis were used to analyze the relation between patient and treatment 
characteristics and achieving SR or FR. A Kruskall-Wallis test, Mann-Withney U tests and 
a logistic regression analysis were used to analyze the relationship between remission status 
and quality of life. 
Results: After a mean treatment duration of 2.4 years 26% met the criteria for SR and 30% 
for FR. Prescription of antipsychotic medication was associated with both achieving SR and 
FR. Approximately half of the patients who achieved SR also achieved FR. Achieving FR 
was associated with better QoL. Patients in SR did not have better QoL than patients not in 
SR. 
Conclusions: Remission of symptoms in patients treated in ACT-teams was not a 
prerequisite for functional remission or vice versa. FR, not SR, was associated with better 
quality of life.
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Introduction
Outcome in schizophrenia is a multidimensional construct, including symptom level, 
functioning and quality of life (Eack & Newhill, 2007; Isaac, Chand, & Murthy, 2007; 
Mortimer, 2007; Priebe, 2007). Symptomatic remission (SR) is often used to measure the 
success of treatment and can be defined as a state characterized by a fall in the severity of 
symptoms with a low to mild symptom threshold over a meaningful period of time 
(Andreasen et al., 2005; Harvey & Bellack, 2009; van Os et al., 2006). Andreasen et al. 
(2005) proposed criteria for SR as a low to mild symptom level (positive, negative and 
disorganized symptoms) for more than six months, with no impact on the individual’s 
behavior. Outcome can also be assessed in terms of functional remission (FR) (Wunderink, 
Sytema, Nienhuis, & Wiersma, 2009), although to date no generally accepted definition of 
FR exists ( Bodén, Sundström, Lindström, & Lindström, 2009; Harvey & Bellack, 2009; 
Lambert, de Marinis, Pfeil, Naber, & Schreiner, 2010; Liberman, Kopelowicz, Venture, & 
Gutkind, 2002). Defining FR may be more difficult because there is no societal norm or 
clear reference for the level of functioning in daily life (for instance about being employed, 
social role, independent living and the quality of social contacts) (Essock & Sederer, 2009; 
Harvey & Bellack, 2009). Some authors propose that FR in psychotic disorder patients 
consists of adequate functioning in a variety of important life domains including social 
relationships, productive activities, activities of daily living and living conditions (Harvey 
& Bellack, 2009). Wunderink et al. (2009) suggest that FR should reflect appropriate social 
role functioning in the main domains of everyday life, such as occupation, social 
relationships, citizenship, and partnership. Based on similarities in the descriptions of FR 
we propose to define FR as adequate or no more than minimal or mild disabilities in social 
functioning, daily-life activities and living conditions. 
 To date, it is unknown whether SR is a prerequisite for FR, and which one of the two 
is associated with quality of life (QoL). Two recent studies (Henry et al., 2010; Wunderink 
et al., 2009) showed that patients meeting the SR criterion did have better levels of 
functioning than patients not in remission. However there was no evidence that achieving SR 
was an essential precondition for appropriate functioning.   
 Results of studies on the associations between SR and/or FR and QoL are 
inconsistent (Dunayevich, Sethuraman, Enerson, Taylor, & Lin, 2006; Galuppi, Turola, 
Nanni, Mazzoni, &  Grassi, 2010; Harvey & Bellack, 2009; Helldin, Kane, Karilampi, 
Norlander, & Archer, 2008; van Os et al., 2006; Wunderink et al., 2009). Some authors 
suggest that there is no clear relation between the level of functioning or symptoms and QoL 
(Harvey & Bellack, 2009; Wunderink et al., 2009), while others have argued that the 
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severity of the symptoms as well as the level of social functioning is of importance for 
quality of life (Dunayevich et al., 2006; Galuppi et al., 2010; Helldin et al., 2008; van Os et 
al., 2006). 
 Therefore in this study we determined the proportion of patients treated in Assertive 
Community Treatment teams (ACT) who achieved SR and/or FR, examined which patient 
and treatment characteristics were associated with achieving SR and/or FR, and explored the 
association between both types of remission, and their bearing on quality of life. 
Methods
Setting and patients
The study involved psychotic disorder patients from seven ACT teams in the city of 
Rotterdam, the Netherlands. Criteria for treatment by an ACT team were (1) age 18 or 
older, (2) having a severe mental illness, usually a psychotic disorder, with or without a 
comorbid substance use disorder (SUD), and (3) a lack of motivation for regular treatment 
at the start of ACT that made assertive outreach necessary. 
Data collection
Data from this study was obtained as part of a routine outcome-monitoring (ROM) 
procedure. The ROM assessments included several instruments and were planned every six 
months. The assessments were completed by independent raters (mostly psychologists), and 
were used in clinical practice to discuss treatment progress with the patient. ROM data-
collection was approved by the Dutch Committee for the Protection of Personal Data. Data 
for the present study were used anonymously. In addition to the ROM assessments, data was 
collected on gender, age, ethnicity (country of birth), education level, age of first contact 
with mental health services, DSM-IV diagnoses (as made by the psychiatrist of the ACT 
team), being prescribed antipsychotic medication (yes or no), and duration of treatment in 
ACT. 
Instruments
Assessment of Symptomatic Remission
To assess SR, we used 8 items of the Positive and Negative Syndrome Scale (PANSS)   
proposed by the Remission in Schizophrenia Working Group (Andreasen et al., 2005). SR 
was defined as scores of  3 over a six-month period or more for eight items: P1 (delusions), 
P2 (conceptual disorganisation), P3 (hallucinatory behaviour), N1 (blunted affect), N4 
(social withdrawal), N6 (lack of spontaneity), G5 (mannerisms/posturing), and G9 (unusual 
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thought content). 
Assessment of Functional Remission
We have proposed to define FR as no more than mild disabilities in social functioning, daily-
life activities and living conditions. It should be emphasized that there is no generally 
accepted definition of FR, and thus no specific instrument to assess it. In the present study, 
we used three items of the Health of the Nation Outcome Scales (HoNOS) to assess FR 
(Mulder et al., 2004; Wing et al., 1998). The HoNOS was originally developed as a 
standardized assessment tool for routine use by mental health services. It consists of 12 
clinician-rated scales, each using five points from 0 (no problem) to 4 (severe/very severe). 
The psychometric properties of the English and Dutch HoNOS scores have been found to be 
acceptable (Mulder et al., 2004; Wing et al., 1998). The following three items were used to 
assess FR: (1) everyday social functioning (item 9: relationship problems); (2) activities of 
daily living and complex skills (item 10: problems of daily living), such as budgeting, 
organising life, occupation recreation, mobility, the use of transport, and shopping; and (3) 
housing (item 11: problems with living conditions). Patients achieved FR if their disabilities 
in social functioning, daily-life activities and their living conditions were no more than 
minimal to mild – in other words, if these HoNOS items were scored  2 over a period of six 
months or more. 
Assessment of Quality of Life
The cumulative needs for care monitor (CNCM) quality of life scale was used to measure 
subjective quality of life (Drukker et al., 2010). This instrument was based on the 
Manchester Short Assessment of quality of life scale (MANSA) (Priebe, Huxley, Knight, & 
Evans, 1999). The scale consists of six items (van Os et al., 2001) including financial 
situation, accommodation, relationship with others, physical health, psychological health, 
and life as a whole, which were rated on a 7-point scale (1=“Couldn’t be worse” to 
7=“Couldn’t be better”). 
Analyses
SPSS version 15.0 was used for all analyses. First, we determined the proportion of patients 
who had been in SR and FR over the last two assessments. Using Pearson’s chi-square test 
we compared patient characteristics: gender, age (18-30, 30-40, 40-50, >50 years), ethnicity 
(born in the Netherlands or elsewhere), education level (none, elementary, lower high 
school and over), comorbid SUD (yes or no) and treatment characteristics: prescription of 
antipsychotic medication (yes or no) and treatment duration (0-1, 1-2, 2-3, >3 years of ACT 
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prior to their assessment) between patients achieving SR and/or FR versus those who did 
not. We also used Pearson’s chi-square test to explore the relationship between patients 
achieving SR and FR. 
After these analyses, logistic regression analyses were performed, including 
baseline values and all patient and treatment characteristics as predictors of SR and FR. 
Note that PANSS baseline values were not included, as they were not available. Logistic 
regression was carried out starting with a stepwise forward selection, predictors required a 
probability value of P<0.25 for entry into the model, then subsequently the predictors were 
removed at a probability value of P>0.05 using the stepwise backward elimination 
procedure and a log likelihood test. Next interaction terms were calculated, followed by a 
forward stepwise (P>0.25) and backward elimination (P>0.05) procedure of these 
interaction terms (Hosmer & Lemeshow, 2000).  
To explore the relationship between remission (SR and FR) and their bearing on 
QoL, we analyzed the relationship between remission status and QoL (total score) during 
the last ROM assessment using a Kruskall Wallis test and Mann-Withney U-tests. 
Afterwards a logistic regression analysis was performed, including baseline QoL scores 
and remission status (SR and FR) as predictors of QoL (dichotomized via median split). 
Results
Patients
Within all seven ACT teams, in total 519 patients were diagnosed with a psychotic disorder. 
ROM outcome data (two repeated complete HoNOS and PANSS assessments) was obtained 
from 278 patients, representing 54% of all ACT patients with a psychotic disorder. Based on 
the patient characteristics these patients appeared to be representative for all ACT patients 
with a psychotic disorder, as we observed that the only statistical significant difference 
between these patient groups was that there were more male patients in our patient selection 
(82% in the ROM group and 77% in the total group). We observed no other statistically 
significant differences with respect to age, ethnicity or education level. 
Most patients were male (82.4%) and had a mean age of 41.4 years (SD=10.8). Only 
44.2% was born in the Netherlands. Diagnosis for all patients included in the study was 
schizophrenia or other psychotic disorder. Forty-nine percent was also diagnosed with a 
comorbid SUD. The mean treatment duration from the start of Assertive Community 
Treatment (ACT) was 2.4 years (SD=1.5) and the first contact with mental health services 
started about a decade before entering in ACT (mean 10.4 years; SD=9.0 years). The time 
period between the two last consecutive ROM assessments, which constituted the remission 
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assessment period, consisted of an average timeframe of 9.6 months (SD=4). 
Proportions of symptomatic and functional remission (table 1)
SR was achieved by 72 (26%) of the 278 patients, and 84 patients (30%) met the criteria for 
FR; 160 patients (58%) achieved neither SR nor FR and 38 patients (14%) achieved both SR 
and FR. 
Of the 72 patients in SR, 38 (53%) also met the criteria for FR; of the 84 patients in 
FR, 38 (45%) were also in SR (table 1). These data do not suggest a sequential relationship 
between SR or FR, indicating that SR and FR do not seem to be pre-requisites for one 
another in this sample. The chi-square test for the association between SR and FR (Ȥ2 
=23.457, df=1, p<0.001) however, showed that the proportion of patients in SR who 
achieved FR (53%), differed from the proportion of patients who did not achieve SR but 
achieved FR (22%) (Odds ratio=3.887; 95% CI=2.205 – 6.854). 
Table 1. Symptomatic and functional remission in 278 patients after a mean of 2.4 
years (SD =1.5) of treatment in ACT teams 
   FR N (%)   NFR N (%)  Total N (%)  
SR N (%)  38 (R 52.8%)  34 (R 47.2%)  72 (R 100%) 
   (C 45.2%)  (C 17.5%)  (C 25.9%)  
NSR N (%)  46 (R 22.3%)  160 (R 77.7%)  206 (R 100%) 
   (C 54.8%)  (C 82.5%)  (C 74.1%)  
Total N (%)  84 (R 30.2%)  194 (R 69.8%)  278 (R 100%) 
   (C 100%)  (C 100%)  (C 100%)  
SR = symptomatic remission; NSR = no symptomatic remission; FR = functional remission; NFR = no  
functional remission; N= number of patients; R= row percentage; C = column percentage. 
Table 2 presents patient characteristics and their associations with SR and FR, 
respectively. These analyses showed that younger age, presence of a SUD and the 
prescription of antipsychotics were associated with achieving SR. Younger age and the 
prescription of antipsychotics were also associated with achieving FR. Logistic 
regression analyses (table 3) showed that only the prescription of antipsychotics 
remained as an independent predictor of achieving both SR and FR.  
Remission & Quality of Life (table 4)
Patients who were in SR (irrespective of FR) had higher QoL scores than patients who 
were not in SR (Z=-2.338, p=.019). The same was found concerning patients in FR 
(irrespective of SR), also reporting a significantly higher QoL compared to those who were 
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not in FR (Z=-4.376, p<.001). When patients were divided into the following four groups: 
(1) SR plus FR, (2) SR but no FR, (3) FR but no SR and (4) no SR plus no FR, they 
showed significant differences in QoL total scores (Kruskall-Wallis test: Ȥ2=21.203, df=3, 
p<.001). Further analyses showed that patients who were both in FR as well as in SR 
(Group 1) had better QoL scores compared to patients who were in neither FR nor SR 
(Group 4) (Z=-4.107, p<.001). However there was no difference in QoL between patients 
who were only in SR (Group 2) versus those who were neither in SR nor FR (Group 4) 
(Z=-.552, p=.581). Interestingly, patients only in FR (Group 3) had better QoL than 
patients who were neither in FR nor SR (Group 4) (Z=-2.825, p=.005). A logistic 
regression analysis confirmed these findings indicating that only FR was independently 
associated with QoL (ȕ=2.584, p=.011; 95% CI = 1.248 – 5.349). 
Table 3. Logistic Regression Analyses for the association between demographic 
variables, SUD and medication use and symptomatic remission and functional remission, 
respectively 
SR: R2= .036 (Nagelkerke), Hosmer & Lemeshow Goodness of Fit: Ȥ² = -, p= -; FR: R2= .064 
(Nagelkerke), Hosmer & Lemeshow Goodness of Fit: Ȥ² = 4.556, p=.102; 1 P<.05 2 P<.01 
Table 4. Quality of life total scores in ACT patients with or without symptomatic or 
functional remission  
QoL total score     FR    NFR  
      Median (IQR)   Median (IQR) 
SR      33 (31 - 37)   29 (24 - 34) 
NSR      32 (28 - 35)   28 (22 - 34) 
SR = symptomatic remission; NSR = no symptomatic remission; FR = functional remission; NFR = no 
functional remission; IQR = interquartile range. 
   95% CI for Exp(B) 
Symptomatic remission (SR) Beta (SE) Lower Exp(B) Upper 
Constant -1.745 (.327)² - 0.175 - 
Prescription of antipsychotic medication 0.884 (0.361)¹ 1.192 2.42 4.912 
      
Functional remission (FR) Beta (SE) Lower Exp(B) Upper 
Constant -.239 (.224) - 0.778 - 
Prescription of antipsychotic medication 1.069 (.37)² 1.409 2.911 6.013 
Baseline FR 1.341 (.284)² 2.193 3.823 6.664 
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Table 2. Characteristics of patients achieving symptomatic and functional remission  
    
N=278       
(%)*  
N (%)**   
in SR 
N (%)**  
not in SR Ȥ²  SR 
N (%)**  
in FR 
N (%)**   
not in FR Ȥ²  FR 
Sex                 
  Male 229 (82.4%) 59 (25.8%) 170 (74.2%) n.s. 69 (30.1%) 160 (69.9%) n.s. 
  Female 49 (17.6%) 13 (26.5%) 36 (73.5%)   15 (30.6%) 34 (69.4%)   
Age                 
  18-30 years 50 (18%) 18 (36%) 32 (64%) p <.1 21 (42%) 29 (58%) p <.1 
  30-40 years 78 (28.1%) 22 (28.2%) 56 (71.8%)   25 (32.1%) 53 (67.9%)   
  40-50 years 84 (30.2%) 23 (27.4%) 61 (72.6%)   26 (31%) 58 (69%)   
  >50 years 64 (23%) 9 (14.1%) 55 (85.9%)   12 (18.8%) 52 (81.3%)   
  Missing 2 (.7%)             
Ethnicity                  
  Native 123 (44.2%) 31 (25.2%) 92 (74.8%) n.s. 34 (27.6%) 89 (72.4%) n.s. 
  Non native 155 (55.8%) 41 (26.5%) 114 (73.5%)   50 (32.3%) 105 (67.7%)   
Level of education                
  None  26 (9.4%) 8 (30.8%) 18 (69.2%) n.s. 6 (23.1%) 20 (76.9%) n.s. 
  Elementary 38 (13.7%) 11 (28.9%) 27 (71.1%)   12 (31.6%) 26 (68.4%)   
  Lower and over 161 (57.9%) 42 (26.1%) 119 (73.9%)   48 (29.8%) 113 (70.2%)   
  Missing 53 (19.1%)             
Substance use               
  SUD 137 (49.3%) 43 (31.4%) 94 (68.6%) p<.05  44 (32.1%) 93 (67.9%) n.s. 
  No SUD 141 (50.7%) 29 (20.6%) 112 (79.4%)   40 (28.4%) 101 (71.6%)   
Medication use               
  Prescription of AP 202 (72.7%) 60 (29.7%) 142 (70.3%) p <.05 73 (36.1%) 129 (63.9%) p <.05 
  No prescription of AP 74 (26.6%) 11 (14.9%) 63 (85.1%)   11 (14.9%) 63 (85.1%)   
  Missing 2 (.7%)             
Treatment duration                
  0-1year 57 (20.5%) 15 (26.3%) 42 (73.7%) n.s. 22 (38.6%) 35 (61.4%) n.s. 
  1-2 years 70 (25.2%) 18 (25.7%) 52 (74.3%)   20 (28.6%) 50 (71.4%)   
  2-3 years 62 (22.3%) 15 (24.2%) 47 (75.8%)   16 (25.8%) 46 (74.2%)   
  >3 years 87 (31.3%) 23 (26.4%) 64 (73.6%)   26 (29.9%) 61 (70.1%)   
  Missing 2 (.7%)             
* Column percentage; ** Row percentage; SR: Symptomatic remission; FR: Functional remission; Ȥ²: Pearson’s chi square test; 
SUD: Substance use related disorder; AP: antipsychotics. 
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Discussion
Remission frequencies
Our results showed that 26% of the patients achieved SR, and 30% achieved FR after a 
mean of two and a half years of ACT. Being prescribed antipsychotic medication was 
associated with achieving SR and FR. FR, but not SR was associated with QoL. 
Symptomatic and functional remission
In our study the prescription of antipsychotic medication was related to both achieving SR 
and FR. It may be that the use of medication increases the chance of achieving SR and FR or 
that those patients accepting medication have a better prognosis, independent of the 
medication itself. The observational design of the present study does not allow us to 
determine causality. 
On average SR rates in patients from our study were slightly inferior to those found 
by Shida et al. (2008) and Lambert et al. (2010) who found that one in three of their 
patients were in SR after a period of about one year. A study in first-episode patients 
reported 52% SR over a two-year follow-up (Wunderink et al., 2009). Other studies even 
reported SR rates of 60% over three to five-year periods (Eberhard, Levander, & 
Lindstrom, 2009; Gasquet, Haro, Tcherny-Lessenot, Chartier, & Lépine, 2008; Haro & 
Salvador-Carulla, 2006) and of 66% over a two-year period (Verghese et al., 1989). These 
discrepancies are likely to be related to the duration of follow-up, treatment history and 
patient characteristics. Patients in ACT often show less treatment engagement and 
medication adherence, possibly leading to a relatively worse outcome. Also our patient 
sample was older as compared the study using first episode patients. With regard to the 
possible impact of age several factors may negatively influence SR. Firstly, the impact of 
prolonged (untreated) illness and secondly higher age may reflect a filtering of chronically 
difficult to engage patients in an ACT team. Most patients treated in our ACT teams were 
in contact with mental health services for more than a decade.  
Interestingly, we found approximately the same FR rates as compared to the study 
by Wunderink and colleagues (2009), who found FR rates of 26.4% after a two-year period 
in first-episode patients using the Groningen Social Disabilities Schedule (GSDS). Other 
studies showed different proportions of patients achieving FR. For example, one study by 
San and colleagues using a restrictive threshold of at least 81 points on the Global 
Assessment of Functioning scale (GAF) reported that social functioning was adequate in 
only 10.2% of all schizophrenia patients (San, Ciudad, Álvarez, Bobes, & Gilaberte, 2007). 
Another study using the WHO Disability Assessment Schedule showed that only 14% of 
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schizophrenia patients had no functional disability after 15 years of follow-up (Wiersma et 
al., 2000). In the present study however, we allowed for some minimal disability, so the 
incongruence between these studies is likely to be related to the use of different scales and 
definitions of FR, which may have affected the remission rates (Lauronen et al., 2007). 
Therefore we were not able to make valid comparisons with other studies. 
 We found no evidence of a temporal sequence for SR following FR, since more 
than half of the patients who achieved SR also achieved FR, and almost half the patients 
who achieved FR also achieved SR. If a temporal sequence would have been the case, 
more patients who achieved SR would also have achieved FR or vice versa. This is only 
partly in line the assumptions of Weiden and  Zygmunt (1997) and Priebe (2007), who 
suggested that the presence of more symptoms is associated with worse functioning. 
Based on our data however, it does not seem necessary to focus on achieving SR first in 
order to achieve FR. 
Remission and quality of life
Patients who achieved FR, irrespective of SR, reported better QoL than patients who 
did not achieve FR. Achieving SR without FR, however, was not associated with a 
better quality of life. The association of FR with QoL suggests that FR is a desirable 
treatment goal for patients, family and clinicians.
These results are in partial disagreement with those of Wunderink et al. (2009), who 
found that neither SR nor FR were associated with QoL. This discrepancy may be due to 
the levels of QoL in their sample of first-episode psychosis patients, which were generally 
much higher than ours. While Harvey and Bellack (2009) suggest that “subjective well-
being does not have a clear correlational relationship with other symptomatic and 
functional features of the illness”, our results indicate that FR is associated with better QoL, 
but that SR is not. By showing that SR tends to be of less importance for patients' well-
being than FR, our results thus contrast with those of other studies (Dunayevich et al., 
2006; Galuppi et al., 2010; Helldin et al., 2008; Hofer et al., 2005). 
Limitations 
Our results were based on 54% of all ACT patients with a psychotic disorder. Although we 
did not find statistical differences between both patient groups, except for gender, the 
generalizability of the results to all ACT patients treated in our center remains unknown. 
Also, our patient group differed from the patient groups in other studies, making it difficult 
to compare results, as stated above.  
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Another  limitation of the work presented here is the missing data in our study. 
Firstly we had no data on PANSS assessments at baseline. Therefore, the true relation 
between patient and treatment characteristics and SR could not be properly assessed, as we 
were not able to adjust for baseline values of SR. Secondly the missing rate of self-reports 
on quality of life was high (38.8%). Although we found no evidence of a relation between 
the missing self-reports and socio-demographic variables, patients with missing self-reports 
tend to have more severe problems (FR). This means that the differences found in QoL 
scores between patients in FR and those not in FR may have been be underestimated. 
An important conceptual limitation of our study is that we used a specific definition 
of FR, based on three items of the HoNOS. Therefore, we acknowledge that our assessment 
of FR was a rather crude measure for FR. Although this definition is in line with proposed 
criteria of FR (Harvey & Bellack, 2009; Wunderink et al., 2009), other studies used other 
scales for assessing FR. Using the HoNOS, however, has the advantage that this scale is 
widely used in clinical practice in many countries and easy to administer. In doing so, we 
feel that it is important to emphasize and underline the expert-opinion of Mausbach and 
colleagues who argue that we should try to use existing measures for assessing functioning 
that are already in routine use (Mausbach, Moore, Bowie, Cardenas, & Patterson, 2009). 
New instruments with the sole purpose to measure FR will increase the risk that these 
instruments will be used only in research but not in clinical practice. For this reason, we 
believe that HoNOS is an appropriate instrument to assess FR.  
Apart from the question which instrument to use for measuring FR (e.g. the GAF, 
WHO-DAS, GSDS, HoNOS or another instrument), differences in cut-off levels are also 
important. We defined FR as the three relevant HoNOS items scoring  2 (mild severity). 
However, FR might also be operationalized more stringently, for example using a cut-off 
score of  1 (minimal severity). In that case only 2.3% of our patients would have achieved 
FR (implying no or minimal disabilities). Using those criteria would mean that FR is nearly 
unachievable for patients receiving ACT, and therefore these stringent criteria do not seem 
appropriate to assess FR.  
Since we found higher FR rates than in other studies (San et al., 2007; Wiersma et al., 
2000), this may suggest that our definition of FR was less stringent. In the absence of a 
consensus definition of FR, this remains unknown. We believe that our definition included 
important life domains (social functioning, daily-life activities and living conditions). It may 
be that when FR would be defined more stringently e.g. as having work, living 
independently and having an appropriate social role, the proportion of patients achieving FR 
might be lower. For that reason, it is likely that our results concerning FR are a product of its 
assessment. After all, anyone in a job will plainly be hampered by severe psychotic 
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symptoms. Thus our outcomes concerning FR rates and its associations with SR are best 
understood as the result of the operationalization of FR, being: proper housing, self-care and 
social contacts. Following from this, it is clear that different assessment methods or cut-off 
criteria contribute to discrepant findings (i.e. 2.3% achieving FR and a different relation 
between FR and SR). However, we feel it is very difficult and complex to create specific FR 
norms as no absolute reference exists, and because these norms may be related to factors 
such as age or a downward economic situation. 
Conclusions 
SR was achieved by 26% of ACT patients after an average period of two and a half years 
and 30% reached FR. SR did not seem to be a pre-requisite for FR or vice versa. Patients 
who achieved FR, irrespective of SR, reported better quality of life than those who did 
not, supporting the choice of FR as a desirable treatment goal for patients, family and 
clinicians. 


Chapter 3.2 - Outcome 
Treatment outcome in patients receiving Assertive Community 
Treatment 
The results of study were published as: Kortrijk, H.E., Mulder, C.L., Roosenschoon, B.J., & 
Wiersma, D. (2010). Treatment outcome in patients receiving Assertive Community 
Treatment. Community Mental Health Journal, 46, 330-336.   
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Abstract: 
Introduction: In an observational study of severely mentally ill patients treated in Assertive 
Community Treatment (ACT) teams, we investigated how treatment outcome was associated 
with demographic factors, clinical factors, and motivation for treatment.  
Methods: To determine psychosocial outcome, patients were routinely assessed using the 
Health of the Nation Outcome Scales (HoNOS). Trends over time were analyzed using a 
mixed model with repeated measures. The HoNOS total score was modeled as a function of 
treatment duration and patient-dependent covariates.  
Results: Data comprised 637 assessments of 139 patients; mean duration of follow-up was 
27.4 months  (SD = 5.4). Substance abuse, higher age, problems with motivation, and lower 
educational level were associated with higher HoNOS total scores (i.e. worse outcome). 
Discussion: To improve treatment outcome, we recommend better implementation of ACT, 
and also the implementation of additional programs targeting subgroups who seem to benefit 
less from ACT.  
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Introduction 
Assertive Community Treatment (ACT) is an intensive treatment model in which 
multidisciplinary teams provide community care for non-motivated patients with a severe 
mental illness (Bond, Drake, Mueser, & Latimer, 2001). If correctly implemented, ACT is 
regarded as an evidence-based intervention (McHugo, Drake, Teague, & Xie, 1999). Its 
primary objectives are to reduce hospital admissions, keep patients in contact with services, 
and improve psychosocial outcome (Marshall & Lockwood, 1998).  
Several studies, most of them American, have provided evidence for the effectiveness 
of ACT (Burns & Santos, 1995), whose main effects were to reduce admissions and to keep 
patients in contact with the mental health services. ACT’s effects on symptoms, housing 
stability, and subjective quality of life were less clear (Marshall & Lockwood, 2008). 
However, in European studies that compared it with standard community care, ACT had no 
effects on psychiatric hospital use, symptoms, or quality of life (Kent & Burns, 2005; Sytema, 
Wunderink, Bloemers, Roorda, & Wiersma, 2007). 
Despite the lack of European evidence for its beneficial clinical effects, ACT has been 
widely implemented in Great-Britain and other European countries (Killaspy et al., 2006), 
including the Netherlands. For this reason, with regard to ACT’s effect on symptom-
reduction, functioning and quality of life, it should be established which patients may benefit 
from ACT and which do not.  
Several studies which defined treatment outcome as level of symptoms, level of 
functioning, employment and quality of life have identified the predictive factors associated 
with poor response to various types of treatment (including ACT). Briefly, these studies 
identified nine such factors: (1) male gender (Grossman, Harrow, Rosen, & Faull, 2006); (2) 
age (Roberts, Blow, Copeland, Barry, & van Stone., 2000); (3) low educational level 
(Lauronen et al., 2007); (4) concomitant substance abuse (Batel, 2000; Dixon, 1999; Drake, 
Bartels, Teague, Noordsy, & Clark, 1993; Greenfield et al., 2006); (5) early manifestations of 
symptoms (Remschmidt, Schulz, Martin, Fleischhaker, & Trott, 1994); (6) negative 
symptoms (Wieselgren, Lindström, & Lindström, 1996); (7) lack of awareness of symptoms 
(Rossi et al., 2000); (8) poor treatment compliance (Gerlach, 2002); and (9) duration of 
untreated psychosis (Singh, 2007).  
However, to our knowledge, no studies have specifically investigated the influence of 
these predictive factors on psychosocial outcome in the context of ACT. Using an 
observational study design in patients receiving ACT over a two to three-year period, we 
therefore examined the influence of three of these predictors on treatment outcome, which  
was defined as level of symptoms and social functioning over time (HoNOS total score). We 
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used the following predictors: substance abuse, motivation for treatment, and demographic 
factors (age, ethnicity, level of education, and gender).  
Methods  
Setting 
The study involved patients from six ACT teams in the city of Rotterdam, the Netherlands. 
There were three criteria for treatment by an ACT team: (1) age 18 or older, (2) diagnosis 
with a severe mental illness (usually a psychotic or bipolar disorder, with or without a 
comorbid addiction disorder); and (3) lack of motivation for treatment at the start of ACT, 
which made assertive outreach necessary. 
Data were collected as part of a routine outcome-monitoring (ROM) procedure, and 
were used in clinical practice to discuss treatment outcome with the patient and the clinician. 
The collection of routine outcome monitoring data, which was done by independent raters 
with a Master’s degree in psychology, was approved by the Dutch Committee for the 
Protection of Personal Data. All data were analyzed anonymously. 
Model fidelity 
To assess the fidelity of the six treatment programs to ACT, we used the Dartmouth Assertive 
Community Treatment Scale (DACTS), which assesses fidelity on the basis of 28 items using 
anchored five-point scales (Bond & Salyers, 2004; Salyers et al., 2003; Teague, Bond, & 
Drake, 1998). Psychometric properties such as internal consistency, inter-rater reliability and 
sensitivity to change over time have been found to be acceptable (Bond & Salyers, 2004; 
Winter & Calsyn, 2000). A mean score of all items between 0 and 2.9 means that a treatment 
team has failed to implement ACT; a score between 3.0 and 4.1 means that ACT has been 
implemented to a moderate degree, and a score between 4.2 and 5 means that it has been fully 
implemented (Salyers et al., 2003; Teague, Bond, & Drake, 1998). 
Outcome measures 
Data were collected over the period from January 2003 to August 2008. At the start of the 
treatment and then at six-month intervals, patients were assessed using the Health of Nation 
Outcome Scales to determine psychosocial outcome (HoNOS; Mulder et al. 2004; Wing et al., 
1998). To this we added one additional observer-rated item to assess motivation for treatment.  
HoNOS was originally developed as a standardized assessment tool for routine use by 
the mental-health services. It consists of 12 observer-rated scales, each using five points from 
0 (no problem) to 4 (severe/very severe), and thus yielding a total score from 0 to 48. The 
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psychometric properties of the English and Dutch HoNOS total scores have been found to be 
acceptable (Mulder et al., 2004; Wing et al., 1998). HoNOS covers the following domains: (1) 
overactive, aggressive, disruptive or agitated behaviour, (2) non-accidental self-harm, (3) 
problem drinking and drug-taking, (4) cognitive problems, (5) physical illness and disability, 
(6) hallucinations and delusions, (7) depressed mood, (8) other psychological symptoms, (9) 
relationship problems, (10) problems with activities of daily living, (11) problems with living 
conditions, and (12) problems with occupation and activities.  
Predictors variables
The scale for assessing motivation for treatment was adapted from the Severity of Psychiatric 
Illness scale (Lyons, 1998; Mulder, Koopmans, & Hengeveld, 2005), and was scored in five 
categories in the same way as the HoNOS scale: (0) strong motivation: significant degree of 
motivation for treatment; (1) clear motivation: there may be some hesitation, but this does not 
lead to problems with motivation; (2) some motivation: there is motivation for treatment but 
also ambivalence or mild passive resistance; (3) poor motivation: the individual appears not to 
be motivated and there is passive resistance; and (4) no motivation / resistance: the individual 
actively resists treatment. On the basis of an interview with the patient and the clinician, the 
motivation for treatment scale was scored by independent raters who were not involved in the 
patients’ treatment. 
To assess substance abuse, patients were routinely assessed on the basis of two 
items—alcohol use and drug use—taken from the Camberwell Assessment of Need (CAN). 
The ratings were based on the interviewee’s perspective (as opposed to the patient’s). The 
CAN severity ratings are 0 (no need), 1 (met need) and 2 (unmet need) (Wennström, 2008).  
 We collected socio-demographic and diagnostic data on gender, age, ethnicity 
(according to the definition of the Statistics Netherlands: i.e. parents’ countries of birth), level 
of education, and DSM-IV-TR diagnoses as made by the psychiatrists of the ACT team.  
Data analysis 
SPSS version 15.0 was used for all analyses. Treatment outcome was defined as the HoNOS 
total score. Linear Mixed Models with repeated measures were used to assess the association 
of the predictors and psychosocial functioning over time. 
Factors of primary interest included time (treatment duration) and psychosocial 
functioning (HoNOS total score). To capture a curvilinear decline which would assume a 
more rapid change in the early months, the model also included a square-root transformation 
of time.  
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Predictors: All covariates were selected on the basis of a theoretically or empirically 
documented association with treatment outcome. Demographic information included 
education, age and ethnicity; other covariates were problems with motivation and substance 
abuse at baseline.  
Model: For the initial specification of the model, we included linear time, square-root 
time, HoNOS total score, demographics (age, level of education and ethnicity), motivation at 
baseline, and substance abuse at baseline. Fixed factors: To obtain the most parsimonious 
model, fixed effects were dropped in subsequent iterations and eliminated, since each effect 
was either not significantly related to the HoNOS total score, or did not appreciably alter 
outcome (likelihood ratio test; Fitzmaurice, 2004).  Patient’s identification number was used 
as a random factor (random intercept deviation). Random effects were modeled if they 
significantly contributed to the model (likelihood ratio test).  
Final model: The fixed effects in the final model were intercept, time and a square-
root transformation of time (which fitted the data better than a linear time slope alone); 
motivation at baseline; substance abuse at baseline; age; and level of education. Repeated 
measures were modeled on the assumption of a first-order autoregressive covariance structure 
(based on REML) (Fitzmaurice, 2004).  
Lastly, in an effort to replicate and supplement earlier findings (Grossman, Harrow, 
Rosen & Faull, 2006), we performed a variation of the primary analyses for men and women 
separately. Because the sample included only a small number of women, we included all 
covariates from the model (as defined above), not just covariates that were statistically 
significant. Non-significant results for the smaller group were examined to ascertain whether 
their size (ȕ) and direction were similar to those of the larger group. Although non-significant 
results might indicate that the sample size was not great enough to allow comparison between 
the groups, any differences in their magnitude or direction indicates that the results are not 
explained solely by sample size. 
Results
Patients 
The data included 637 assessments from a total of 139 patients. On average, assessments were 
6.9 months apart (SD = 1.4). The mean treatment duration of follow-up was 27.4 months (SD 
= 5.4). The mean age was 38.3 years (SD = 9.5). Diagnosis was schizophrenia or other 
psychosis for 72.3% of the patients. The patients’ characteristics are described in table 1.  
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Table 1. Patient characteristics                                
                                                  N  %   
Sex male     115  82.7% 
 female     24  17.3% 
Age <30     29  20.9% 
 30 – 39     48  44.5% 
 40 – 49     48  44.5%  
 50 – 59     12  8.6% 
 > 60     2  1.4% 
Level of education 
 no education / elementary   31  22.3% 
 secondary school    56  40.3% 
 upper high school and over  42  30.2% 
 missing     10  7.2% 
Ethnicity 
ethnic Dutch and western immigrants 65  46.7% 
 non-western immigrants (parents)  71  51.1%   
 missing     3  2.2% 
Diagnosis 
 schizophrenia    86  61.7% 
 other psychosis    15  10.6% 
 affective disorders   9  7.3% 
 substance abuse*    72  51.7% 
 missing     23  16.5% 
Previous voluntary and involuntary admissions  
 yes     76  54.7% 
 no     29  20.9%  
 missing     34  24.4% 
HoNOS total score (baseline) 
 10     7  5.1% 
11-15     23  16.6% 
 15     78  49% 
not all items available / missing**  31  22.3%  
Motivation for treatment (baseline) 
 mean score (SD)     2.29 (1.12) 
*: substance abuse as a primary or secondary diagnosis; **: these patients were included in the analyses  
Model fidelity 
The mean of the total DACTS scores of the six ACT teams was 3.5 (range: 3.4 – 3.6), 
meaning that ACT had been implemented with moderate success. The lowest scores were 
awarded to various categories pertaining to substance abuse: substance-abuse specialist on 
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staff (m= 2.8), individualized substance-abuse treatment (m= 2.8), dual-disorder treatment 
groups (m= 1.2) and dual disorders (dd) model (m=3). 
Determinants of treatment outcome for the whole group 
In the final model, the following predictors were significantly associated with the HoNOS 
total score: substance abuse at baseline (CAN score 2: serious problem on items 12 (alcohol) 
or 13 (drugs) versus 0: no problem or 1: intervention); motivation for treatment at baseline; 
education level (no education or elementary school versus lower high school and over); and 
age (< 30 years versus  30 years).  
Analysis of changes during follow-up in the HoNOS total score revealed a significant 
improvement over time (table 2: linear time: F = 7.841, p= .005, square-root time: F = 14.534, 
p<.001). Of all predictors, substance abuse at baseline was most strongly associated with the 
HoNOS total score: the main effect was (ȕ = 3.47, F = 24.414, p < .001). Because the HoNOS 
incorporates problematic alcohol use and drug taking it is evident that the HoNOS total score 
will positively correlate with substance abuse. Therefore we did 2 analyses, (1) on the relation 
between the HoNOS total score (including problematic alcohol use and drug taking (above 
analysis)) and substance abuse and (2) on the relation between the HoNOS total score 
(excluding problematic alcohol use and drug taking) and substance abuse. The second 
analysis shows that, substance abuse still remains a predictive factor (ȕ = 1.60, F = 5.874, p = 
.017). 
The results also showed that age was independently associated with the HoNOS total 
score (ȕ = 2.26, F = 7.341, p = .007), meaning that older patients had higher overall HoNOS 
total scores. Problems with motivation at baseline were also associated with higher overall 
HoNOS total scores (ȕ = .733, F = 6.460, p = .012). Lastly, analyses revealed that the level of 
education was significantly associated with HoNOS total score (ȕ = -1.916, F = 5.028, p = 
.027), as patients without education or elementary school had higher overall HoNOS total 
scores than patients whose education level was lower high school or above.  
Gender and outcome 
Table 2 also shows the men and women’s respective levels of psychosocial functioning. The 
results showed differences in the significance and direction of the associations. In men, poorer 
treatment outcome was predicted by substance abuse, age (30 or older), and level of education 
(no education, or elementary school only). In women, the pattern of associations was 
different, in that only substance abuse and problems with motivation for treatment were 
strongly and significantly associated. In addition, there was also a non-significant association 
with age, in the opposite direction than that of male patients. Because the association with 
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education was also non-significant in women, its significance was different than it was with 
men. 
 The two covariates – time and square-root transformations of time – were also 
different for men and women, men showing a significant decline over time, and women 
showing a non-significant decline.  
Table 2. Prediction of HoNOS total scores among men and women 
Predictors  ȕ (total)        SE  ȕ (men)         SE  ȕ (women)  SE 
Intercept  26.57**      3.69  29.40**       4.07  18.98*        8.99              
Linear time  3.27**        1.21  3.98**         1.32  -.11             2.82 
Square-root time  -14.56**     3.91  -17.23**      4.27  -1.51           9.20 
Substance abuse  3.47**      .70  3.14**       .82  6.30**        1.65 
Age   2.26**        .83  2.55**         .89  -2.53           2.85 
Level of education -1.92*      .85  -2.21*       .99  -.981           1.42 
Motivation for treatment .73*      .29  .65       .34  1.80**        .53 
* p< .05 
** P< .01  
Discussion 
The fidelity score of the DACTS model showed that the six teams had implemented ACT 
moderately successfully, but that treatment for dual disorder had been implemented relatively 
unsuccessfully.  
Although the patients’ psychosocial functioning improved significantly over time, the 
gains seem to have been concentrated mainly in the first months of treatment; later on, the 
level of functioning appeared to stabilize. Despite this early improvement, two factors 
indicate a need for long-term ACT: patients’ level of functioning over time, and the risk that 
their lack of motivation for treatment will cause their situation to worsen. It should also be 
stated that the significant improvement in psychosocial functioning was restricted to men, 
although the non-significant results for women may have been a product of the sample size.  
Our analysis also showed that the level of psychosocial functioning was significantly 
hampered by substance abuse, age over 30, low level of education (either no education, or 
elementary school only), and problems with motivation for treatment. In that these patient 
characteristics were associated with significantly more problematic functioning over time, our 
results confirmed earlier findings on treatment outcome in other patients with a severe mental 
illness (Batel, 2000; Dixon, 1999; Drake, Bartels, Teague, Noordsy, & Clark, 1993; Gerlach, 
2002; Greenfield et al., 2006; Lauronen et al., 2007; Roberts, Blow, Copeland, Barry, & van 
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Stone, 2000). Our finding that older patients had higher HoNOS total scores may have been 
due to the fact that the duration of mental illness (Jenner, 2003) or of untreated psychosis was 
longer in these patients, each a factor that has been associated with worse prognosis (Singh, 
2007). 
Our study further demonstrated that the pattern with which these variables were 
associated with psychosocial outcome was different between men and women. The 
differences between the sexes’ levels of psychosocial functioning—women tending to have 
fewer psychosocial problems over time, but also improving less—may have been due to a 
floor effect.  
However, the fact that substance abuse had more adverse consequences for women 
than for men may have been because women seemed more prone to perilous activities, such 
as turning to prostitution as a means to earn the money they needed to support their substance 
use. This led to problems regarding physical health and daily living conditions, and is in line 
with previous research by RachBeisel, Scott and Dixon (1999), who suggested that substance 
abuse among women is associated with increased risks for physical health problems and 
sexually transmitted diseases.  
The third difference between men and women, problems with motivation for 
treatment, also resulted in a higher risk (i.e. stronger association) for psychosocial problems in 
women than in men, which may be related to more disruptive behavior, and which therefore 
leads women to have more problems with motivation for treatment.  
For men, risk factors were being aged 30 or older, low level of education, and 
substance abuse. This is in agreement with findings that older patients had poorer global 
functioning (Roberts et al., 2000), and may indicate that these patients are more at risk of 
neglecting their personal care than women are. These findings also supplement those of Gur, 
Petty and Turetsky (1996) by showing more specifically how the clinical features of patients 
with a severe mental illness are moderated by aging and gender.  
The association with low level of education may indicate that such patients have more 
difficulty managing or coping with problems in their lives. Neisser et al. (1996) showed that 
because educational level was moderately highly correlated with intelligence, it may also 
reflect a patient’s ability to make use of any services on offer, and to foresee the consequences 
of their behavior. Because a low level of education may also lead to greater isolation from the 
labour market (Wolbers, 2000), it may also complicate rehabilitation.  
 Bhugra, Leff, Mallett, Der and Corridan (1997) showed that non-western ethnicity was 
associated with poorer treatment outcome, a finding we were unable to replicate, due possibly 
to differences in outcome assessment: whereas Bhugra et al. used employment status, we 
defined outcome more broadly in terms of psychosocial functioning as measured by the 
Part III - Outcome 

 
ϲϵ
HoNOS. Our study therefore suggests that, in terms of psychosocial functioning over time, 
non-western immigrants do not differ from other patients.  
Limitations of the study 
We should acknowledge two limitations of the present study. The first concerns the design. 
Because this was a naturalistic follow-up study that used routine outcome-monitoring data, 
we had no information on other factors that may have co-determined the outcomes, such as 
negative symptoms, lack of awareness of symptoms, and duration of untreated psychosis. 
Neither does the design make it possible to draw any causal inferences, although Shrier et al. 
(2007) suggests that, like randomized controlled trials, an observational study design can also 
contribute to evidence-based research.
 The second limitation concerns the small number of women in the analyses, which 
was a product of the substantial overrepresentation of male patients in the ACT teams. We 
therefore checked non-significant results for the female patients to see if they were similar in 
magnitude (ȕ) and direction to those in the larger group. Although non-significant results may 
indicate that the sample size was not enough for purposes of comparing the groups, the 
differences in magnitude or direction we found here indicate that the results were not 
explained solely by sample size. 
Conclusion 
Since model fidelity has been shown to be associated with better outcome (Bond et al., 2004; 
Latimer, 1999; McGrew et al., 1994; McHugo, 1999), our results suggest that our ACT teams 
should improve their fidelity with the ACT model. We also conclude that special attention 
should be paid to patients who seem to benefit less from ACT.  
Our results emphasize the importance of implementing the ACT-model fully, 
including substance abuse treatment programs. This can be done by implementing IDDT 
(Drake et al., 2001), or other substance abuse programs. McHugo, Drake, Teague and Xie 
(1999) showed that faithfully implemented dual-disorder programs achieved better treatment 
outcomes. These recommendations agreed with our DACTS findings, which also support a 
better implementation of ACT, especially with regard to the dual-disorder elements that 
achieved low DACTS scores in this study. 
Because our results also indicate that treatment outcome was significantly hampered 
by low education (including mental retardation), we propose the implementation of programs 
based on behavioral therapy for mentally retarded patients. One example of such a program is 
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token economy (Comaty, Stasio, & Advokat, 2001), which has also shown to increase 
adaptive behavior in schizophrenic patients (Dickerson, TenHula, & Green-Paden, 2005).  
To address problems of motivation for treatment, we recommend the structural 
implementation of Motivational Interviewing (Martino, Carroll, O’Malley, & Rounsaville, 
2000; Gerlach, 2002). The central purpose of motivational interviewing is to examine and 
resolve ambivalence in treatment goals. Research by Bien et al. (1993) and Brown and Miller 
(1993) has shown that patients who were given motivational interviewing had participated 
more fully in treatment, and appeared to be more motivated than those who had not received 
this intervention. If motivational interviewing is implemented, motivationally challenged 
patients may benefit more from assertive community treatment. 
To meet the special needs of patients in different age categories, we also argue for the 
development of innovative programs such as the differentiation of ACT teams according to 
patients’ age (i.e., young, adult and elderly). Because clinicians working in ACT teams 
serving a subpopulation such as the elderly, may have special skills for dealing with specific 
needs, such as somatic and cognitive problems. Therefore these teams may be better equipped 
to deal with specific problems related to age. Finally, because several important factors such 
as problems with recovery and substance abuse have shown to be different for men and 
women (Grossman, Harrow, Rosen, & Faull, 2006; Mangrum, Spence, & Steinley-
Bumgarner, 2006), it may be necessary to adopt a gender-specific approach. This will mean 
that separate treatment programs are adapted to the specific needs of men and women.  


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Chapter 4.1 - Motivation for treatment 
Changes in motivation for treatment in precontemplating dually 
diagnosed patients receiving Assertive Community Treatment 
Kortrijk, H.E., Mulder C.L., van Vliet, D. van Leeuwen, C., Jochems, E.,  & Staring, A.B.P. 
(2012). Changes in motivation for treatment in precontemplating dually diagnosed patients 
receiving Assertive Community Treatment. Community Mental Health Journal, under 
revision.
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Abstract 
In a population of dually diagnosed patients receiving Assertive Community Treatment 
(ACT) we used the theoretical framework of the TransTheoretical Model (TTM) to establish 
(a) the proportions and characteristics of patients who were not motivated for treatment for 
psychiatric symptoms and substance use, (b) the proportion of patients who moved towards 
behavioral change after about one year, and examine how this change was related with 
clinical outcome; and (c) the sequence of change processes. Chi-square tests and T-tests were 
used to compare the patient characteristics and outcomes of patients who remained in 
precontemplation with those who progressed. During follow-up, 47% of the patients came out 
of the precontemplation phase for treatment of psychiatric symptoms and 38% for substance 
use behavior. Those who remained in precontemplation benefited less from treatment. Of 
those who did move forward, most appeared to become motivated for psychiatric treatment 
before becoming motivated to reduce substance use. 
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Introduction 
The TransTheoretical Model (TTM) is a stage-based theory of behavioral change in which the 
Stages of Change (SoC) represent a temporal framework of motivational readiness for 
changes in lifestyle. It identifies five stages of behavior change: precontemplation, 
contemplation, preparation, action and maintenance (DiClemente & Prochaska, 1998). 
Although movement through these stages is thought to be effectuated by three factors 
(processes of change, decisional balance and temptation/self-efficacy) (Prochaska & Velicer, 
1997), the findings are inconclusive (Dijkstra, Tromp, & Conijn, 2003; Herzog, Abrams, 
Emmons, Linnan, & Shadel, 1999; Wright, Velicer, & Prochaska, 2009).  
A review by Littell and Girvin (2002) concluded that although the model 
oversimplifies the process of change, the TTM has greatly helped to define behavioral change 
for substance-use behaviors and psychiatric treatment models. The TTM is used in the 
evidence-based practice of Integrated Dual Diagnosis Treatment (IDDT) (Drake et al., 2001), 
a method that provides integrated treatment for dual diagnosis (DD) patients who suffer 
simultaneously from a severe mental illness (SMI) and a substance-use-related disorder 
(SUD). A coexisting SUD is common among patients with SMI, approximately 50% are 
diagnosed with a SUD somewhere during their lifetime (Mueser & Noordsy, 1996; Regier et 
al., 1990). DD patients are often difficult to engage in treatment, and their prognosis is poor 
(Green, Drake, Brunette, & Noordsy, 2007; Kortrijk, Mulder, Roosenschoon, & Wiersma, 
2010). IDDT provides TTM-stage-based interventions that aim specifically to enhance SoC-
progress for substance use, and hopefully to improve outcome (Drake, Bartels, Teague, 
Noordsy, & Clark, 1993; Drake et al., 2001; Minkoff, 1998; Mueser & Noordsy, 1996; 
Prochaska, Diclemente, & Norcross, 1992).  
The TTM can be used not only to improve our understanding of the SoC in substance-
use behavior (Vilela, Jungerman, Laranjeira, & Callaghan, 2009), but also to conceptualize 
patients’ motivation to be treated for severe mental illness (which can be manifested through 
their medication adherence and treatment attendance) (Corrigan, McCracken, & Holmes, 
2001; Finnell & Osborne, 2006). This motivation is not necessarily congruent with their SoC 
for substance use (DiClemente, 1999; Heesch, Velasquez, & von Sternberg, 2005).  
Although the TTM has been used in many different patient populations, it is still 
unclear whether it applies to patients with a dual diagnosis, and, if so, how. Bellack and 
DiClemente (1999) assume that substance use in patients with schizophrenia serves to reduce 
their psychotic symptoms and to lighten the side-effects of neuroleptics. While a patient is 
still undergoing the psychiatric condition and neuroleptic treatment, change in substance-use 
behaviors is thus likely to be more difficult. Some authors suggest that causality lies the other 
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way around: that substance use – such as cannabis exposure – in vulnerable people increases 
their risk of psychosis and relapses (Hickman et al., 2009; Smit, Bolier, & Cuijpers, 2004). 
Evidence for both hypotheses in the literature remains inconsistent, suggesting that both 
pathways may lead to a dual diagnosis.  
Neither is much known about transitions in the SoC in DD patients – about what 
differentiates changers from non-changers, and about which factors are associated with 
specific stage allocations. In a population of DD patients receiving Assertive Community 
Treatment (ACT), we therefore explored the transitions in the SoC, examining their 
motivation for treatment of psychiatric symptoms and for changing substance-use behavior.  
We had three specific objectives. The first was to determine the proportion of patients 
who had come out of the precontemplation stage after one year of ACT. Here, we focused on 
their motivation both to be treated for their psychiatric symptoms and to change their 
substance-use behaviors. The second was to compare the relationship between patient 
characteristics and clinical outcome in patients who remained in precontemplation (either for 
psychiatric symptoms or substance use) with those in patients who moved forward. Our third 
objective was to seek information indicating which motivation for change came first: the 
motivation to be treated for psychiatric symptoms, or the motivation to change substance-use 
behaviors. 
Methods 
Setting 
The study involved patients from seven ACT teams in the city of Rotterdam, the Netherlands. 
Criteria for treatment by an ACT team were (a) age 18 or older, (b) having a severe mental 
illness, usually a psychotic or bipolar disorder (with or without a co-morbid SUD); and (c) a 
lack of motivation to be treated at the start of ACT, such that assertive outreach was 
necessary. For this study we selected patients with a co-morbid substance use disorder. All 
ACT teams provided integrated treatment for both psychiatric symptoms and substance use. 
The model fidelity of the ACT teams was assessed using the Dartmouth Assertive 
Community Treatment Scale (DACTS; Teague, Bond, & Drake, 1998). The mean of the total 
DACTS scores of the ACT teams was 3.5 (range: 2.9 – 3.8), meaning that, on average, ACT 
had been implemented with moderate success. On the ‘human resources’ subscale, model 
fidelity was high (i.e., items that were awarded with scores 4-5). Low scores (items that were 
awarded with scores 1-2) were awarded to various items pertaining to the ‘nature of services’ 
subscale – items such as intensity of services, frequency of contact, provision of dual disorder 
treatment groups, and role of consumers on team. 
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Design 
Data from this observational study were obtained as part of a routine outcome monitoring 
(ROM) procedure in a naturalistic setting. Assessments were performed by trained 
independent raters (mostly psychologists) and were planned every six months. These ROM 
assessments were available for clinicians so that they could be used in clinical practice to 
discuss treatment progress with the patient. The data-collection of ROM was approved by the 
Dutch Committee for the Protection of Personal Data. Data for this study refer to the period 
from February 2004 to October 2010 and were used anonymously. 
Measurements 
Data was collected on gender, age, ethnicity (country of birth), education level, and DSM-IV 
diagnoses (as made by the psychiatrist of the ACT team).  
TransTheoretical Model - Stages of Change 
Two different SoC scores were assessed, one for motivation to be treated for psychiatric 
symptoms (usually psychotic symptoms), and one for motivation to change substance-use 
behaviors. Motivational levels were assessed using the SoC as described by Prochaska and 
DiClemente (1983). The rating for the SoC for treatment of psychiatric symptoms was based 
on all the information available to the rater; it concerned either medication adherence (for 
patients who were prescribed psychotropic medication) or treatment attendance (for those 
who were not).  
The TTM states that patients in the precontemplation stage do not recognize that they 
have the symptoms of a psychiatric illness and do not intend to change any time soon. This 
means that the patient is not taking and does not consider taking the medication prescribed by 
the physician; alternatively, if he or she has not been prescribed medication, the patient is not 
attending office based treatment sessions (e.g. psycho education, coping skills training or 
Cognitive Behavioral Therapy) and not considering doing so, although he or she may allow 
staff to keep in touch by home visits for example. Next, in the contemplation stage, patients 
are ambivalent towards change; they are considering the arguments for and against change, 
but have not yet planned any change in lifestyle. In the case of psychiatric treatment, this 
means that patients are not taking the medication (or, if no medication has been prescribed, 
are not attending treatment sessions), but are thinking about doing so sometime during the 
next six months. In the preparation stage, patients acknowledge the relevance of changing, 
and intend to make a behavior change. They now start planning to use medication as 
prescribed by the physician, or, if this has not been prescribed, to attend treatment sessions 
sometime in the next 30 days. In the action stage, patients are undertaking behavior change, at 
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least in the short term. They are consistently taking the medication, or, if this has not been 
prescribed, attending the treatment sessions prescribed by the physician. Finally, patients in 
the maintenance stage achieve long-term change (over more than six months). They 
consistently use medication, or, if this has not been prescribed, have consistently attended 
treatment sessions for over six months (Corrigan et al., 2001; DiClemente, Bellino, & 
Neavins, 1999; Finnell & Osborne, 2006; Rüsch & Corrigan, 2002). 
In our study, we also based the rating for the SoC for substance-use behavior on all 
information available to the rater. SoC were conceptualized in a manner similar to that 
described above, with the difference that it now concerned substance use. However 
DiClemente (1999) has argued that, as a concept, motivation for treatment is not equivalent to 
motivation for change, since a patient may be open to participating in treatment without being 
ready to abstain from alcohol or drugs. So, it should be noted that whereas the SoC for 
psychiatric symptoms is regarded as the patients’ motivation to be treated for their psychiatric 
symptoms, the SoC for substance use is regarded as their motivation for changing substance-
use behaviors. Thus, when it is applied to this field, the SoC does not describe treatment 
acceptance, but behavior concerned with reducing or quitting substance use. Therefore, the 
first stage of change for substance use (precontemplation phase) was characterized by no 
recognition of problematic behavior and no intention to change alcohol or drug use anytime 
soon, and the last stage was defined as having abstained for more than six months, although 
addiction could still be identified as part of the treatment (DiClemente et al., 1999; Prochaska 
et al., 1992). 
Psychosocial functioning 
Psychosocial functioning was assessed using the Health of the Nation Outcome Scales 
(HoNOS), which was originally developed as a standardized assessment tool for routine use 
by the mental-health services. It consists of 12 observer-rated scales, each using five points 
from 0 (no problem) to 4 (severe/very severe), and thus yielding a total score from 0 to 48. 
The psychometric properties of the English and Dutch HoNOS total scores have been found 
to be acceptable (Mulder et al., 2004; Wing et al., 1998). The HoNOS covers the following 
domains: (1) overactive, aggressive, disruptive or agitated behavior, (2) non-accidental self-
harm, (3) problem drinking and drug-taking, (4) cognitive problems, (5) physical illness and 
disability, (6) hallucinations and delusions, (7) depressed mood, (8) other psychological 
symptoms, (9) relationship problems, (10) problems with activities of daily living, (11) 
problems with living conditions, and (12) problems with occupation and activities. 
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Treatment needs 
The Camberwell Assessment of Need Short Appraisal Schedule (CANSAS) consists of 22 
items (Slade, Beck, Bindman, Thornicroft, & Wright, 1999), assesses the need for care, and is 
a modified version of the Camberwell Assessment of Need (CAN; Phelan et al., 1995). It 
assesses health and social needs across the following 22 domains: accommodation, food, 
looking after the home, self-care, daytime activities, physical health, psychotic symptoms, 
information, psychological distress, safety to self, safety to others, alcohol, drugs, company, 
intimate relationships, sexual expression, childcare, basic education, telephone, transport, 
money, and benefits. Each item is scored 0 (no problem), 1 (met need) or 2 (unmet need). The 
reliability of the CANSAS is acceptable (Trauer, Tobias, & Slade, 2008). 
Analyses 
SPSS version 15.0 was used for all analyses. Three patient groups were constructed – some 
with overlap – on the basis of their TTM-stage at their first assessment. Group 1 involved 
patients who, at their first SoC assessment, had been in the precontemplation phase for 
treatment of their psychiatric symptoms; group 2 involved those who had been in the 
precontemplation phase for changing their substance-use behavior; and group 3 involved 
those who had been in the precontemplation phase both for treatment of psychiatric symptoms 
and for substance use.  
Patient groups 1 and 2 were selected for the first and second study objectives: (1) to 
determine the proportion of patients who remained in or came out of the precontemplation 
phase after about one year, and (2) to determine differences in patient characteristics (gender, 
age, ethnicity, education and diagnosis) and outcome variables (change scores between first 
and follow-up assessment on the HoNOS total score and the number of unmet needs on the 
CANSAS) between those who stayed in the precontemplation phase versus those who moved 
forward. For these analyses we used Chi square and T-test. Using the timeframes 0-1 year, 1-
2 years, and >2 years of ACT before the first SoC assessment, we also assessed whether 
treatment duration before the first SoC assessment was associated with progression on the 
SoC.  
Patients in group 3 were selected for the third study objective: to seek information 
indicative about which change comes first, the motivation to be treated for psychiatric 
symptoms, or the motivation to change substance-use behaviors. For this, we calculated a 
cross-tabulation of the proportion of patients who remained in or came out of the 
precontemplation phase with regard to motivation to be treated for psychiatric symptoms or to 
change substance-use behaviors. 
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Results 
Patients 
The data comprised assessments of 253 DD patients who had been assessed repeatedly using 
the TTM for the motivations to accept treatment for psychiatric symptoms and to change 
substance-use behaviors. Of the patients included, 87 were in precontemplation for treatment 
of their psychiatric symptoms (34%; group 1), and 152 were in precontemplation concerning 
their substance use (60%; group 2). Ninety-three percent of the patients were male, the 
average age was 41 years (SD=10.2), and 44.8% had been born in the Netherlands. The mean 
treatment duration from the start of ACT to the first TTM assessment was less than a year (0.8 
year, SD=1.0). The first contact with mental health services had started about a decade before 
entering ACT (11.9 years, SD=9.4). Around 74% had been diagnosed with schizophrenia or 
another psychotic disorder, and all had been diagnosed with a SUD. 
Proportions of patients coming out of the precontemplation phase (Group 1 and 2) 
During a mean follow-up period of 0.9 years (SD=0.5) we found the following results. Group 
1: with regard to being treated for psychiatric symptoms, 47% of patients (46 out of 87) came 
out of the precontemplation phase. Group 2: with regard to their substance use, fewer patients 
came out of precontemplation: 38% (58 out of 152). 
Patient characteristics, clinical outcome, and progress on the SoC (Group 1 and 2) 
First of all, the results showed that progression through the SoC for treatment of psychiatric 
symptoms or motivation to change substance-use behaviors was not related to any patient 
characteristics or to duration of treatment in ACT before the first SoC assessment (all p-
values >0.5). Neither were baseline values from the HoNOS and CANSAS scores for patients 
who remained in precontemplation significantly different (p>.05) than those for patients who 
had progressed (see table 1 and 2).  
Group 1: Relative to patients who remained in precontemplation, those who had come 
out of it for treatment for psychiatric symptoms made greater improvement in HoNOS total 
scores and had more favorable changes in the total number of unmet needs on the CANSAS 
(p-values <.05). Group 2: Relative to patients who remained in precontemplation, those who 
had come out of it for substance use made greater improvement in HoNOS total scores, and 
had more favorable changes in the total number of unmet needs on the CANSAS (p values 
<.05) (see table 1 and 2). 
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Progression through SoC in patients in precontemplation for both treatment of psychiatric 
symptoms and substance-use behaviors (Group 3) 
Table 3 shows the association between progression through the SoC regarding 
precontemplaters for both groups. The results showed that 19 of the 23 patients (83%) who 
came out of precontemplation for substance use also came out of it for psychiatric symptoms. 
However, only 19 of the 34 patients (56%) who came out of precontemplation for psychiatric 
symptoms also came out of it for substance use.  
Discussion 
In our sample of dual diagnosis ACT patients, 34% were in the precontemplation phase 
regarding their motivation for treatment of their psychiatric symptoms, and 60% were in 
precontemplation regarding their motivation to change substance-use behaviors. Although this 
data is presented as a baseline, it is difficult, if not impossible to determine the exact point in 
time of their treatment histories at which these assessments had been taken, considering that, 
before their first assessment, most had been in contact with mental health services for 
over a decade. 
Interestingly, these proportions show that more patients were in the precontemplation 
phase for treatment of their substance use than for treatment of psychiatric symptoms. While 
this might imply that dual diagnosis patients seek treatment for their psychiatric symptoms 
rather than for their substance use, it may also be related to the nature of the services, whose 
main focus may thus be on psychiatric illness at the expense of treatment for substance use. 
Coming out of precontemplation 
Our finding that 47% of the patients came out of the precontemplation phase for psychiatric 
treatment and that 38% came out of it for treatment of substance-use behaviors suggests that, 
after approximately one year of ACT, most precontemplating ACT patients do not increase 
their motivation for behavioral change as outlined by the SoC. We realize that these findings 
are limited by a relatively small sample size, and also by the possibility that stage transitions 
(fluctuations in motivation) were not picked up due to our reliance on periodic ROM 
assessments and a relatively short (i.e., one-year) follow-up period. Notwithstanding these 
limitations, there appears to be a group of ACT patients who remain in precontemplation and 
who may be chronically difficult to engage in treatment for either their psychiatric symptoms 
or their substance use. These proportions may be somewhat discouraging, particularly in view 
of the potentially devastating impact of service disengagement, especially for those who 
require ongoing treatment (Kreyenbuhl, Nossel, & Dixon, 2009; Staring et al., 2006; Torrey 
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& Zdanowicz 2001). This is exacerbated by the fact that the same applies to problems related 
to substance use (Green et al., 2007).  
To interpret these results correctly, it should be noted that motivation is typically 
regarded as a dynamic state within a person that fluctuates over time in response to both 
internal and external factors (Deci & Ryan, 1985). Patients with severe mental illnesses also 
have several reasons for disengaging from service. Falling into roughly two types – reasons 
that manifest unwillingness, and reasons that reflect disabilities (Constantino, DeGeorge, 
Dadlani, & Overtree, 2009; Lecomte et al., 2008; Mueser, Rosenberg, Goodman, & 
Trumbetta, 2002; Silverstein, 2010; Tait, Birchwood, & Trower, 2003) – these make it 
particularly difficult to interpret lack of motivation for treatment. Are the patients who remain 
in precontemplation the consequence of ineffective services (ACT) that do not properly target 
this therapeutic problem? Or of certain patient characteristics? Or of an interaction between 
the two? 
Stages of change and clinical outcome 
For the second study objective we compared patient characteristics and clinical outcome in 
those who stayed in the precontemplation phase (either for psychiatric or substance use 
treatment) with those of patients who moved forward. This showed that progression through 
the SoC model was related to better clinical outcome. Change in motivation for treatment of 
patients’ psychiatric symptoms was positively related to more favorable outcomes as 
measured by the HoNOS and CANSAS. The results for substance use were similar, indicating 
that patients who remained in precontemplation for treatment of their psychiatric symptoms or 
substance-use behaviors benefited less from treatment.  
Changes in motivation in patients in precontemplation for both psychiatric treatment and 
substance use 
The third study objective was to investigate whether patients first became motivated for 
treatment of their psychiatric symptoms, or first became motivated for treatment of their 
substance use. Our results showed that 83% of the patients who came out of precontemplation 
for substance use also came out of precontemplation for psychiatric symptoms, against only 
56% the other way round. In other words, motivation to change substance-use behaviors was, 
in most cases, accompanied by change in motivation for treatment of psychiatric symptoms, 
not vice-versa.  
These results therefore provide some indirect evidence that, in most cases, patients 
first moved out of precontemplation for motivation for treatment of psychiatric symptoms, 
and then out of precontemplation for substance use. This is consistent with the insights of 
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Bellack and DiClemente (1999), who assumed that substance use may, in a patient's 
perception, help to alleviate or reduce psychotic symptoms. Meaning that substance use will 
be harder to change as long as the psychiatric condition and its treatment continue, we 
therefore share their point of view. However, we accept that other factors may also have 
contributed: for example, as psychiatric symptoms may cause more suffering than substance 
use does, patients may be more motivated to accept treatment for them. Or perhaps because 
change in substance-use behaviors is associated with more lifestyle changes compared to 
accepting treatment for their psychiatric symptoms. Finally, because IDDT was not fully 
implemented (for example, in some ACT teams no dual diagnosis groups were running), and 
because treatment of substance-use problems was therefore not optimal, the results may be 
due to the nature of the services delivered. 
To give a better understanding of what the interventions were to improve motivation, 
three examples describe practices employed by clinicians in the ACT teams:  
  
Motivating patients to change – three examples 
(1) ACT staff may apply positive reinforcement to increase treatment 
adherence. One of the interventions that was started in the ACT teams to reinforce 
dually diagnosed patients to accept their medication was by paying them small 
amounts of money. The results of this pilot-study were very promising: all patients 
accepted their depot injections and only one was re-admitted (Staring, Mulder, & 
Priebe, 2010). Despite the ethical criticism (Marteau, Ashcroft, & Oliver, 2009), 
this project of 'money for medication' appeared to be a rewarding and effective 
intervention to move some ACT patients from precontemplation towards 
accepting treatment. 
(2) In order to treat addiction problems clinicians used motivational 
interviewing techniques (Miller &  Rollnick, 1991) to increase motivation to 
change substance use. Using these interventions, clinicians tried to raise 
awareness of the effects of drug use on health or lifestyle by exploring the 
subjective benefits as well as the  negative effects of using substances. This may 
help patients realize that substance use has both pros and cons, and that change 
may be necessary to reach their personal goals. 
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(3) In case motivational strategies fail, the team may have used  housing as 
leverage to improve treatment adherence (Monahan et al., 2005):  
“You wish to keep living in this house, but you get very agitated and confused 
while coping with all types of hassles, and your landlord is complaining. 
Medication could help in becoming less agitated and might help in keeping the 
house.” 
Thus, although these practices were used by clinicians, a substantial number of patients did 
not come out of the precontemplation phase. It may be that the clinicians need to use more or 
other positive reinforcement strategies, have better training in motivational interviewing, or 
use more leverage to increase motivation. Additional  research is needed to know which 
(combination) of these measures is effective to improve motivation.      
Limitations 
Although we believe that our findings on the association between SoC and clinical outcome 
are relevant and provide useful insights, there is considerable controversy about the 
methodological quality of the SoC and the TTM (Bridle et al., 2005). The debate includes (1) 
the effectiveness of TTM interventions to facilitate SoC progression (West, 2005), (2) the 
arbitrary dividing lines between the stages, (3) the fact that SoC definitions are a composite of 
different constructs, (4) the assumption that patients make coherent and stable plans, and (5) a 
focus on conscious decision-making (Bridle et al., 2005).  
Given the observational nature of this research, our study design had limitations. With 
regard to the nature of the services, for instance, we know that many patients have contact 
with different services next to their ACT, making it practically impossible to provide clear 
data on duration and intensity of treatment (or treatments) and services. Similarly, we may 
have missed fluctuations in motivation, and may not have taken into account important 
background information such as referral source. Referral source may be an important factor to 
consider, as treatment adherence may be better or easer maintained for patients referred from 
the hospital compared to ‘new’ patients or those referred from outpatient programs. However, 
we found no differences in progress on the SoC between patients with a court ordered 
procedure at baseline and those without (see table 1). 
Further, considering that 55% was born outside the Netherlands, various cultural 
issues may have (co)determined motivation for treatment. Even though it is difficult to reflect 
on specific cultural aspects, because they are an ethnically diverse group (20% born in 
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Suriname, 9% in the Dutch-Antilles, 7% in Morocco and 19% in other countries), it is 
important to acknowledge that different cultural backgrounds may have affected the 
frequency of substance use (Room, 2006) and the acceptance of psychiatric treatment (e.g. 
due to stigma or various explanatory models of illness), which requires flexibility in treatment 
strategies from the ACT staff (Archie et al., 2010). Despite these limitations, however, we 
feel that our results are important to evidence-based psychiatry, since they provide new 
insight into the motivational processes of dually diagnosed patients in outpatient treatment. 
Previous research on the SoC has largely neglected the population of patients with severe 
mental illness and co-existing substance use, and has been based on a more motivated and less 
severely ill patient population. Our study provides evidence that outcomes on substance use 
and psychiatric symptoms in the context of ACT are associated with the degree of motivation 
to engage in treatment. 
Conclusion 
While this study has provided some preliminary evidence that the SoC are helpful in 
understanding the motivational processes underlying treatment engagement and treatment 
outcome in patients with a dual diagnosis, more research is needed to understand the exact 
mechanisms of change (and non-change) in this complex patient population. What remains to 
be determined is whether transitions in the SoC are dependent on other TTM constructs (such 
as the processes of change, self-efficacy, and decisional balance), or on other factors such as 
the therapeutic alliance, neurocognitive functioning and insight into illness.  
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Chapter 4.2 - Motivation for treatment 
Involuntary admission may support treatment outcome and motivation 
in patients receiving Assertive Community Treatment
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The results of study were published as: Kortrijk, H.E., Staring, A.B.P, van Baars A.W.B., & 
Mulder, C.L. (2010). Involuntary admission may support treatment  outcome and motivation 
in patients receiving Assertive Community Treatment. Social Psychiatry Psychiatric 
Epidemiology, 45, 245-252.
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Abstract 
Objective: Patients with severe mental illness who are treated in Assertive Community 
Treatment  (ACT) teams are sometimes involuntarily admitted when they are dangerous to 
themselves or others, and are not motivated for treatment. However, the consequences of 
involuntary admission in terms of psychosocial outcome and treatment motivation are largely 
unknown. We hypothesized that involuntary admission would improve psychosocial outcome 
and not adversely affect their treatment motivation.  
Methods: In the context of routine six-monthly outcome monitoring in the period January 
2003 to March 2008, we used the Health of the Nation Outcome Scales (HoNOS) and a 
motivation-for-treatment scale to assess 260 severely mentally ill patients at risk for 
involuntary admission. Mixed models with repeated measures were used for data analyses.  
Results: During the observation period, 77 patients (30%) were involuntarily admitted. 
Relative to patients who were not involuntarily admitted, these patients improved 
significantly in HoNOS total scores (F=17,815, df=1, p<.001) and in motivation for treatment 
(F=28.139, df=1, p<.001). Patients who were not involuntarily admitted had better HoNOS 
and motivation scores at baseline, but did not improve. 
Conclusions: Involuntary admission in the context of ACT was associated with improvements 
in psychosocial outcome and motivation for treatment. There are no indications that 
involuntary admission leads to deterioration in psychosocial outcome or worsening of 
motivation for treatment.  


Part IV - Motivation for treatment
 


ϴϵ
Introduction
Assertive Community Treatment (ACT) is a model for treating patients with severe mental 
illness who are difficult to engage in treatment (Fiander, Burns, McHugo, & Drake, 2003; 
Priebe, Watts, Chase, & Matanov, 2005). Its two main components are assertive outreach and 
the provision of medical and social care (Burns, Catty, & Wright, 2006). If patients in ACT 
teams constitute a danger to themselves or others and are not motivated for treatment, 
clinicians can start a procedure for involuntary admission to a psychiatric hospital. 
 However, a key empirical question is whether involuntary admissions are effective 
(Monahan et al., 1995). Therefore the use of involuntary admissions should be vigilantly 
monitored (Keski-Valkama et al., 2007). We found no studies that focused on treatment 
outcome and motivation in patients that were involuntarily admitted during Assertive 
Community Treatment. Few studies investigated the effects of involuntary admission. Most 
studies showed that psychiatric symptoms in involuntarily admitted patients improved 
(Katsako & Priebe, 2006). Motivation for treatment, however, was adversely affected by 
involuntary admission as compared to voluntary admission in some studies, while other 
studies showed no differential effects (Kallert, Glöckner, & Schützwhol, 2007). Part of this 
discrepancy may be explained by differences in percentages of patients regarding their 
admission as justified and/or the treatment as beneficial, varying from 33 to 81% (Gardner et 
al., 1999; Kaltiala-Heino, Laippala, & Salokangas, 1997; Katsakou & Priebe, 2007; Rain et 
al., 2003).           
 This naturalistic prospective follow-up study focused on psychosocial outcome and 
motivation for treatment in a cohort of severely mentally ill patients who were treated in 
Assertive Community Treatment teams and were also at risk for involuntary admission. We 
hypothesized that involuntarily admission would be likely to improve their psychosocial 
outcome, and that it would not adversely affect their motivation for treatment.  
Methods  
Setting  
The study involved patients from four ACT teams in the Dutch city of Rotterdam. Criteria for 
treatment by an ACT team were (1) having a severe mental illness, usually a psychotic or 
bipolar disorder, with or without a comorbid addiction disorder, (2) having problems in three 
or more of the following domains: physical illness, relationships, activities of daily living, 
housing, occupation and daily activities, and (3) a lack of motivation for treatment at the start 
of ACT, the combination of which made assertive outreach necessary.    
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 No written informed consent was required, as data were collected as part of a routine 
outcome monitoring (ROM) procedure, and were used in clinical practice to discuss treatment 
outcome with the patient and the clinician. The collection of routine outcome assessment data 
was approved by the Dutch Committee for the Protection of Personal Data. Data for the 
present study were analysed anonymously.  
Dutch Mental Health Act  
The Dutch Mental Health Act (1994) stipulates that patients aged 12 years and older can be 
involuntarily admitted if they are suffering from a mental disorder that causes danger to 
themselves or others, and if involuntary admission is the only way to prevent this danger (the 
'ultimate remedy' principle). There are three procedures for involuntary commitment.  
 The first is emergency admission (i.e., admission within 24 hours). To make such an 
admission, a patient is examined by an independent physician (usually a psychiatrist) not 
involved in his or her treatment, who examines and assesses the danger he or she poses to 
himself/herself or others. This physician then completes a medical report stating the mental 
disorder, and the nature of the danger he or she represents. On the basis of this information, 
and after consulting with the independent physician, the mayor issues an emergency 
admission. Within five working days, a judge must then decide whether or not to authorize a 
continuation of the admission (up to a total of three weeks from the date of admission).  
 The second procedure is court-ordered admission, in which admission usually takes 
place within two weeks. This can be obtained after the patient has been examined by a 
psychiatrist not involved in his/her treatment, who assesses the danger they pose to their own 
health and safety or that of others. On the basis of this information and after consultation with 
the psychiatrist, a judge decides whether or not to authorize the patient’s involuntary 
admission for a maximum period of six months. Earlier release is possible if the medical 
director of a psychiatric hospital considers that the patient is no longer dangerous.  
 The third procedure is court ordered outpatient treatment. Patients can be released 
from hospital on certain conditions. This involves a process similar to that described for 
court-ordered admission, after which a judge may decide to authorize an outpatient treatment 
order for a maximum of six months. During the period the court ordered outpatient treatment 
is in force, the patient agrees to comply with a treatment plan whereby the danger can be 
averted. If the patient does not comply with the treatment plan, he or she can be involuntarily 
admitted.           
 In the Netherlands however involuntary hospital admission does not involve 
involuntary treatment, although the majority of the patients do receive treatment. Since the 
treatment was not registered in the dataset, we cannot control for this.   
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 For the present study, all patients who were involuntarily admitted using an 
emergency admission procedure or on the basis of a court order were included in the 
involuntary admission group.  
Outcome measures 
Data were collected from January 2003 to March 2008. At the start of the treatment and then 
at six-month intervals, patients were assessed using the Health of Nation Outcome Scales to 
determine psychosocial outcome (Mulder, et al., 2004; Wing et al., 1998), plus one additional 
observer-rated item to assess motivation for treatment.      
 The HoNOS was developed as a standardized assessment tool for routine use in 
mental health services. It consists of 12 observer-rated scales, each using five points from 0 
(no problem) to 4 (severe/very severe), and thus yielding a total score from 0 to 48. The 
psychometric properties of the English and Dutch HoNOS total scores were acceptable 
(Mulder, et al., 2004; Wing, et al., 1998). HoNOS covers the following domains: (1) 
overactive, aggressive, disruptive or agitated behaviour, (2) non-accidental self-harm, (3) 
problem drinking and drug-taking, (4) cognitive problems, (5) physical illness and disability, 
(6) hallucinations and delusions, (7) depressed mood, (8) other psychological symptoms, (9) 
relationship problems, (10) problems with activities of daily living, (11) problems with living 
conditions, and (12) problems with occupation and activities.     
 The scale for assessing motivation for treatment was adapted from the Severity of 
Psychiatric Illness scale (Lyons, 1998; Mulder, Koopmans, & Hengeveld, 2005) and was 
scored in the same way as the HoNOS scales. The degree to which patients were motivated 
for treatment was expressed in five possible categories: (0) strong motivation: significant 
degree of motivation for treatment, (1) clear motivation: there may be some hesitation, but 
this does not lead to problems with motivation; (2) some motivation: there is motivation for 
treatment but also ambivalence or mild passive resistance; (3) poor motivation: the individual 
appears not to be motivated and there is passive resistance; and (4) resistance/no motivation: 
the individual actively resists treatment.  
 On the basis of an interview with the patient and the clinician, the HoNOS and the 
motivation for treatment scale were scored by independent raters who were not involved in 
the patients’ treatment. It was possible for assessments to take place either in an outpatient 
situation or in a psychiatric hospital at the time of a scheduled routine outcome assessment.  
 Apart from the routine outcome monitoring data, data were collected on gender, age, 
ethnicity (country of birth of the parents) and DSM-IV-TR diagnoses as assessed by the 
psychiatrists of the ACT team.   
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Analyses 
Patients were divided into two groups: patients who were involuntarily admitted during the 
observation period (group 1) and those who were not involuntarily admitted (group 2). For the 
first group we used data from three assessments: (a) the assessment before involuntary 
admission (time 1), (b) the assessment six months later (time 2), during involuntary 
admission, and (c) a final assessment again six months later (time 3). Group 1 was further 
divided into two subgroups, (1a) patients discharged at time 3, and (1b) patients still 
involuntarily admitted at time 3. The mean time for patients to become involuntarily admitted 
after the start of ACT was 8.2 months (SD=10.1). This was taken as the point of reference for 
group 2, whose trend over time was also analysed using three consecutive assessments, with 
the second assessment in the ROM dataset as a starting point. The durations of ACT for group 
1 and 2 were thus levelled out.         
 For all analyses, SPSS version 15.0 was used. Trends over time for the HoNOS total 
scores and the scale for assessing motivation for treatment were analyzed using a mixed 
model with repeated measures. Patients’ identification number were used as random factor 
assuming a first order autoregressive structure. Differences over time, in HoNOS total scores 
and motivation for treatment scores, between involuntarily admitted patients and patients that 
were not involuntarily admitted were analysed using involuntary admission as a covariate. 
Because mixed models make it possible to account for missing data, patients with incomplete 
data sets were not excluded from the analysis. 
Results  
Patients (Table 1)  
ROM data were available for 260 ACT patients; the mean observation period was 12.9 
months (SD=2.74). 77 (30%) Patients were involuntarily admitted during the observation 
period. Most of these patients had a psychotic disorder (89.4%); their mean HoNOS total 
score at the assessment before involuntary admission was 22.50 (SD=7.31). 32 (12%) Patients 
were involuntarily admitted only during time 2, whereas 26 (10%) patients were involuntarily 
admitted at both time 2 and time 3, meaning that their minimal admission period was six 
months; 19 involuntarily admitted patients (7.3%) lacked assessment three, and no 
information was available on the status at the relevant point in time.    
 183 Patients (70%) were not involuntarily admitted during the observation period; 
their mean HoNOS total score at the first assessment was 15.06 (SD=5.56 ). Of these patients 
75% had a psychotic disorder.  
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Changes  in HoNOS total scores 
There were significant differences in the HoNOS total scores between involuntarily admitted 
patients and patients who were not involuntarily admitted during follow-up assessments 
(F=18.708, df=1, p<.001) as well as a time*group interaction (F=22.363, df=2, p<.001); this 
means that patients who were involuntarily admitted during ACT improved more than those 
who were not (Figure 1, Table 2). 
Table 1. Characteristics of patients in ACT-teams who were involuntarily admitted (n = 77) 
and who were not involuntarily admitted (n = 183) 
    Involuntarily admission  No involuntarily admission 
n = 77    n = 183 
    M (SD) %  M (SD) %
Age    38.38 (12.50)   39.58 (11.98)  
Sex (male)     73%     79% 
Ethnicity  
 - native     46%    54%  
Diagnosis : 
- Psychotic disorder*   89.4%    57.5% 
Emergency admission    9.1%    0% 
Court-order admission    90.9%    0% 
*: significant differences between involuntarily admitted and non-involuntarily admitted patients (p<0.05) 
We also found significant differences between patients discharged at time 3 and 
patients still admitted at time 3 (F=12.507,df 1, p=.001), i.e. patients who remained 
involuntarily admitted had higher total HoNOS scores on all assessments than those who were 
discharged (ȕ = 4.19, p=.001); this indicated that the patients who were involuntarily admitted 
for a longer period had more problems. There was no interaction between time and groups 
(F=.355, df=2, p=.717) for these groups of patients, meaning that longer involuntarily 
admission was not associated with more improvement in HoNOS total scores.  
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Table 2. Test of fixed effects (HoNOS total score)
      F-value  df  P 
Intercept     1524.193 1  <.001 
Assessment     0.003  2  0.997 
Admission     18.708  1  <.001 
Assessment*Admission    22.363  2  <.001
Test of fixed effects showing significance of intercept, assessment (time), admission and the interaction between assessment 
time and admission. In this model, a significant interaction would indicate dissimilarities in the associations between 
involuntarily admitted patients and non involuntarily admitted patients and HoNOS total scores over time. 
Table 3. Mean (M (SD)) HoNOS total scores of involuntarily admitted patients and patients 
that were not involuntarily admitted during ACT (higher scores indicate more severe 
problems)
Involuntarily admitted patients and patients without involuntary admission during follow-up* 
M time 1 (SD)  M time 2 (SD)             M time 3 (SD) 
Involuntarily admitted patients (n=77) 22.50 (7.31)   17.47 (5.42)  14.46 (5.44) 
      Admitted at time 2 (n=32)**  21.67 (7.85)  16.32 (5.59)  13.38 (5.89) 
      Admitted at times 2 & 3 (n=26)*** 26.22 (5.39)  20.64 (4.93)  16.62 (4.19) 
Non admitted patients (n=183)**** 15.06 (5.56)  15.04 (4.89)  15.05 (4.94) 
*: Time 1 = before involuntary admission; time 2 = during involuntary admission; time 3 = after involuntary admission for 
the discharged group and during involuntary admission for the prolonged admitted group. Assessments 1,2,and 3 were six 
months apart. There were 19 missings for assessment 3. 
**: Involuntarily admitted at time 2 and later discharged. 
***: Involuntarily admitted at time 2 and still admitted at time 3. 
****: Patients not involuntarily admitted during follow up. 
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Figure 1 Six-monthly HoNOS total scores for involuntarily admitted patients and patients 
that were not involuntarily admitted during ACT  
Changes  in motivation for treatment 
Patients who were involuntarily admitted during the observation period displayed more 
problems with motivation for treatment (F=25.178, df=1, p<.001) than those who were not. 
There was a time*group interaction (F=6.255, df=2, p=.002), meaning that patients who were 
involuntarily admitted showed more improvement in motivation for treatment over time than 
patients who were not (Figure 2, Table 4).  
Patients who remained admitted at time 3 had more problems with motivation for 
treatment than those who were discharged at time 3 (F=9.601, df=1, p=.003). There was no 
interaction between time and groups (F=.551, df=2, p=.579), meaning that longer admission 
was not associated with less improvement in motivation for treatment. 
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Table 4 Test of fixed effects (Motivation for treatment score) 
      F-value  df  P 
Intercept     252.858 1  <.001 
Time      2.141  2  0.119 
Admission     25.178  1  <.001 
Time*Admission    6.255  2  0.002
Test of fixed effects showing significance of intercept, assessment (time), admission and the interaction between assessment 
time and admission. In this model, a significant interaction would indicate dissimilarities in the associations between 
involuntarily admitted patients and non involuntarily admitted patients and problems with motivation scores over time. 
Table 5 Mean (M (SD)) motivation for treatment scores of involuntarily admitted patients 
and patients that were not involuntarily admitted during ACT(higher scores indicate lower 
motivation) 
Involuntarily admitted patients and patients without involuntary admission during follow-up* 
M time 1 (SD)  M time 2 (SD)             M time 3 (SD) 
Involuntarily admitted patients (n = 77) 2.60 (1.35)  2.15 (1.33)  1.64 (1.29) 
     Admitted at time 2 (n=32)**  2.29 (1.46)  1.87 (1.34)  1.44 (1.42) 
     Admitted at times 2 & 3 (n=26)*** 3.12 (.90)  2.73 (1.22)  1.96 (1.00) 
Non-admitted patients (n=183)**** 1.50 (1.21)  1.24 (1.26)  1.38 (1.36)
*: Time 1 = before involuntary admission; time 2 = during involuntary admission; time 3 = after involuntary admission for 
the discharged group and during involuntary admission for the prolonged admitted group. Assessments 1,2,and 3 were six 
months apart. There were 19 missings for assessment 3. 
**: Involuntarily admitted at time 2 and later discharged. 
***: Involuntarily admitted at time 2 and still admitted at time 3. 
****: Patients not involuntarily admitted during follow up. 
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Figure 2 Six monthly problems with motivation for treatment scores for involuntarily 
admitted patients and involuntarily admitted patients that were not involuntarily admitted 
during ACT  
Discussion  
This study in patients receiving ACT showed that involuntary admission did not adversely 
affect psychosocial functioning and motivation for treatment. The results rather suggest that 
involuntary admission may be associated with improved psychosocial outcome and an 
increased motivation for treatment. 
Psychosocial outcome 
All patients, whether involuntarily admitted or not, had on average very severe psychosocial 
problems at baseline (i.e. their HoNOS total scores were higher than 15; Parabiaghi, Barbato, 
D’Avanzo, Erlicher, & Lora, 2005). The involuntary admitted patients had significantly more 
psychosocial problems (HoNOS total scores) at baseline compared to the patients that were 
not involuntarily admitted. This probably reflects the reason for the admission. Involuntarily 
admitted patients showed an improvement over time in psychosocial outcome. On average 
this was a reliable improvement in HoNOS total scores according to criteria defined by 
Parabiaghi et al. (2005)  (i.e. a change of more than 7 points on the HoNOS total score). The 
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reason for the improvement of the involuntarily admitted patients could be explained by two 
factors, namely favourable effects of treatment and/or a selection of natural fluctuations of the 
illness over time. The mean HoNOS total scores of patients that were not involuntarily 
admitted did not change.  
Our results also showed that, patients who were discharged within six months of 
admission reached the same level of psychosocial functioning as those who had not been 
involuntarily admitted during ACT. While those who stayed in hospital displayed more 
psychosocial problems than discharged patients, they still improved during involuntary 
admission in the same manner.  
Finally, during follow-up, the total HoNOS scores of the involuntarily admitted and 
the patients that were not involuntarily admitted remained severe (an approximate score of 15 
for both groups). An intensive form of outpatient treatment, such as ACT, thus remained 
necessary in both cohorts of patients.  
In line with earlier studies (Kallert et al., 2007; Kataskou & Priebe, 2007) these 
findings indicate that involuntary admissions are associated with improvement in 
psychosocial functioning in severely mentally ill and dangerous patients who are not 
motivated for treatment. However it should be noted that subjectively reported outcome and 
outcome measured by assessing change in level of functioning differs (Wallsten, Kjellin, & 
Lindström, 2006).  
Motivation for treatment 
Patients who were involuntarily admitted during the observation period showed less 
motivation for treatment than patients who were not admitted. Again this is what may be 
expected, as the criteria for involuntarily admission include resistance to therapy. This is in 
line with a previous study (Mulder, Koopmans, & Hengeveld, 2005) which showed that lack 
of motivation for treatment is a common phenomenon among severely mentally ill patients in 
emergency psychiatric services. Problems with motivation for treatment decreased more 
steeply in patients who had been involuntarily admitted than in those who had not. The results 
also show that patients who were discharged within six months of admission reached nearly 
the same level of motivation for treatment as those who were not admitted. Although patients 
who remained in hospital for more than six months had more motivational problems than 
discharged patients, they still improved in the same manner during involuntary admission. 
 These results contrast with findings from a cross-sectional survey of individuals with 
schizophrenia spectrum disorders (Swartz, Swanson, & Hannon, 2003) in which patients who 
were involuntarily admitted were reluctant to seek outpatient treatment due to a fear of 
coerced treatment. In that case, however, it was unknown whether the reluctance had 
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increased after the involuntary admission, or whether the patients involved had already been 
reluctant before the involuntary admission. Our results show, paradoxically, that involuntary 
admission is associated with improved motivation for treatment.  
The differences in motivation for treatment over time between the involuntarily 
admitted patients and the patients that were not involuntarily admitted during ACT may be 
explained by the use of medication during admission, leading to less (psychotic) symptoms 
and thereby probably to more illness insight, which is associated with better motivation for 
treatment (Mintz, Dobson, & Romney, 2003). The lack of treatment engagement and 
adherence among patients that were still involuntarily admitted after six months may explain 
the differences in psychosocial functioning (Craw & Compton, 2006) from patients that were 
discharged. Underlying this may be that the discharged patients experienced that their 
admission reduced their psychosocial problems (i.e. less psychosocial problems compared to 
the patients who were still admitted) and did meet their basic needs, as was found through the 
decrease in HoNOS’ problem scores.  
At the end of the follow-up, 26 patients were still involuntarily admitted. These 
patients had significantly more psychosocial and motivational problems, which probably 
made their prolonged admission necessary (Sellwood & Tarrier, 1994). Or, on the other hand, 
it may reflect an inability to provide more suiting alternative care for a group of more 
demanding patients (Lorant, Depuydt, Gillain, Guillet, & Dubois, 2007). 
Limitations of the study 
Since this was a naturalistic follow-up study, using routine outcome monitoring data, we did 
not have information on other factors that may have co-determined our outcomes, including 
voluntary admission, exact length of voluntary or involuntary hospital stay, or specific 
pharmacological treatments. As patients who are not involuntarily admitted in the Netherlands 
cannot be forced to take medication, but those who are involuntarily admitted can, it is likely 
that the these patients received more medication than patients who were not involuntarily 
admitted.  
Patients were not randomly assigned to involuntary admission. Obviously, 
involuntarily admitted and non involuntarily admitted patients have various clinical 
differences that influence the decision on whether or not they should be involuntarily 
admitted. As the primary reason for involuntary admission is the dangerousness inherent to a 
patient’s mental illness, it would be ethically problematic to conduct a randomized trial. This 
makes it impossible to draw causal conclusions.  
Similarly, because our patients were not randomly assigned to involuntary admission, 
regression to the mean may have influenced the results. We nonetheless find it unlikely that 
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this statistical artefact would have influenced our results. There are two reasons for this. First, 
patients were selected because they had been involuntarily admitted, not because they had 
extreme scores on the HoNOS. Second, we quantified the RTM effect on the basis of the 
method described by Hopkins, 2002 (New View of Statistics: Regression to the Mean. 
Retrieved from http://www.sportsci.org/resource/stats/regmean.html, 2008) and found that 
HoNOS total scores could regress 1.8 points towards the mean. It is therefore unlikely that 
our results were caused solely by an error bias. However, we cannot draw causal assumptions 
on the reason for improvement (i.e. favourable treatment effects or that the results are due to a 
selection based on natural fluctuations in illness severity). The results nevertheless show 
significant associations between involuntary admission and improvement on the HoNOS total 
score and motivation for treatment. 
Our findings show that the number of patients with a psychotic disorder was much 
higher in the involuntarily admitted group than in the group was not involuntarily 
admitted. When we analyzed the data using only patients with psychotic disorders, our results 
did not change (results not shown). We therefore conclude that this overrepresentation of 
patients with psychotic disorders did not play a confounding role in our observation that 
involuntary admission was associated with decreases in HoNOS scores and motivation.  
Motivation was assessed using only one item. Researchers conducting future studies 
should consider including more comprehensive instruments measuring motivation for 
treatment, such as the Service Engagement Scale [20] as well as new instruments for 
assessing patients’ motivation for different treatments.  
Conclusion 
Our findings in severely mentally ill patients receiving ACT indicate that involuntary 
admission is associated with improvements in psychosocial outcome and an increase in 
motivation for treatment. When clinicians decide on the involuntary admission of a patient, 
they can take these findings into account, which suggest that patients do not need to become 
less motivated for treatment after involuntary admission, and also that patients may benefit 
psychosocially from involuntary admission. However, because individual patients may still 
experience negative side-effects such as a decrease in motivation for treatment, involuntary 
admission should only be used where no other treatment options are available. Future studies 
should aim to define subgroups of patients who do not benefit from involuntary admission 
and who become less motivated for treatment. 
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5.1. Discussion 
This overall discussion groups the main findings of the thesis and draws final conclusions 
regarding the main research questions. The thesis had a threefold objective, and posed three 
main research questions concerning selection biases in outcome data, treatment outcome of 
patients in contact with ACT, and these patients’ problems with motivation for treatment.  
The clinical implications are discussed for each research question and suggestions for 
future research are presented. We describe a clinical vignette of a person receiving ACT, that, 
besides being illustrative, contributes to our discussion as it accentuates the complexity of the 
delivery and evaluation of ACT services. The chapter ends in a discussion of the limitations 
and strengths of the studies. 
Vignette  
Sergio is fifty-three years old and has a long history of homelessness. In the past decade he 
stayed at shelters for the homeless and lived an isolated life without friends and family.  
He was diagnosed with schizophrenia and had paranoid delusions about the 
government, believing they were out to get him. These feelings of imminent danger were so 
strong that he had paranoid outbursts and accused everyone of wrongdoing. While most 
people laughed it off, others avoided him or became fed up with his hostility. Following a 
violent incident, the shelter felt they could no longer manage him and referred him to an 
Assertive Community Treatment (ACT) program. Sergio disagreed with his referral, and 
persistently refused contact. Despite threats, complaints and  demands to be left alone, he was 
visited every week. Most of the time these visits were very brief, as Sergio would walk out 
instantly or angrily demanded that they should take off right away. This, however, changed 
after a year or so, as he had grown accustomed to the visits and stopped protesting. Then, 
after more than 2.5  years, he finally accepted help with housing. This formed the basis for 
further cooperation between Sergio and the social workers from the ACT program. 
       
As illustrated in the vignette above, patients referred to an ACT program are often living on 
the edge of society, suffer from severe psychosocial problems and may have persistent 
problems with motivation for treatment. In Sergio’s case it is worth mentioning that it took 
more than two and-a-half years before he finally accepted help from the ACT team.  
 What this vignette shows, is that building a trusting relationship may take a lot of time, 
effort and patience. While such a long term-effort may be necessary for building a 
relationship based on trust, this also raises questions, about whether or not these services are 
sustainable. Since it is unknown how long, if at all, it will take for a patient to become 
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motivated for treatment. Note that in this vignette the first years of treatment did not lead to 
any significant and measurable improvement in the level of psychosocial problems, which 
demonstrates the difficulties in demonstrating its effects.  
  
5.2 Discussion of key findings: Biases in outcome data  
Our first research question related to whether there are selection biases in ROM datasets, and, 
if so, which impact this may have on estimates of the effectiveness of the services delivered. 
This is a relevant question, as it is widely known that biases in observational research are not 
uncommon, and difficult to get around. Often  these biases are associated with patient 
characteristics, treatment proficiencies or attrition rates (Grimes & Schulz, 2002).  
We found that patient groups that were treated for a short, medium or a long period of 
time in ACT differed from each other in relation to diagnosis and outcome. Thus, patients in 
ACT teams with different treatment durations constitute, to some extent, distinguishable 
groups. It appeared that patients with relatively higher levels of psychosocial problems at the 
start of treatment and those with poor prognosis remain in ACT for a longer period of time. 
These findings are well illustrated by the vignette. 
It can therefore be concluded that the interpretation of long-term outcomes of ACT is 
hampered by this bias – one that is best described as a filter for patients who still need long-
term treatment because they have not yet recovered from their psychiatric condition. This was 
confirmed in another study (using assessments from the same patient population) 
demonstrating that most referrals were made to less intensive services (Mulder & Kortrijk, 
2012). There thus appears to be a selection bias of non-responders who were selected on the 
basis of an undesirable condition: no treatment response (or only a marginal response) related 
to continued exposure to services (Aschengrau & Seage III, 2008). If such a bias is not 
properly acknowledged, this may lead to questionable conclusions on the performance (long 
term) of mental healthcare services. In our case, it is likely to underestimate the effectiveness 
of ACT.  
Implications 
When describing the outcomes of treatment of patients in ACT (and possibly of any form of 
long term mental health care), we have to deal with selection biases based on selective 
attrition. This means that duration of treatment and attrition needs to be taken into account 
when analyzing ROM data. 
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Recommendations for future research 
To generate a more comprehensive understanding of selection biases in ROM data, future 
studies should examine attrition and the reasons for it. They should also relate these 
phenomena to treatment duration and clinical outcomes. We could compare attrition (rates 
and reasons for attrition) across different ACT-teams within and between mental health 
institutions, to see whether ACT teams are successful in maintaining contact with difficult to 
engage patients and to improve their psychosocial problems in the long run. Without 
information on attrition we will not be able to understand treatment outcome in the context of 
long-term mental health services such as ACT.         

5.3 Discussion of key findings: Treatment outcome 
The second research question concerned clinical outcomes of patients in contact with ACT 
teams and those who were involuntarily admitted during ACT. Before discussing the 
outcomes of these studies, we need to point out four relevant issues so that these studies and 
their relationships can be properly understood: (1) differences in patient samples, (2) different 
assessment methods, (3) service implementation and (4) the arbitrariness of starting points in 
long term treatment.  
Ad 1. Note that the outcome studies in this thesis comprised of (slightly) different 
patient populations. Our first study concerned symptomatic and functional remission and 
involved a subset of patients with psychotic disorders who were treated in ACT teams. This 
differs from the second and third outcome studies which made use the HoNOS total scores 
over time from all ACT patients.  
Ad 2. In our first study (chapter: 3.1), we investigated clinical outcome on the basis of 
remission criteria (Andreasen et al., 2005). To determine the proportions of patients achieving 
remission we used the two most recent assessments (constituting the remission assessment). 
This means that we presented a ‘snapshot’ of remission frequencies at a given point in time 
during treatment. The second and third studies (chapter: 3.2 and 4.2) used continuous 
outcomes – the actual sum-score of an instrument – of repeated assessments of the HoNOS 
over time. The advantage of using continuous scores such as the HoNOS total scores is that 
they may be better understood by clinicians, who know what certain total scores (such as 
those in the HoNOS) actually represent (Mulder, 2010). Also, the total score may be more 
sensitive to change and provides more specific information on the level of functioning. 
However, it should be kept in mind that in a large sample, small differences can be detected 
as statistically significant (Coe, 2002). Further, merely summing up improvements and 
deteriorations in total score may cancel out any change in individuals that has occurred 
(Trauer, 2010 a) obscuring relevant findings concerning the proportions of patients achieving 
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a meaningful outcome. To address the research question on the clinical outcomes, both 
approaches (using remission criteria as well as total scores) could be used as complementary 
strategies, both providing relevant information about the course of the psychiatric and social 
problems. Importantly, as the use of the HoNOS is becoming widespread both nationally and 
internationally, our outcomes research offers the possibility of comparisons with other future 
studies (Kisely, Campbell, Cartwright, Cox, & Campbell, 2010), 
Ad 3. It is of great significance to have background information about the services 
which were offered to have a better understanding of the outcomes in our studies. Therefore 
information about the degree of intervention implementation can be helpful. For this purpose 
the fidelity of the ACT programs was assessed using the Dartmouth Assertive Community 
Treatment Scale (DACTS) and revealed that the ACT teams had a moderately successful 
implementation of ACT, in which treatment for dual disorder had been implemented 
relatively unsuccessfully. 
Ad 4. Another relevant aspect in these studies that needs consideration are the baseline 
ROM assessments, as they actually represent a rather arbitrary starting point in a patients 
treatment career. Most patients were in contact with mental health services for over a decade, 
it is thus difficult to hold on to the idea that the baseline assessments used in the studies 
presented in this thesis were a true starting point of psychiatric treatment.  
5.3.1 Discussion of key findings: Treatment outcome - Remission
In the first study we used remission of symptoms and functioning as an outcome parameter. 
Remission is a relevant outcome and is frequently used in studies to evaluate treatment 
success in psychiatric illnesses such as schizophrenia (Andreasen et al., 2005),  mood-
disorders (Zimmerman, McGlinchey, Young, & Chelminsky, 2006), or anxiety disorders 
(Doyle & Pollack, 2003). Using remission as a desirable and achievable outcome makes it 
possible to compare study outcomes, and even to improve healthcare by setting goals to 
achieve a certain percentage of patients in remission (in line with recent developments in 
benchmark initiatives).  
In our outcome study of symptomatic and functional remission (SR; FR) in psychotic 
disorder patients receiving ACT, we found after a mean treatment duration of approximately 
30 months that 26% met the criteria for SR and 30% for FR. However, the comparison with  
remission rates of other studies is difficult. SR rates reported in other studies vary 
substantially, mostly higher, up to more than 60 percent (Bak et al., 2007; Eberhard, 
Levander, & Lindstrom, 2009; Gasquet, Haro, Tcherny-Lessenot, Chartier, & Lépine, 2008; 
Haro, Salvador-Carulla, 2006; Lambert, Marinis de, Pfeil, Naber, & Schreiner, 2010; Shida et 
al., 2008; Wunderink, Sytema, Nienhuis, & Wiersma, 2009). This may be related to duration 
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of follow-up, study design, treatment history and patient characteristics. Regarding FR, other 
studies (Lauronen et al., 2007; San, Ciudad, Álvarez, Bobes, & Gilaberte, 2007; Wiersma et 
al., 2000; Wunderink et al., 2009) also showed different proportions of FR, of course the use 
of other scales and definitions of FR make valid comparisons difficult.Interestingly, however, 
our study demonstrated that regaining SR did not appear to be a prerequisite for FR or vice 
versa and, importantly, FR, not SR, was associated with better quality of life.  
 We should acknowledge that our assessment of FR was a rather crude measure for FR 
as it was defined as adequate or no more than mild disabilities in social functioning, daily-life 
activities and living conditions. This is not entirely in line with the Dutch national remission 
working group, who proposed a somewhat more comprehensive assessment of FR that also 
included adequate daytime activities (e.g. participating in meaningful leisure activities or 
work) (National Remission Working group (NRW) of the Dutch Association of Psychiatry; 
Wiersma et al., in preparation)). However, our criteria were easy to assess using the HoNOS, 
an instrument already in routine use. The results showed that FR was an achievable goal, and 
that it was associated with quality of life which underlined its relevance in clinical practice. 
5.3.2 Discussion of key findings: Treatment outcome - psychosocial functioning 
In the second outcome study we examined outcome over time in patients who had received 
more than 2 years of ACT. Outcome was defined as the level of symptoms and social 
functioning over time (total sum of the 12 individual HoNOS items). We found that the 
patients’ psychosocial functioning improved significantly over time, although the health gains 
seem to have been concentrated in the first six months of treatment (2 to 3 HoNOS points). 
Looking at the entire ACT population at ‘baseline’ (N=1167), we saw that they had a mean 
HoNOS total score of  15.8 (SD =5.4). So the change in total score was approximately 0.5 
SD, which may be indicative of an on average meaningful change and noticeable for a careful 
observer (Burgess, Pirkis, & Coombs, 2009; Eisen, Ranganathan, Seal, & Spiro III, 2007; 
Norman, Sloan, & Wyrwhich, 2003). While the HoNOS is an internationally widely used 
instrument, it is surprising that there is no consensus about how to determine how services are 
performing based on the HoNOS (Burgess, Pirkis, & Coombs, 2009). Despite this, we have 
reason to believe that on average patients in contact with ACT got noticeably better, at the 
same time admitting that the benefits were only modest. Our results also showed that the 
patients’ level of functioning appeared to stabilize later, and that this stabilized curve does not 
necessarily mean that nothing changes at the individual level; the proportions of patients who 
improve may be more or less the same as the proportion who deteriorate. 
We also found that the level of psychosocial functioning was significantly associated 
with four patient characteristics: co-occuring substance use, age over 30, low level of 
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education (possibly reflecting pre-existing problems such as an intellectual disability, but it 
may also reflect an early manifestation of the illness), and problems with motivation for 
treatment. These characteristics were associated with problematic functioning over time, and 
confirmed earlier findings on treatment outcome in other patients with a severe mental illness 
(Batel, 2000; Dixon, 1999; Drake, Bartels, Teague, Noordsy, & Clarke, 1993; Gerlach, 2002; 
Greenfield et al., 2006; Lauronen et al., 2007; Roberts, Blow, Copeland, Barry, & van Stone, 
2000).  
Most of these characteristics appeared to have had a different impact on male and 
female patients: overall, female patients functioned better, although the impact of substance 
use and problems with motivation for treatment was more severe. However, it should be 
acknowledged that relatively few females (17%) were included in the study. 
Taken together, these outcome studies demonstrate that on average significant health 
gains are made by  patients in contact with ACT services. Overall, the improvements in 
problem severity were concentrated mainly in the first months of treatment. In subsequent 
years, the mean problem score on group level did not change. Again, this does not mean that 
functioning on individual level did not change (Trauer, 2010 a). Although it is still unknown 
whether these early gains would have been lost if ACT had been stopped, this seems likely 
from a clinical point of view. In addition at a given point in time (after an average of 2.4 years 
of ACT) we found that about a quarter of those in contact with ACT services regained 
remission of symptoms or functioning. This supports the statement that a substantial 
proportion of patients in contact with assertive outreach services might improve, and that 
there is hope that patients suffering from an SMI may overcome their problems.  
At the same time, it also means that there is a large proportion of non-responders 
within the ACT patient population (i.e. of people who do not regain remission at all). These 
patients remain in ACT and constitute a group with severe and (until now) treatment-resistant 
problems.  
To achieve better treatment results, it may be helpful to improve the implementation of 
ACT as an association has been found between DACTS fidelity scores and effectiveness of 
ACT (van Vught, et al. 2011). It is expected that implementation of other evidence-based 
practices can also lead to better outcome such as Integrated Dual Diagnosis Treatment (IDDT; 
Brunette & Mueser, 2006), Individual Placement and Support (IPS; Bond, Drake, & Becker, 
2002), Family Interventions (Pilling et al., 2002), Illness Management Recovery (IMR; 
Mueser et al., 2002), Token Economy interventions (Dixon et al., 2009), Motivational 
Interviewing (MI; Manthey, Blajeski, & Monroe-DeVita, 2012) and other psychosocial 
treatments (Dixon et al., 2009). However, until victory is attained and Schizophrenia can be 
cured we must also recognize that we may not be able to prevent high levels of disability 
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(Hunter, Cameron, & Norrie, 2009) despite our efforts to improve community life of patients 
so that they can learn to live beyond their illness.  
Our third outcome study concerned outcomes in patients who had been committed to a 
psychiatric hospital. While remarkably few studies have reported on the effects of such 
involuntary admission on psychosocial outcomes, our findings indicated that, as expected, it 
was associated with improvements in psychosocial outcome. This supports the claim that 
involuntary admission, even though it naturally remains an ultimum remedium, can be used to 
support treatment outcome.  
Implications 
1) Although association is not causation, our evidence supports the suggestion that 
ACT helps a group of patients with a SMI to get better, in the sense that ACT successfully 
meets (some of) their needs. However, not all patients seem able to profit from ACT (based 
on the ROM assessments) and the levels of psychosocial problems remain relatively stable in 
later years, for which they remain in need of the intensive services of an ACT-team. 
2) As substance-abuse programs have been relatively poorly implemented, and as 
patients using substances have more psychosocial problems, we recommend ACT teams to 
improve treatment of substance-abuse. The same is probably true for other patients whose 
outcome seems to be poor (e.g. patients with a low level of education), who may also be 
better helped by specialized ACT programs. 
3) To achieve functional remission (FR), it does not seem necessary to focus on 
achieving symptomatic remission (SR) first. While we realize that this advice is a product of 
our assessment of FR – after all, anyone in a job will plainly be hampered by severe psychotic 
symptoms – SR does not appear to be a conditio sine qua non for achieving proper housing, 
self-care and social contacts.  
4) Our outcome studies identified several predictors of treatment outcome that may 
aid the development of a casemix classification system for SMI patients, i.e. ROM data can be 
used as an information tool and provide information related to clinical complexity. Among 
other predictors this could be used to predict the cost of the delivered services.  
5) Involuntary admission was associated with improvements in psychosocial 
functioning, justifying its use in patients who meet the criteria for involuntary admission.  
Recommendations for future research 
1) Investigate the group of non-responders to ACT, and determine which factors 
(treatment, patient or environmental factors) contribute to non-response. Of course, of 
particular interest are the factors which we can influence in the service delivery process. 


Part V - Discussion 




ϭϬϵ
2) Define the subgroup of patients who do not benefit from involuntarily 
hospitalization in terms of improving of symptoms and functioning. Although the primary 
goal of involuntary admission is averting danger, this is potentially very important, as it could 
inform the clinician whether or not it is likely that a patient may profit from involuntary 
admission, and what kind of additional interventions may be necessary.  
5.4 Discussion of key findings: Motivation for treatment  
5.4.1 Discussion of key findings: Motivation for treatment in patients receiving ACT and its 
relation with clinical outcome 
Motivation for treatment is a crucial element for treatment success since patients who are not 
motivated or even refuse treatment  will make no effort to change, and will thus not take 
medication, or quit substance use. Despite the importance of motivation for treatment 
outcome, relatively little is known about motivation for treatment among patients receiving 
ACT. This is remarkable, since problems with motivation for treatment are one of the 
inclusion criteria for the provision of ACT services.  
Our results showed that, at their first assessment, 35% of dual diagnosis patients were 
in pre-contemplation for treatment of their psychiatric symptoms, and 62% for treatment of 
their substance-use behaviors. This means that a substantial proportion of patients were not 
motivated for treatment at start, especially for substance use. After about one year of ACT, 
47% came out of pre-contemplation phase for psychiatric symptoms and 38% for substance 
use. Nevertheless, most did not progress towards a behavior change after one year of ACT. 
Interestingly, we also found that most dual diagnosis patients seemed first to become 
motivated for psychiatric treatment, and later for substance use reduction. It remains unclear 
how this was related to the nature of the services, as the implementation of services 
specifically targeting substance use was relatively poor in the ACT teams.  
All in all, the results show that it can take several years before a patient in ACT 
becomes motivated for treatment (which was illustrated in the case of Sergio at the beginning 
of this chapter). In case patients remain unmotivated for their psychiatric problems, a 
termination of ACT may be considered, for instance when no dangerousness criteria apply 
(such as risks of suicide or self-harm, the safety of others, or the arousal of aggression of 
others, but also a severe social breakdown or self-neglect). In case of Sergio long term ACT 
services was also justified since he was at risk of becoming aggressive. However, in our view 
a lifelong exposure to ACT services can only be justified in relation to the level of problems, 
meaning that the principles of subsidiarity, effectiveness and proportionality must be taken 
into account. 
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5.4.2 Discussion of key findings: Involuntary admission and its relation with motivation for 
treatment.  
Patients treated in ACT are at risk of involuntarily admission when they are a danger to 
themselves or others and are not motivated for treatment. Surprisingly, the outcomes of 
involuntary admissions in terms of treatment motivation are largely unknown.  
As involuntary admissions are not uncommon, and practice-based evidence may 
increase the knowledge-base on this topic, our study is therefore relevant. The findings 
showed that approximately 30% of the patients with a SMI receiving ACT were admitted 
involuntarily, and that this was associated with amelioration in problems with motivation for 
treatment (post-hoc analysis revealed that motivation for treatment deteriorates in 12% of the 
patients, remains stable in 38% and improves in 50%). Note that despite the involuntary 
initiation of treatment we did not differentiate between extrinsic and intrinsic motivation. 
However, importantly, we found no evidence at a group level that involuntary admission 
would worsen motivation for treatment. Still, this does not mean that at the individual level all 
patients became more motivated for treatment, as the post-hoc analysis revealed that some 
have become less motivated. 
Further, we have to acknowledge that our assessment of motivation for treatment 
(HoNOS- addendum) was a rather rudimentary measure for motivation for treatment. We 
used a single item assessment of motivation for treatment which is potentially problematic, as 
it is a rather ambiguous concept (Drieschner, Lammers, & van der Staak, 2004) and may refer 
to different treatment related cognitive or behavioral elements which makes it difficult to 
interpret. Despite this limitation, it does allow for a useful and relevant insight to the degree in 
which a patient actively participates in the offered treatment program. Furthermore a ROM 
procedure makes it necessary to have a relatively short assessment of most relevant domains, 
therefore an extensive thorough assessments is not achievable.  
Clinical implications: 
1) In dually diagnosed patients receiving ACT, patients first appear to move out of  
pre-contemplation of treatment of psychiatric symptoms, and then out of pre-contemplation of 
treatment for substance abuse. This may mean that substance abuse is harder to change than 
psychiatric symptoms, or that patients first need to be stabilized in terms of psychiatric 
symptoms before substance abuse can be adequately addressed.  
2) On a group level, patients who are involuntarily admitted do seem to become more 
motivated for  treatment.    
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Future research:  
1) To improve our understanding of the effectiveness of services for dually diagnosed 
patients, future research should examine the course of motivation for treatment of psychiatric 
symptoms as well as of substance abuse problems.  
2) In our studies on motivation for treatment, we narrowed motivation down to one 
item which is essential in ROM procedures but does not cover the entire complexity of the 
motivational problem. Therefore we feel that clinical research is needed to understand the 
exact mechanisms of change (and non-change) in patients with a SMI. One relevant research 
question concerns the extent to which the stages of change depend on the processes of change, 
self-efficacy, and decisional balance; or on other factors, such as the therapeutic alliance, 
neurocognitive functioning, and insight into illness (Jochems, Mulder, van Dam, & 
Duivenvoorden, 2011). Also, we did not distinguish between extrinsic and intrinsic 
motivation. Therefore future research might explore extrinsic and intrinsic motivation for 
treatment of patients who were involuntarily admitted to learn which aspects of motivation 
can be improved. 
3) Future studies should aim to define subgroups of patients who do not benefit from   
involuntary admissions and who become less motivated for treatment. These studies should 
also focus on issues such as negative and positive experiences during involuntary admission. 
For instance, it would be interesting to learn to what extent positive or negative experiences 
during involuntary admissions play a role in motivation for treatment (Baars, Wierdsma, 
Hengeveld, & Mulder, 2010).   
5.5 General limitations and strengths
Despite increasing awareness of the importance of outcomes research, we also understand that 
inherently to the use of ROM data for research purposes there are serious methodological 
limitations.  
The most important limitation is that all our studies lacked experimental elements 
(Stroup et al., 2000). We should therefore recognize the existence of potentially uncontrolled 
confounding elements that may have influenced outcome, such as unstandardized and not-
allocated treatment. As we have no evidence that comparable patients who do not receive 
ACT do not get better (Trauer, 2010 a), neither can we rule out other possible explanations for 
their improvement. We should thus keep in mind that these observational data allow us to 
draw no causal statements on the effects of ACT. 
Further, not only is our study design susceptible to biases, we should also 
acknowledge that there is evidence of a selection bias. First, patients are selected for treatment 
(new or continued) on the basis of their serious condition (Rosenbaum, 2005). Second, 


Part V - Discussion 



ϭϭϮ
experience from the field tells us that the ROM procedure unintentionally may have omitted 
patients who refused assessments. Also, in the studies presented in this thesis, we have no 
empirical data on these patients. Similarly, in case of cooperation of unmotivated patients, 
they may not have disclosed reliable information about themselves, stressing that nothing was 
wrong with them and that ACT was unnecessary. Although the protocol stated that raters in 
these cases should try to organize an interview with the treating clinician to fill in the 
clinician-rated scales, they did not always succeed. And when they did succeed, the 
assessment was unquestionably less precise, either being incomplete or containing errors. We 
should therefore be aware that a significant proportion of patients (i.e., those who consistently 
refused every contact with ACT and ultimately were discharged) inevitably had more missing 
and imprecise assessments than those who adhered to treatment. Previous research shows that 
this may come near to 5% of the ACT patient population (Mulder & Kortrijk, 2012). This will 
apply particularly to self-reports on quality of life and to a lesser extent to the clinician-rated 
scales. As clinical experience suggested that poor treatment adherence may be a manifestation 
of serious psychological problems (besides many other aspects), this may be problematic. 
Therefore clinicians/raters should try to fill in the clinician rated outcome scales even when 
patients are unmotivated for treatment and do not show up for appointments. 
The third evidence of selection bias is that patients who are in acute crisis may be less 
frequently assessed than patients not in crisis situation, not only because they refused contact 
or were unable to fill in the self-reports, but also because the designated clinician frequently 
argued that it was not the most opportune moment for an assessment, possibly feeling that one 
would not do them justice.  
These factors represent a systematic distortion of the samples used in our studies. 
Together with the lack of experimental design this means that we were unable to test the 
effectiveness of ACT under the most ideal conditions. Each factor has a different and perhaps 
even counteracting effect on the estimates of treatment outcome. The first (selection bias of 
non-responders) may produce an underestimation of treatment success. The second (omission 
due to patients refusing treatment) and third (less frequent assessment of patients in acute 
crisis) may have had a mixed impact on outcomes, potentially overestimating treatment 
success (i.e., giving the false impression of few patients in acute crisis), but underestimating 
the overall severity of the patient group.  
Another limitation is the possibility of a regression-to-the-mean phenomenon (Barnett, 
van der Pols, & Dobson, 2004), which is common in studies of patients with chronic health 
conditions. This occurs if patients are referred to treatment when they are at their worst, and 
so improvements in their condition may be related to natural fluctuations instead of the 
beneficial effect of treatment. We cannot rule out these phenomena in our outcome studies.  
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We must recognize that the baseline values used in our studies did not necessarily 
reflect the starting point of patients’ treatment career. Rather it represented a point in time in 
which ACT services were considered appropriate. Also the inability to assess all patients 
during their intake phase (due to the uncertainty of whether or not ACT was appropriate or 
due to problems with motivation for treatment) means that we do not have a true starting point 
of psychiatric treatment.  
In addition to the limitations mentioned above, other elements in our studies may have 
compromised the results. First, in some cases, repeated assessments were made by different 
assessors. This may be problematic even if the psychometric properties of the instruments are 
satisfactory, as rater drifts may produce unwanted artifacts.  
Secondly, since its introduction at Bavo-Europoort, the ROM procedure has 
undergone several changes and improvements. In the meantime, as extra instruments have 
been incorporated in the original ROM procedure, some patients have baseline assessments of 
instrument X but not of instrument Y, while those who were recently referred to ACT had 
baseline assessments of both instruments. We were also faced with an ever-growing number 
of (in)complete assessments. As a result the number of included patients increased each time 
we used all available records and the studies in this thesis consist of more or less different 
samples.  
Although we used instruments in our ROM procedure which were in agreement with 
the Dutch National Remission Working group (Mulder et al., 2010) our choice can be debated 
as, obviously, we were not able to monitor all relevant aspects of treatment. For instance, 
regarding the example of Sergio (vignette), most clinicians would agree that a lot of 
therapeutic work has been done in the past years, in particular in building a relationship with 
Sergio. This means that using ROM datasets such as the one in our studies missed relevant 
information e.g. on the therapeutic relationship, illness management or coping strategies.  
Another issue concerning ROM is that to date in clinical practice few clinicians 
actually use the assessed outcomes for following progress of their patients. Perhaps this is 
because ROM is not equally popular among all clinicians. Facing the problem of low ROM 
rates, managers have placed great emphasis on getting ROM assessments done, i.e. making 
sure that most patients have a ROM assessment each year. However ROM therefore is at risk 
of becoming part of an administrative control (which will not contribute to its popularity). 
This may be exacerbated by recent developments in which insurance companies are creating 
financial incentives for outcome measurement. Whereas, at the same time, there is little 
emphasis on the use of ROM as a treatment tool, which appears to be somewhat neglected. 
For that reason we believe that it is important to facilitate the use of ROM in treatment. This 
not only requires adequate feedback systems, but also training in how ROM can be used in 
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treatment, for instance by demonstrating how techniques of problem solving treatment can be 
used to discuss ROM results.  
Besides these limitations there are also several methodological strengths worth noting. 
The main strengths of our studies include: (1) Its longitudinal character, we were able to use 
repeated outcome assessments in several studies. (2) The frequent follow-up assessments (in 
many cases even twice a year) over a long follow-up period. (3) Our studies comprised of 
representative samples of difficult-to-engage patients, because we were able to include 
assessments of patients refusing treatment, not just the treatment adherers. Furthermore, most 
of our studies used an adequate sample size, so these studies may be a good reflection of the 
ACT population. 4) We used data from a rather comprehensive ROM procedure and were 
therefore able to take many relevant factors into account. (5) We used outcome measures who 
are (inter)nationally widely used, which has the potential benefit that it may enable future 
effectiveness comparisons. (6) We should also underline that most instruments have 
satisfactory psychometric properties. (7) Additionally, the use of independent raters may have 
positively affected the reliability. (8) Last but not least we were able to provide information 
on the ACT services via DACTS scores. The actual level of implementation may also be 
considered reflective of contemporary ACT services in the Netherlands, because the mean 
level of implementation of ACT services in our studies corresponds to the mean level of  
implementation found in a Dutch ACT fidelity study (van Vugt et al., 2011).  
All in all, when we take the limitations and strengths into account we should stress that 
we are unable to provide the definitive answer to the treatment-outcome question. However, 
because the analyses were based on a representative community sample of difficult-to-engage 
patients, and the studies comprised of sufficient data to provide reliable estimates of outcomes 
we are certain of their relevance, as they provide treatment outcomes from a “real world” 
healthcare setting. Although outcome evaluation of ACT using ROM data can never provide 
the answers to all of the relevant questions. We therefore recognize the importance of the 
internal validity of clinical trials as well as their ability to make more comprehensive 
assessments of factors such as functional remission and motivation for treatment, which our 
ROM procedure assessed rather crudely.  
Although randomized trials remain important, we feel that outcomes research too is 
urgently needed, because it helps us understand what is really achieved in daily practice, 
needing ongoing reexamination. Therefore we argue against the popular belief that only 
RCT’s produce trustworthy and useful insights;Concato, Shah, & Horwitz, 2000; Krumholz, 
2009). Furthermore as outcome research may improve (i.e. modify) service planning and 
delivery, we hope it may also lead to better outcomes. 
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Summary 
Part 1: Introduction and aims of the thesis 
Assertive Community Treatment (ACT) is the most studied service-delivery model for 
patients with a severe mental illness who lack motivation for treatment. Most studies 
demonstrating its effectiveness were performed in the US some time ago, and found that 
ACT was effective in keeping patients in contact with services, reducing the duration of 
hospitalization, and improving clinical and social outcome. However, more recently, 
European studies that compared ACT with standard care did not show these effects, and 
ACT was proved to be more effective only in keeping patients in contact with services.  
This discrepancy may be due to differences in control or experimental groups: in 
European countries, certain aspects of ACT were already part of ‘care as usual’, but also 
differences in model fidelity may account for the discrepant findings. Importantly, 
however, most of these randomized controlled trials used rather short follow-up periods, 
and included a small number of patients. This might mean that we know little about 
longer-term outcomes in patients receiving ACT under real-life conditions.  
To bridge this gap and to gain insight into the long-term course of illness of  
patients in ACT teams, we gathered routine outcome monitoring data collected over the 
2002–2011 period.  This gave us the opportunity to study real-life outcomes of patients 
in ACT teams over a relatively long period of time. To increase our insight into 
treatment outcome under real-life conditions, ROM data was used to study the outcomes 
of ACT. This thesis had three aims: (1) to investigate whether there were selection 
biases in our ROM dataset, and whether any potential biases might impact estimates of 
the effectiveness of ACT services; (2) to determine the clinical outcomes of patients 
receiving ACT, or those who had been admitted involuntarily during their ACT, and to 
identify the factors associated with outcome; and (3) to establish the proportion of 
patients who had problems with their motivation for treatment, and investigate the 
proportion of patients who did become motivated as ACT proceeded. We also 
investigated changes in motivation of patients who had been admitted involuntarily. 
Part 2: Outcome measurement
Part 2 deals with methodological issues regarding the use of routine outcome data for 
research purposes. When evaluating ACT on the basis of ROM  data, statistical 
inferences are susceptible to biases caused by patient self-selection, meaning that 
certain patients receive ACT longer than others. We therefore investigated whether 
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there were selection biases in our ROM dataset, and, if so, what impact this might have 
had on estimates of the effectiveness of the services delivered.  
We found that a higher number of patients who had received long-term ACT had been 
diagnosed with a psychotic disorder and/or substance use disorder than patients who had a 
shorter treatment duration. Patients who had a longer treatment duration also had worse 
baseline values as compared to those who had a shorter treatment duration. We also found 
that the relationships between the determinants and outcome variables were different for each 
of the treatment-duration categories. On the basis of these findings, we concluded that 
patients in ACT teams with different treatment durations constitute of distinguishable groups 
with different levels of functioning. If this selection of patients with a relatively poor 
prognosis is not properly acknowledged, this may lead to questionable conclusions on the 
(long term)  performance of mental healthcare services. In our case, it is likely to 
underestimate the effectiveness of ACT. This should be taken into account when using 
outcome data for studying the effectiveness of ACT.  
Part 3: Outcome 
Part 3 contains two studies of treatment outcome in patients receiving ACT. In the first study, 
we determined the proportion and characteristics of patients treated in ACT teams who 
achieved symptomatic remission and/or functional remission. We also investigated the 
associations between both types of remission, and their bearing on quality of life.  
Three items (relationship problems, problems of daily living and problems with living 
conditions) of the  HoNOS (Health of the Nation Outcome Scales) were used for assessing 
functional remission. The Positive and Negative Syndrome Scale remission criteria items 
were used for assessing symptomatic remission. We found that after a mean treatment 
duration of 2.4 years, 26% of the 278 patients met the criteria for symptomatic remission, and 
30% met those for functional remission. Prescription of antipsychotic medication was 
associated with achieving both symptomatic and functional remission. Remission of 
symptoms in patients treated in ACT teams was not a prerequisite for functional remission, or 
vice versa. Functional remission and not symptomatic remission was associated with better 
quality of life. Our results therefore showed that functional remission was an achievable goal, 
and that it was associated with quality of life – which thereby underlined its relevance in 
clinical practice. 
In the second outcome study we investigated treatment outcome over time and how 
outcome was associated with demographic factors, clinical factors, and motivation for 
treatment. During a follow-up period of about 2.3 years in 139 patients we found that the 
patients’ psychosocial functioning improved significantly over time, and that the health gains 
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seem to have been concentrated in the first months of treatment. In subsequent years the mean 
HoNOS score on group level remained relatively stable and reflected serious problems for 
which ACT remained necessary. Substance abuse, higher age (30+), problems with 
motivation, and lower educational level were associated with higher HoNOS total scores over 
time (i.e. worse outcome). Males were over-represented and most of these characteristics 
appeared to have had different impacts on male and female patients 
Part 4: Motivation for treatment 
Focusing on the impact of motivation for treatment on clinical outcome, part 4 consists of two 
studies. In the first study we investigated a population of dually diagnosed patients receiving 
ACT, and determined the proportions and characteristics of those who were not motivated for 
treatment for psychiatric symptoms and substance use. We also examined the proportion of 
patients who became motivated for treatment after about one year, and investigated how this 
change was related with clinical outcome.  
Of the 253 patients included, at baseline 34% were unmotivated for treatment of their 
psychiatric symptoms and 60% were unmotivated for treatment of their substance use; 28% 
were unmotivated for both. During follow-up we found that 47% of these patients became 
motivated for treatment of psychiatric symptoms and 38% for treatment of substance use. 
Those who remained unmotivated benefited less from treatment. Most patients appeared to 
become motivated for psychiatric treatment before becoming motivated to reduce substance 
use.  
 The second study investigated the effects of involuntarily admission in terms of 
psychosocial outcome and treatment motivation. We hypothesized that involuntary admission 
would be associated with improved psychosocial outcome and would not adversely affect 
their treatment motivation.  
During the observation period, 77 patients (30% of the 260 ACT patients) were 
admitted involuntarily. Relative to those who were not admitted involuntarily, they improved 
significantly in HoNOS total scores and in motivation for treatment. Patients who were not 
admitted involuntarily had better HoNOS and motivation scores at baseline, but did not 
improve. We concluded that, on average, involuntary admission in the context of ACT was 
associated with improvements in psychosocial outcome and motivation for treatment. 
However, it should be noted that there may be differences between subjectively reported 
outcome (for example quality of life, on which we did not reported in the study) and outcome 
as assessed by clinicians in terms of psychosocial functioning. The results nonetheless 
supported the claim that involuntary admission, even though it naturally remains an ultimum 
remedium, can be used to support treatment outcome. 
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Part 5: General discussion 
In this chapter we discussed the main findings of the studies, and concluded that, over the last 
decade, increasing awareness of the importance of external validity in evaluation has brought 
considerable momentum to outcomes research. It is therefore relevant to study whether the 
patients’ health improves when they are treated by ACT teams. However, as we describe in 
Part 2, we realize that the use of ROM data for research purposes has serious methodological 
limitations, including a selection bias of patients requiring long term ACT.  
In the outcome studies presented in Part 3, we found evidence that a substantial 
proportion of patients in contact with assertive outreach services improved, and that there is 
hope for patients suffering from a complex SMI to overcome their problems. However, on 
average, most of the health gains seemed to have been concentrated in the first period of 
ACT. The studies also showed that there was a large proportion of non-responders within the 
ACT patient population (i.e. of people who do not regain remission at all). These patients 
remain in ACT and constitute a group with severe and – as yet – treatment-resistant problems. 
To achieve better treatment results, we recommend the implementation of interventions 
targeting substance use or motivation for treatment. 
We also found indirect evidence that, to achieve functional remission, it does not seem 
necessary first to focus on regaining symptomatic remission; this may have been a result of 
our operationalization of functional remission. In addition, functional remission, not 
symptomatic remission, was associated with better quality of life. This indicates that our 
assessment of functional remission using the HoNOS is relevant for clinical practice. 
In our studies on motivation for treatment, we found that this factor plays an important 
role in treatment outcome. Our studies also showed that a substantial proportion of patients 
were unmotivated for treatment and that it may take several years before they finally become 
motivated. 
 Part 5 is concluded with a discussion on the strengths and limitations of the studies. 
We stress that no causal conclusions can be drawn on the basis of the studies described in this 
thesis. As our study design lacked experimental elements, we were also unable to test the 
effectiveness of ACT under the most ideal conditions. Several factors may therefore have 
influenced the treatment outcomes and had a different – perhaps even counteractive – effect 
on the estimates. The first factor, a selection bias of non-responders, may have produced an 
underestimation of treatment success. The second and third, which are related to the omission 
of assessments of patients in acute crisis or those refusing treatment, may overestimate 
treatment success (i.e., giving the false impression of few patients in acute crisis), while 
underestimating the overall severity of the patient group.  
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Besides these limitations, it is important to note that our studies comprised 
representative samples of difficult-to-engage patients. We were therefore able to provide 
reliable estimates of relevant outcomes, from a “real world” healthcare setting which helps us 
to understand what is achieved in daily practice. We can now value what has been achieved 
and judge whether the services were successful.
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Samenvatting 
Deel 1: Introductie en doelen van het proefschrift 
Assertive Community Treatment (ACT) is het best onderzochte organisatiemodel voor de 
behandeling van patiënten met ernstige psychiatrische aandoeningen die niet gemotiveerd zijn 
voor behandeling. De eerste studies die de effecten van ACT hebben onderzocht zijn 
uitgevoerd in de VS. Deze studies toonden aan dat ACT, vergeleken met standaard zorg, beter 
was voor het in zorg houden van patiënten, en leidde tot minder opnamedagen en beter 
psychosociaal functioneren. Echter, recentere Europese studies lieten minder gunstige 
effecten zien van ACT, al toonden sommige studies wel aan dat ACT beter was dan standaard 
zorg ten aanzien van het in zorg houden van patiënten. Het feit dat de Europese studies, voor 
een belangrijk deel uitgevoerd in het Verenigd Koninkrijk, vrijwel geen verschillen lieten zien 
tussen ACT en standaard zorg kan mogelijk verklaard worden doordat de standaard zorg in 
deze studies al veel elementen van ACT bevatte, maar anderzijds mogelijk ook doordat de 
ACT conditie minder modelgetrouw was. 
 Boven bedoelde studies betroffen gerandomiseerde onderzoeken met controlegroepen 
(RCT’s). Dit type onderzoek geldt als de gouden standaard binnen het wetenschappelijk 
onderzoek, omdat de effecten die in deze studies worden gevonden zijn toe te schrijven aan de 
interventie. Echter deze studies hadden ook beperkingen, zoals een relatief korte follow-up 
periode, kleine aantallen patiënten en veel patiënten die weigerden mee te werken aan het 
onderzoek. Daarnaast is de getrouwheid aan het ACT-model in deze RCT’s vaak van een 
hoger niveau dan in de dagelijkse praktijk. Deze factoren zorgen voor een kloof tussen de 
kennis over effecten van behandeling verkregen uit RCT’s en de dagelijkse praktijk. Om deze 
kloof te overbruggen is naast kennis uit RCT’s ook kennis uit de dagelijkse praktijk nodig, 
waarbij de meetgegevens verkregen worden bij ‘real life’ patiënten. Gegevens die verzameld 
worden in het kader van routine outcome monitoring (ROM; periodiek meten van toestand 
van patiënt tijdens behandeling) kunnen hiervoor gebruikt worden. Echter, hoewel we 
concluderen dat kennis van beide typen onderzoek (RCT’s en ROM) nuttig zijn voor het 
maken van een inschatting over de behandeleffecten van ACT, is het erg lastig om deze 
kennis aan elkaar te koppelen. Dit komt doordat er verschillen kunnen zijn tussen gegevens 
verzameld door middel van RCT’s en ROM procedures in (a) patiënten populaties, (b) 
kenmerken van de setting en de behandeling, (c) duur van de follow-up en (d) uitkomst 
maten.  
 Om de behandelresultaten van ACT in de dagelijkse praktijk te onderzoeken, hebben 
we enkele studies gedaan die ACT evalueren aan de hand van ROM data (verkregen in de 
periode van 2002 tot 2011). Het doel van deze studies was drieledig: (1) onderzoeken of er 
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sprake was van een selectie bias in de ROM data en zo ja, hoe dit de beoordeling van 
behandeluitkomsten van ACT kon beïnvloedden, (2) het beschrijven van behandelresultaten 
bij (a) patiënten in ACT teams en (b) patiënten die tijdens ACT onvrijwillig waren 
opgenomen; en exploreren welke factoren een bijdrage leverden aan een goede of een slechte 
uitkomst, (3) bepalen in hoeverre problemen met motivatie voor behandeling zich voordeden 
bij ACT patiënten, en of de problemen met motivatie na 1 jaar behandeling verbeterden en 
welke impact dat had op behandeluitkomsten.  
Deel 2: Uitkomstmetingen  
In het 2e deel werden methodologische problemen onderzocht die zich voor kunnen doen bij 
het gebruik van ROM data voor onderzoeksdoeleinden. Een van de problemen is selectiebias.  
Uit het onderzoek kwam naar voren dat een langere behandelduur in ACT samenhing met  
diagnose (psychotische stoornis en/of middelengebruik) en meer psychosociale problemen op 
baseline. Ook toonden we aan dat er verschillen bestonden tussen groepen met een korte, 
middellange en lang behandelduur, in de relatie tussen baseline en uitkomst variabelen. Deze 
bevindingen lieten zien dat patiënten met een verschillende behandelduur van elkaar te 
onderscheiden groepen betreffen. Onderzoek naar lange termijn uitkomsten van ACT kan 
daardoor beïnvloed worden, doordat er een selectieve groep patiënten bestaat die ACT nodig 
blijft houden: patiënten met complexe problematiek blijven in ACT. Bij het beoordelen van 
de effectiviteit van ACT kan hiermee rekening gehouden worden, door de duur van de 
geleverde zorg als variabele mee te nemen.  
Deel 3: Uitkomsten 
 Het 3e deel bevat twee studies naar behandeluitkomsten van patiënten in ACT. In de eerste 
studie is bestudeerd welk deel van de patiënten in symptomatische en functionele remissie 
(SR; FR) kwam. Daarnaast werd onderzocht wat de relatie was tussen het bereiken van 
remissie en patiëntkenmerken, wat de relatie tussen SR en FR onderling was en hoe ze 
gerelateerd waren aan de ervaren kwaliteit van leven.  
Voor de operationalisatie van FR hebben we gebruik gemaakt van 3 items van de 
Health of the Nation Outcome Scales (HoNOS; items huisvesting, ADL en sociale contacten).   
 Uit deze studie bleek dat na een gemiddelde behandelduur van 2.4 jaar 26% van de 
278 patiënten met een psychotische stoornis in SR kwam en 30% in FR. Een voorspeller voor 
deze uitkomsten was een voorschrift van antipsychotische medicatie (proxy voor 
medicatiegebruik). SR bleek overigens in deze studie geen voorwaarde te zijn voor het 
behalen van FR (of vice versa). FR, niet SR, bleek gerelateerd aan een betere kwaliteit van 
leven.  
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 In de tweede studie naar behandeluitkomsten van ACT hebben we het beloop van het 
psychosociaal functioneren van 139 patiënten onderzocht (72% was gediagnosticeerd met een 
psychotische stoornis en alle patiënten waren meer dan 2 jaar in behandeling bij ACT). Uit 
deze studie bleek dat het psychosociaal functioneren van de ACT patiënten verbeterde, echter 
de verbetering concentreerde in de eerste periode van behandeling. Daarna stabiliseerde het 
niveau van psychosociaal functioneren, waardoor het groepsgemiddelde nauwelijks 
veranderde. Middelengebruik, een leeftijd boven de 30 (proxy voor ziekteduur), problemen 
met motivatie voor behandeling en een laag opleidingsniveau waren factoren die 
samenhingen met meer psychosociale problemen. Opvallend was dat de patiënten populatie 
hoofdzakelijk bestond uit mannen, maar ook dat bovengenoemde factoren een verschillende 
impact leken te hebben voor mannen dan voor vrouwen.  
Deel 4: Motivatie voor behandeling 
Het 4e deel van dit proefschrift richt zich hoofdzakelijk op het concept motivatie voor 
behandeling en bevat 2 studies. In de eerste studie hebben we onderzocht welk deel van de 
patiënten met een dubbele diagnose niet gemotiveerd was voor behandeling van 
psychiatrische en/of verslavingsproblemen. Vervolgens is na 1 jaar ACT beoordeeld welk 
deel van de patiënten gemotiveerd geraakt was voor behandeling en onderzocht of 
behandeluitkomsten gerelateerd waren aan verandering in motivatie. De resultaten laten zien 
dat bij aanvang 34% van de 253 patiënten ongemotiveerd was voor behandeling van 
psychiatrische symptomen, 60% ongemotiveerd om middelengebruik te veranderen en 28% 
ongemotiveerd voor beide. Na 1 jaar bleek dat 47% gemotiveerd was geraakt voor 
behandeling van psychiatrische symptomen en 38% voor het veranderen van 
middelengebruik. Patiënten die ongemotiveerd bleven hadden minder profijt van behandeling. 
We hebben aanwijzingen gevonden dat patiënten meestal eerst gemotiveerd raken voor 
psychiatrische behandeling en daarna voor het veranderen van hun middelengebruik.  
In de tweede studie hebben we de effecten onderzocht van een gedwongen opname 
tijdens ACT op zowel het niveau van psychosociale problemen als de problemen met 
motivatie voor behandeling. Onze verwachting was dat een opname zowel het psychosociaal 
functioneren verbeterde als de motivatie voor behandeling. Tijdens de observatieperiode 
werden 77 (30% van de 260 ACT patiënten) opgenomen. Ten opzichte van de patiënten die 
niet waren opgenomen verbeterde de HoNOS totaal score (maat voor psychosociaal 
functioneren) en namen de problemen met motivatie voor behandeling af. Echter deze groep 
patiënten bleef ernstige problemen houden, net als de patiënten die niet werden opgenomen. 
De patiënten die niet gedwongen waren opgenomen verbeterden niet op groepsniveau.  
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Deel 5: Discussie 
Tenslotte omvat het 5e deel een algemene discussie van de bevindingen. We hebben 
geconstateerd dat in het afgelopen decennium er een toenemende bewustwording is voor het 
belang van externe validiteit van onderzoek, waardoor er meer aandacht ontstaan is voor 
onderzoek naar de effecten van behandelingen in dagelijkse klinische praktijk. Observationeel 
onderzoek kan hierin een grote rol spelen omdat dit type onderzoek helpt zicht te krijgen op 
datgene wat in de dagelijkse praktijk bereikt wordt. Echter dit type onderzoek kent 
methodologische beperkingen, waaronder een potentiële selectiebias, welke uitvoerig in deel 
2 is besproken. Daarin hebben we aangetoond dat patiënten met ernstige problematiek 
‘geselecteerd worden’ voor een langere behandeling binnen ACT.  
Het 3e deel van dit proefschrift bestaat uit 2 onderzoeken naar behandeluitkomsten 
van ACT patiënten. De resultaten van deze studies laten zien dat een deel van de ACT 
patiënten kan profiteren van behandeling. Echter, de gezondheidswinst heeft voornamelijk 
plaats gevonden in de eerste periode van behandeling. Dit betekent dat er tegelijkertijd ook 
veel patiënten in ACT blijven die niet of weinig reageren op behandeling en geen remissie 
van symptomen of functioneren bereiken. Om betere uitkomsten te bereiken wordt 
aanbevolen om het behandelaanbod te verbeteren ten aanzien van middelengebruik en 
problemen met motivatie voor behandeling. Daarnaast zijn er aanwijzingen gevonden dat het 
niet nodig is om in de behandeling eerst SR te bereiken en dan pas FR. Echter deze bevinding 
is nauw verbonden aan onze assessment van FR (hooguit beperkte problemen met sociale 
contacten en een voldoende niveau van ADL en woonomstandigheden). Wanneer het hebben 
van werk ook onderdeel van FR was, zouden waarschijnlijk minder patiënten FR hebben 
bereikt en zal FR zich anders verhouden tot SR. Toch is onze assessment van FR relevant, 
aangezien FR en niet SR samenhangt met ervaren kwaliteit van leven. Daarnaast wordt de 
HoNOS, het instrument dat we voor FR hebben gebruikt, (inter)nationaal al routinematig 
afgenomen en dat maakt het gebruik van dit instrument voor de routinematige assessment van 
FR aantrekkelijk.  
Het vierde deel omvat studies naar motivatie voor behandeling en de invloed die 
problemen met motivatie voor behandeling hebben op behandeluitkomsten. Deze studies laten 
zien dat er na 1 jaar ACT een grote groep patiënten bestaat die nog steeds niet gemotiveerd is 
voor behandeling. Dit betekent dat het soms meerdere jaren kan duren voordat ACT patiënten 
gemotiveerd raken voor behandeling. Verder hebben we aangetoond dat bij gedwongen 
opnames tijdens ACT zowel het psychosociaal functioneren als de motivatie voor 
behandeling verbeterde. Afsluitend hebben we uitdrukkelijk gesteld dat op basis van de 
uitgevoerde studies geen causale verbanden aangetoond kunnen worden. Dit komt doordat in 
de onderzoeken experimentele elementen ontbreken. Hierdoor kunnen de resultaten worden 
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beïnvloed door storende factoren, bijvoorbeeld wanneer vooral patiënten met complexe 
problemen langdurig in ACT blijven. Zo kon er een selectie van patiënten ontstaan met een 
relatief ongunstige behandelprognose. Dit kan ertoe leiden dat het behandeleffect van ACT 
wordt onderschat. Daarnaast kunnen ook andere storende factoren van invloed zijn. Er zijn 
namelijk relatief weinig assessments afgenomen van patiënten in acute crisis en van hen die 
contact met hulpverleners van ACT blijvend hebben geweigerd. Dit kan onterecht het beeld 
wekken van behandelsuccessen en tegelijkertijd de ernst van de problematiek onderschatten.  
Door deze factoren zijn we niet in staat het definitieve antwoord te geven op de vraag 
naar: ‘de behandeluitkomst’. Echter doordat deze studies een grote groep ACT patiënten 
bevatten en komen uit de alledaagse praktijk van ACT, geloven we dat deze studies eraan 
bijdragen om te begrijpen wat in de dagelijkse praktijk van ACT bereikt wordt. Dit is een 
belangrijk gegeven omdat we zo niet alleen in staat zijn om ACT beter op zijn waarde te 
schatten, maar ook om te beoordelen of we met onze behandelingen op de goede weg zijn.
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Appendix I - Example of computerized ROM record  
%DVLVJHJHYHQV3%*VFRUHYDQPHWLQJ
+RH]LMQGHJHJHYHQVYHU]DPHOG" 6FRUH $QWZRRUG
+R126  LQWHUYLHZPHWFOLsQW
UHPLVVLHWRRO  LQWHUYLHZPHWFOLsQW
&$16$6  LQWHUYLHZPHWFOLsQW
YHLOLJKHLGJHZHOG  LQWHUYLHZPHWFOLsQW
42/WHYUHGHQKHLGPHW]RUJ  RQWEUHHNW

+R126+HDOWKRIWKH1DWLRQDO2XWFRPH6FDOHV7RWDOHEHYRONLQJVFRUHYDQPHWLQJ
0HWLQJKXLGLJHPHWLQJ


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ϭϰϲ
/HJHQGD+R126VFRUH
 JHHQSUREOHHP
 RQGHUJHVFKLNWSUREOHHPYHUHLVWJHHQDFWLH
 OLFKWSUREOHHPPDDUGXLGHOLMNDDQZH]LJ
 PDWLJHUQVWLJSUREOHHP
 HUQVWLJWRW]HHUHUQVWLJSUREOHHP

+R126+HDOWKRIWKH1DWLRQDO2XWFRPH6FDOHVVFRUHYDQKXLGLJHPHWLQJ
,WHP+R126 :HONSUREOHHPQUSUREOHHP :HONSUREOHHPQDDPSUREOHHP

:HONRYHULJSV\FKRIJHGUDJVSUREO
  *HVSDQQHQKHLG

+R126+HDOWKRIWKH1DWLRQDO2XWFRPH6FDOHVVFRUHV
6FKDDO 6FRUH0HWLQJ

6FRUH0HWLQJ

+\SHUDFWLHIDJUHVVLHIGHVWUXFWLHI  
2S]HWWHOLMNH]HOIYHUZRQGLQJ  
3UREOHPDWLVFKDOFRKRORIGUXJJHEUXLN  
&RJQLWLHYHSUREOHPHQ  
/LFKDPHOLMNHEHSHUNLQJHQ  
+DOOXFLQDWLHVHQZDDQYRRUVWHOOLQJHQ  
'HSUHVVLHYHVWHPPLQJ  
2YHULJHSV\FKLVFKHHQJHGUDJVSUREO  
3UREOHPHQPHWUHODWLHV  
3UREOHPHQPHW$'/  
3UREOHPHQPHWZRRQRPVWDQGLJKHGHQ  
0RJHOLMNKHGHQGDJEHVWHGLQJ  
DGG0DQLIRUPHRQWUHPPLQJ  
DGG*HEUHNDDQPRWLYDWLH  
DGG*HEUHNDDQPHGLFDWLHFRPSOLDQFH  

+R126+HDOWKRIWKH1DWLRQDO2XWFRPH6FDOHVVFRUHYHUORRSPHWLQJHQ

+R126WRWDDOVFRUH

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ϭϰϳ
5HPLVVLHWRRORSEDVLVYDQ3$166VFRUHYHUORRSPHWLQJHQ
6\PSWRPDWLVFKHUHPLVVLH 6FRUH0HWLQJ

6FRUH0HWLQJ

$DQWDOLWHPVERYHQGH  

/HJHQGDUHPLVVLHWRRO
'HSDWLsQWKHHIWJHHQVFKL]RIUHQLHRILVLQV\PSWRPDWLVFKHUHPLVVLHDOVKHW
DDQWDOLWHPVERYHQGH
ELMWZHH
RSHHQYROJHQGHPHWLQJHQLV


&$16$62QYHUYXOGH]RUJEHKRHIWHQKXLGLJHPHWLQJ
6FKDDOUDQJH 6FRUH %HKRHIWH
$'/  9RRU]LHQ
**=  %HKRHIWLJ
5HKDELOLWDWLH  =HHUEHKRHIWLJ
9RRU]LHQLQJHQ  9RRU]LHQ
7RWDDOVFRUH  %HKRHIWLJ

&$16$6=RUJEHKRHIWHQHQRQYHUYXOGH]RUJEHKRHIWHQ

7RWDDODDQWDORQYHUYXOGH]RUJEHKRHIWHQ

7RWDDODDQWDO]RUJEHKRHIWHQ


&$16$6VFRUHRSLWHPQLYHDX
,WHP 6FRUH0HWLQJ

6FRUH0HWLQJ

+XLVYHVWLQJ  
9RHGLQJ  
=RUJYRRUKHWKXLVKRXGHQ  
=HOIYHU]RUJLQJ  
$FWLYLWHLWHQRYHUGDJ  
/LFKDPHOLMNHJH]RQGKHLG  
3V\FKRWLVFKHV\PSWRPHQ  
,QIRUPDWLHRYHU]LHNWHHQEHKDQGHOLQJ  
3V\FKLVFKRQZHOEHYLQGHQ  
9HLOLJKHLGYDQGHSHUVRRQ]HOI  
9HLOLJKHLGYRRUDQGHUHQ  
*$)VFKDDO6\PSWRPHQHQ+DQGLFDS%HOHPPHULQJHQVFRUHYHUORRS
6FKDDO 6FRUH0HWLQJ

6FRUH0HWLQJ

*$)V\PSWRPHQ  
*$)EHOHPPHULQJ  
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ϭϰϴ
&$16$6VFRUHRSLWHPQLYHDX
,WHP 6FRUH0HWLQJ

6FRUH0HWLQJ

$OFRKRO  
'UXJVPHGLFDWLH  
*H]HOVFKDS  
,QWLHPHUHODWLHV  
%HOHYLQJYDQGHVH[XDOLWHLW  
=RUJHQYRRUGHNLQGHUHQ  
(OHPHQWDLURQGHUZLMVHGXFDWLH  
7HOHIRRQFRPPXQLFDWLH  
9HUYRHUPRELOLWHLW  
*HOG  
8LWNHULQJ  
%HWDDOGZHUN  
%LMZHUNLQJHQYDQPHGLFDWLH  
=LQJHYLQJHQKHUVWHO  
-XULGLVFK  
6ODDS  
/HJHQGD&$16$6VFRUH
 JHHQ]RUJEHKRHIWH
 ZHO]RUJEHKRHIWHPDDUVWUXFWXUHHOEHYUHGLJHQGRSJHORVW
 ZHO]RUJEHKRHIWHPDDUJHHQRIHHQRQEHYUHGLJHQGHRSORVVLQJ
42/HQWHYUHGHQKHLGPHW]RUJVFRUH
+RHWHYUHGHQEHQWXPHWUDQJH 6FRUH0HWLQJ

6FRUH0HWLQJ

:RRQVLWXDWLH  
6RFLDOHUHODWLHV  
/LFKDPHOLMNHJH]RQGKHLG  
3V\FKLVFKHJH]RQGKHLG  
)LQDQFLsOHVLWXDWLH  
:HUNVLWXDWLH  
/HYHQDOVJHKHHO  
3URIHVVLRQHOHKXOS  
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